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Abstract 
 
In addition to the catalytically active kinase domain, many kinases feature regulatory domains 
that govern their activity. Modulating and interfering with these inter-domain interactions 
presents a major opportunity for understanding biological systems and developing innovative 
therapeutics. Therefore, small molecule inhibitors that target these interactions with an allo-
steric mode of action have great value and higher intrinsic selectivity, as these interactions are 
often unique for a single kinase or kinase family. Protein Kinase B (PKB, also known as Akt) 
is such a multi-domain kinase and represents an important target in cancer research. A number 
of allosteric inhibitors have been reported for Akt over the last years, with one of them cur-
rently in clinical phase II trials. Their mode of action requires the presence of a regulatory PH 
domain as they bind at the PH/kinase domain interface, locking Akt into an inactive confor-
mation. This unique binding site enables an extraordinary high selectivity and therefore low 
off-target toxicity. However, all known inter-domain inhibitors so far are based on the same 
scaffold, and the discovery of new chemical entities is hampered by the lack of methods to 
identify such inhibitors in high-throughput screens. This thesis describes the development of 
iFLiK (interface-FLiK), a fluorescence-based assay that can monitor such inter-domain inter-
actions. Guided by X-ray crystal structures, the assay was designed to sense the conforma-
tional changes of the protein associated with these interactions by attaching an environmental-
ly sensitive fluorophore to a suitable site. In order to establish the assay, a series of probe 
molecules were synthesised and tested for their inhibitory activity in in vitro and cellular as-
says. Furthermore, the proteins required for iFLiK were expressed in insect cells and labelled 
with various fluorophores, systematically assessing their suitability to report on protein con-
formations. iFLiK could easily distinguish allosteric from classic ATP-competitive inhibitors, 
thereby providing a proof of principle that solvatochromic fluorophores are capable to moni-
tor protein-protein interactions when attaching the sensor to the correct position. After exten-
sive and careful assay optimisation and validation with orthogonal assay systems, an in-house 
library was screened with iFLiK. Novel compounds with a scaffold that was previously not 
described as allosteric Akt inhibitors were identified. 
  
  
 
Zusammenfassung 
 
Die Aktivität vieler Proteinkinasen wird durch das Zusammenspiel der Kinasedomäne mit 
zusätzlichen regulatorischen Domänen gesteuert. Daher besitzen niedermolekulare Verbin-
dungen, die solche Interdomänen-Interaktionen allosterisch adressieren und modulieren kön-
nen, einen großen Wert in der chemischen Biologie und der Pharmaforschung, da diese Inter-
aktionen oft spezifisch für bestimmte Kinasen bzw. Kinasefamilien sind, und somit im Ge-
gensatz zu klassischen ATP-kompetitiven Inhibitoren eine höhere Selektivität versprechen. 
Die Proteinkinase B (PKB, auch genannt Akt) ist eine solche Multidomänen-Kinase und stellt 
ein wichtiges Zielprotein in der Krebsforschung dar. Im Hochdurchsatzscreening wurden in 
den letzten Jahren eine neue Familie von allosterischen Akt Inhibitoren entdeckt, deren 
Wirkmechanismus die Anwesenheit einer regulatorischen PH Domäne voraussetzt, da sie in 
einer Bindungstasche an der Grenzfläche zwischen der Kinase- und PH Domäne binden und 
dadurch Akt in einer inaktiven Konformation arretieren. Diese einzigartige Bindetasche führt 
zu einer außergewöhnlich hohen Selektivität und somit in vivo potenziell niedrigen Toxizität 
durch Reduktion unerwünschter Arzneimittelwirkungen. Allerdings basieren alle bisher be-
kannten Interdomänen-Inhibitoren auf demselben chemischen Grundgerüst, und die Identifi-
zierung von neuartigen Leitstrukturen wird durch den Mangel an geeigneten Hochdurchsatz-
methoden ausgebremst. In der vorliegenden Arbeit wird die Entwicklung von iFLiK (inter-
face-FLiK) beschrieben, einem Fluoreszenz-basierten Assay, der solche Interdomänen-
Interaktionen detektieren kann. Die für iFLiK benötigten Proteine wurden anhand kristallo-
graphischer Informationen konzipiert, in Insektenzellen exprimiert und schließlich mit ver-
schiedenen Fluorophoren gekuppelt, um ihre Eignung als Sensoren für Proteinkonformationen 
systematisch zu untersuchen. Zur Etablierung des Assays wurden zudem eine Reihe von Son-
denmolekülen synthetisiert und auf ihre biologische Aktivität in vitro und in BT474 Zellen 
untersucht. Mit iFLiK konnten allosterische Inhibitoren von ATP-kompetitiven unterschieden 
und somit ein Machbarkeitsbeweis erbracht werden, dass solvatochrome Fluorophore zur De-
tektion von Protein-Protein-Interaktionen geeignet sind, wenn der Fluorophor an der korrek-
ten Stelle angebracht ist. Nach sorgsamer und eingehender Assayoptimierung sowie Validie-
rung mit orthogonalen Assaysystemen wurde eine interne Substanzbibliothek mit iFLiK 
durchmustert. Dadurch konnten Verbindungen mit einem neuartigen Grundgerüst gefunden 
werden, die vorher nicht als allosterische Akt Inhibitoren bekannt waren. 
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1 Introduction 
Second only to cardiovascular failures, cancer is still one of the leading causes of death in the 
western world, accounting for 13% of all deaths worldwide in 2008.
1,2
 Prognoses for the  
future project the number of deaths to reach 13.1 million in 2030. The most lethal forms of  
cancer are breast, prostate, colorectal, lung, cervical, pancreas and stomach cancers.
3
 
Hanahan and Weinberg have summarised the characteristics that define cancer: Tumour cells 
grow indefinitely, become independent from growth signals, are able to avoid apoptosis,  
promote increased angiogenesis, possess the ability to invade into foreign tissue, evade  
immune system responses and reprogramme their energy metabolism.
4
 A variety of therapies 
have been developed over the years to address these indications, ranging from surgical  
removal of affected tissue to radiotherapy. Due to the lack of knowledge about the precise 
mechanisms of cancer in the last century, treating patients with chemotherapy had focussed 
primarily on prohibiting cell replication altogether by deploying cytostatic agents. While there 
have been many successful cases of patients recovering from cancer after chemotherapy, it 
has proven ineffective as a general method to cure cancer. In addition, this unspecific  
approach to cancer treatment had severe side effects such as nausea, loss of hair, fatigue and 
anaemia. 
Over the course of the last decade, an increasing understanding of the molecular mechanisms 
that lead to cancer has enabled targeted therapies. Imatinib as a prime example has shown that 
protein kinase inhibitors can be powerful drugs for the effective long-term treatment of  
cancer.
5
 This has put kinases into the focus of modern drug discovery and cancer research. 
1.1 Protein Kinases 
Kinases are enzymes belonging to the class of transferases that catalyse the transfer of the  
γ-phosphate group of ATP onto a substrate, which is one of the most important classes of 
post-translational modifications. In the case of protein kinases, these substrates are other  
proteins and serve as crucial components of signalling pathways. These kinase-catalysed 
phosporylations often change the charge or conformation of their substrates, thereby activa-
ting or inactivating them, influencing the formation of multi-protein complexes or altering 
their subcellular localisation. Kinases have complex functions in the regulation of cellular 
processes such as proliferation, differentiation, metabolism and apoptosis. As their molecular 
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counterparts, phosphatases catalyse dephosphorylation reactions to counteract kinases. Rela-
tively unspecific by themselves, they gain their selectivity in an ensemble of other proteins by 
forming multi-component complexes. 
Misregulation of kinase activity is the cause for many diseases, ranging from Alzheimer’s 
disease, diabetes mellitus and atherosclerosis to Parkinson's disease, obesity and inflammatory 
diseases as well as amyotrophic lateral sclerosis and, most prominently, cancers of various 
kinds. This misregulation can manifest in different forms, e.g. gene amplification or transcrip-
tional changes that lead to overexpression of the protein, altered enzyme activity by mutation 
or a misregulation of the respective phosphatase antagonist. 
1.1.1 Kinase Structure and Regulation 
Albeit diverse in their primary amino acid sequence, the 518 genetically encoded human  
protein kinases are remarkably similar in their three-dimensional structure. The pivotal feature 
of all kinases is the catalytically active kinase domain, consisting of an N-terminal lobe  
(N-lobe), usually containing an array of β-sheets, and a C-terminal lobe (C-lobe) dominated 
by α-helices, both connected via the flexible hinge region. The active site is located between  
these two subdomains, containing the ATP binding pocket, which contacts the hinge region, 
and the adjacent substrate-binding pocket (Figure 1). An (often sterically demanding) amino 
acid is located at the N-terminal end of the hinge region, limiting the size of the binding  
pocket and thusly known as gatekeeper residue. Substrate access to the active site is  
controlled by a flexible loop, the activation loop (A-loop), starting with the conserved amino 
acid sequence Asp-Phe-Gly (DFG). The aspartate is crucial in the coordinative network of 
hydrogen bonds to the phosphate groups of ATP, which is further activated for the catalytic 
transfer onto the substrate by complexation with Mg
2+
. In the active state of a protein kinase, 
this DFG-motif occupies a hydrophobic back pocket adjacent to the ATP binding site next to 
the αC-helix of the N-lobe. In the inactive state, the DFG-motif can swing out of the hydro-
phobic back pocket, resulting in an A-loop conformation that partially blocks the ATP and 
substrate binding site.
6
 In most cases, these conformational changes are the result of phos-
phorylations of residues located within the activation loop, which are responsible for kinase 
activation. However, not all kinases are known to be able to adopt such a DFG-out confor-
mation, and the overall regulation of kinases is much more complex and requires additional 
regulatory elements. 
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Figure 1 Structural features of a typical kinase domain (co-crystal structure of PKA with AMP-PNP shown 
here, PDB code 1ATP). The αC-helix is coloured in cyan, activation loop in magenta, glycin-rich 
loop in yellow and the substrate in dark grey. The ATP analogue AMP-PNP (orange sticks) forms 
hydrogen bonds to the backbone of amino acids in the hinge region. 
While kinase-catalysed phosporylations affect the activity of their substrates, protein kinases 
themselves are often regulated in highly intricate sequences. Apart from the canonical kinase 
domain, in which the aforementioned A-loop phosphorylations determine their catalytic acti-
vity, many kinases also feature additional domains which can regulate their activity. 
One example of such allosteric regulation via regulatory domains is the Abelson murine leu-
kemia viral oncogene homologue (Abl, also known as JTK, p150, Abl1 or c-Abl). Abl is an 
extensively investigated protein kinase, and involved in signalling pathways regulating cell 
proliferation, differentiation and apoptosis, and misregulation of Abl has been associated with 
tumorigenesis.
7
 A prominent example of a malignancy induced by the misregulation of Abl is 
chronic myelogenous leukemia (CML), which is characterised by an increased growth of  
myeloid cells in the bone marrow.
8
 It is caused by the translocation of a segment of the break-
point cluster region (BCR) on chromosome 22 to the Abl gene on chromosome 9, yielding a 
new, fused BCR-Abl enzyme.
9
 This fusion protein shows tyrosine kinase hyperactivity and is 
insensitive to native regulatory signals. In addition to the catalytically active kinase domain, 
Abl possesses an N-terminal cap, two Src homology domains (SH3 and SH2), a DNA-binding 
domain and an actin-binding domain.
10
 The N-terminal cap can be myristoylated, which plays 
a major role in the auto-inhibition of the Abl phosphorylation activity.
11
 X-ray crystallo-
graphy reveals that the myristate moiety is lodged in a deep pocket within the C-lobe of the 
kinase domain and causes a 90° bend of the αI-helix. This bending of residues 518-530  
enables the SH3 and SH2 domains to approach and bind to the kinase domain (PDB entry 
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1OPL).
12
 Mutations of the residues connecting the SH3 and SH2 domain have shown that 
these two domains interact strongly with each other, thereby acting as a rigid clamp on the 
kinase domain.
13
 Upon phosphorylation of Tyr245 by Src-family kinases, the SH domains 
adopt a different association pattern with the kinase domain: The SH2 domain now sits on top 
of the N-lobe, while the SH3 domain appears to be flexible in solution.
14
 In the constitutively 
active fusion protein BCR-Abl, the regulatory N-terminal cap has been replaced, rendering it 
incapable of myristoylation-induced auto-inhibition. 
Another example is the AGC-family member phosphoinositide-dependent kinase-1 (PDK1), 
which is considered a master kinase and upstream activator of many other AGC kinases vital 
for growth factor and insulin signalling such as Akt, S6K, PKC and SGK.
15
 PDK1 was first 
purified and characterised by Alessi et al. in 1997,
16
 and later validated as a potential anti-
cancer drug target.
17
 PDK1 features a catalytically active kinase domain with a hydrophobic 
groove on the N-lobe as well as a PH domain for the recognition of PIP3 and recruitment to 
the plasma membrane.
18
 However, in contrast to the other family members, PDK1 does not 
possess the C-terminal hydrophobic motif (HM) which binds intramolecularly to the hydro-
phobic groove.
19
 Instead, the hydrophobic groove in PDK1 serves as a recognition site for the 
HMs of its substrate kinases.
15
 This recruitment mechanism enables PDK1 to phosphorylate 
the activation loop of the substrate kinase and thereby activating its basal kinase activity.
20
 
After A-loop phosphorylation, the substrate HM is expelled from the PDK1 hydrophobic 
groove, complements with its own hydrophobic groove and fully activates the substrate  
kinase. In 1999, Balendran et al. discovered that the C-terminus of the Protein Kinase C-
related protein kinase-2 (PRK2) interacts with the hydrophobic groove of PDK1, and termed 
it the PDK1-interacting fragment (PIF).
21
 Hence, the hydrophobic groove became known as 
the PIF binding pocket. When treated with PIF, the activity of PDK1 increases dramatically. 
The c-Jun N-terminal kinases (JNKs), comprising the three isoforms JNK1, JNK2 and JNK3, 
are a subgroup of the MAP kinase family and are commonly known as stress activated  
kinases.
22
 Like many members of the MAP kinase family, the activity of JNKs is regulated by 
upstream kinases such as MKK4 or MKK7 via A-loop phosphorylation.
23
 To achieve selec-
tivity in the regulation of MAPKs, their activation is predominantly mediated by scaffolding 
proteins. Originally identified by Whitmarsh et al. in 1998 in yeast two-hybrid cells, the JNK 
interacting protein 1 (JIP1) was found to selectively bind to JNK1 and its upstream activators 
MKK7 and MLK3.
24
 Bringing these enzymes in spatial proximity to each other, JIP1 forms a 
quaternary complex in which MLK3 can phosphorylate MKK7, which in turn activates JNK1. 
Although this demonstrated the physiological role of JIP1 in the activation of JNK1, overex-
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pression of JIP1 has been found to inhibit JNK1 activity, possibly by retaining the JNK1-JIP1 
complex in the cytosol.
25
 In 2004, Heo et al. published the crystal structure of JNK1 in  
complex with pepJIP1, a 11-mer peptide consisting of the sequence which is essential for the 
interaction of JIP1 with JNK1 (PDB entry 1UKI).
26
 The structure showed that pepJIP1 binds 
to the C-lobe of JNK1 and induces a rotation of the N-lobe against the C-lobe by 15°. This 
results in a less ordered activation loop, which might render it more accessible for the  
phosphorylation by MKK7. Recent molecular dynamics simulations suggest that the electro-
static contribution to the free energy of binding of the JNK1-pepJIP1 complex is decisive for 
its high selectivity.
27
  
Like many receptor tyrosine kinases, the epidermal growth factor receptor (EGFR) forms  
homo-dimers in an equilibrium. Binding of the native epidermal growth factor to the extra-
cellular receptor domains stabilise the activated dimeric state, leading to an autophospho-
rylation of the intracellular kinase domains.
28
 Another receptor tyrosine kinase, the insulin-
like growth factor receptor (IGF-1R), consists of two extracellular ligand-binding domains  
(α-subunits) and two cytoplasmic domains (β-subunits).29 The α-subunits are covalently 
cross-linked via disulfide bridges and form a receptor complex that can bind to its native  
ligand IGF-1 and insulin. The β-subunits consist of the transmembrane- and the kinase  
domain. Upon ligand binding, the IGF-1R tetramer undergoes conformational changes, which 
triggers autophosphorylation of its kinase domain, resulting in a gain of IGF-1R phospho-
rylation activity and the initiation of MAPK and PI3K signalling pathways.
30,31
 
The activity of cyclin-dependent kinases (CDKs) is dependent on their binding interaction 
with cyclins, which represents a unique feature throughout the kinome. The various subtypes 
of cyclins (cyclin A, B, D and E in humans) are regulatory proteins that are expressed at  
different stages in the cell cycle, each activating individual CDKs.
32
 CDK2 forms active  
complexes with cyclins A and E. The crystal structure of the CDK2 in complex with cyclin A 
solved by Jeffrey et al. revealed the specific interactions between these two proteins (PDB 
entry 1FIN).
33
 Cyclin A binds firmly and extensively to the N- and C-lobe of the kinase  
domain via hydrophobic and polar interactions. In particular, it binds to the activation loop 
and the so-called PSTAIRE-motif on the αC-helix, causing a 90° rotation of the helix, thereby 
restructuring the ATP binding pocket and stabilising an active conformation. A number of 
cyclin-interacting proteins are known, such as p21WAF1, p57Kip2, p16INK4a, p18INK6 and 
p27Kip1, which function as native CDK inhibitors (CDKIs), representing important tumor 
suppressor proteins. The N-terminal inhibitory domain of the cyclin-dependent kinase inhi-
bitor 1B (p27Kip1 or CDKN1B) was found to bind to the CDK2/cyclin A complex by inter-
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acting with the CDK2 N-lobe and the cyclin A cyclin box, preventing the activation of CDK2 
by blocking the ATP binding pocket (PDB entry 1JSU).
34
 Presumably, other CDKIs exhibit 
similar interactions with their respective target CDK/cyclin complex. 
The mammalian target of rapamycin (mTOR) is a member of the phosphatidylinositol 3-
kinase related kinases (PIKKs) and is involved in the PI3K/Akt/mTOR signalling pathway 
mentioned above. It can form two different complexes with different sets of proteins, the 
mTOR complex 1 (mTORC1) with raptor, mLST8 and PRAS40, and the mTOR complex 2 
(mTORC2) with rictor, mSIN1 and mLST8, each with distinct biological functions.
35
 The 
natural product rapamycin, isolated from the bacterium Streptomyces hygroscopicus, inhibits 
mTORC1 in an allosteric fashion. Mediated by hydrophobic interactions with the 12 kDa 
FK506-binding protein (FKBP12), it forms a complex that is able to inhibit the activity of 
mTORC1 by binding to the C-terminus of mTOR, also termed the FKBP12-rapamycin  
binding (FRB) domain.
36
 Interestingly, FKBP12 does not seem to interact with mTOR direct-
ly, the majority of contacts are formed by rapamycin. Probably, this binding relays conforma-
tional changes throughout mTOR and interferes with mTORC1 complex formation.
37
  
However, the exact inhibition mechanism remains unclear. 
1.1.2 Kinase Inhibitors 
From a pharmacologic perspective, small-molecule kinase inhibitors are ideal reagents for 
perturbing and investigating kinase function at any stage of cellular development.
38
 Variations 
in the kinase inhibitor concentration allow for graded phenotypes and a transient temporal 
control. Such features are essential for quantifying the flux of information that passes through 
molecular networks and for elucidating network architecture and dynamics to, for example, 
assess potentially druggable nodes beyond individual genes and proteins.
39
  
The development of kinase inhibitors traditionally focusses on ATP-competitive small mole-
cules, as all kinases require ATP as a cofactor. However, ATP-competitive inhibitors (or 
type I inhibitors) are generally troubled by selectivity issues, since the ATP binding pocket is 
highly conserved across the whole kinome (Figure 2).
40
 One solution is to target the so-called 
hydrophobic back pocket adjacent to the ATP binding site, which is less conserved and there-
fore offers better chances of selectivity.
6
 By occupying the back pocket, the conserved DFG 
motif is pushed out into the ATP binding region, thus blocking the access of ATP to the hinge 
region, and the activation loop is kept in an inactive conformation, the DFG-out conformation 
(type III inhibitors). Inhibitors that contact the hinge region but also stretch into the hydro-
phobic back pocket are thusly categorised as type II inhibitors. Recently, it has been sugges-
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ted that the increased potency of type II and II inhibitors arise from the increased drug resi-
dence time on the target kinase, as binding such an inhibitor induces and stabilises the inac-
tive conformation, removing it from the equilibrium between the active DFG-in and the  
inactive DFG-out conformation and thereby shifting it towards the inhibited state.
41
 In the 
inactive conformation, dissociation of the inhibitor from the kinase is decreased, as the disso-
ciation trajectory is blocked by residues of the activation loop.
42
 Finally, type IV inhibitors are 
compounds which bind at remote sites on the kinase and regulate its activity e.g. by stabili-
sing inactive conformations.
43
 
   
   
Figure 2 Examples of type I-III kinase inhibitors and their different binding modes in cSrc. Left: Dasatinib 
(PDB code 3G5D) as an example of a type I kinase, occupying the adenine binding region and 
forming hydrogen bonds to the gatekeeper and the hinge region. The activation loop is in the DFG-
in conformation. Middle: The type II inhibitor RL45 (PDB code 3GCQ) occupies both the adenine 
binding region and the hydrophobic back pocket, forcing the DFG motif into an inactive DFG-out 
conformation. Right: The type III inhibitor RL37 (PDB code 3F3U) resides only in the hydro-
phobic back pocket and inhibits by arresting the DFG motif in the DFG-out conformation, which 
thereby blocks binding of ATP. 
The BCR-Abl inhibitor imatinib is the first clinically approved kinase inhibitor. In a high-
throughput screening campaign, compounds of the 2-phenylaminopyrimidine series were 
identified as hits and were further developed into a successful drug.
44
 This immense success 
heralded the beginning of extensive clinical development of kinase inhibitors as anti-cancer 
drugs. As of today, 15 small molecule kinase inhibitors have been approved by the FDA (Ta-
ble 2 and Figure 3): The multitarget type I inhibitors axitinib (trade name Inlyta by Pfizer), 
pazopanib (trade name Votrient by GlaxoSmithKline) and sunitinib (trade name Sutent by 
Pfizer) primarily adress VEGFR and PDGFR, and were approved for the treatment of renal 
cell carcinoma in 2012, 2009 and 2006, respectively. Another type I inhibitor bosutinib (trade 
name Bosulif by Pfizer) targets the BCR-Abl kinase and was approved in 2012 for CML.  
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Crizotinib (trade name Xalkori by Pfizer) is a type I EML4-ALK inhibitor and was approved 
for non-small cell lung cancer in 2011. Dasatinib (trade name Sprycel by Bristol-Myers 
Squibb) is another type I multitarget inhibitor, that was approved in 2006 for prostate cancer. 
The type I EGFR inhibitors erlotinib (trade name Tarceva by Roche) and gefitinib (trade 
name Iressa by AstraZeneca) were approved by the FDA for the treatment of NSCLC in 2005 
and 2003, respectively. The first clinically approved kinase inhibitor imatinib (trade name 
Gleevec by Novartis) inhibits BCR-Abl in a type II fashion, approved in 2001 for the treat-
ment of CML and in 2002 for GIST. The type I inhibitor lapatinib (trade name Tyverb by 
GlaxoSmithKline, approved in 2007) addresses EGFR and HER2 in breast cancer. In 2007 
and 2012, respectively, the type II BCR-Abl inhibitors nilotinib (trade name Tasigna by  
Novartis) and ponatinib (trade name Iclusig by ARIAD Pharmaceuticals) were approved as 
second-line treatment for CML. Ruxolitinib (trade name Jakavi by Novartis) was approved in 
2011 for the treatment of myelofibrosis by inhibiting JAK. The broadband type II inhibitor 
sorafenib (trade name Nexavar by Bayer) was approved for renal cancer in 2005 and liver 
cancer in 2007. The type I inhibitor Vemurafenib (trade name Zelboraf by Roche) targets 
BRAF and was approved in 2011 for the treatment of melanoma. 
Table 2 Summary of current kinase inhibitors approved for cancer treatment by the FDA. RCC = renal cell 
carcinoma. CML = chronic myeloid leukemia. NSCLC = non-small cell lung cancer. ALL = acute 
lymphoblastic leukemia. GIST = gastrointestinal stromal tumor. 
Inhibitor Trade name Company 
Mode of 
action 
Target kinases FDA approval 
Axitinib Inlyta Pfizer Type I VEGFR, PDGFR, cKIT 2012: RCC 
Bosutinib Bosulif Pfizer Type I BCR-Abl 2012: CML 
Crizotinib Xalkori Pfizer Type I EML4-ALK 2011: NSCLC 
Dasatinib Sprycel BMS Type I BCR-Abl, cKIT 2006: CML, ALL 
Erlotinib Tarceva Roche Type I EGFR 2005: NSCLC 
Gefitinib Iressa AstraZeneca Type I EGFR 2003: NSCLC 
Imatinib Gleevec Novartis Type II BCR-Abl 
2001: CML 
2002: GIST 
Lapatinib Tyverb GSK Type I HER2, EGFR 2007: breast cancer 
Nilotinib Tasigna Novartis Type II 
BCR-Abl, cKIT, LCK, 
DDR, PDGFR 
2007: CML 
Pazopanib Votrient GSK Type I VEGFR, PDGFR, cKIT 2009: NSCLC 
Ruxolitinib Jakavi Novartis Type I JAK 2011: myelofibrosis 
Ponatinib Iclusig ARIAD Type II BCR-Abl 2012: CML, ALL 
Sorafenib Nexavar Bayer Type II VEGFR, PDGFR 
2005: RCC 
2007: liver cancer 
Sunitinib Sutent Pfizer Type I VEGFR, PDGFR, cKIT 2006: RCC, GIST 
Vemurafenib Zelboraf Roche Type I BRAF 2011: melanoma 
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Figure 3 Structures of current kinase inhibitors approved for cancer treatment by the FDA. 
While inhibiting multiple kinases has been shown to have therapeutic value in some cases by 
circumventing feedback loops, selective inhibitors are required to understand the function of 
single kinases.
45
 Although a few examples of highly selective ATP-competitive kinase inhibi-
tors exist and highlight the power of modern medicinal chemistry research, in the majority of 
cases, such type I inhibitors are troubled by selectivity issues. Compounds with a purely allo-
steric mode of action offer distinctive advantages that make them particularly interesting for 
research. First, they do not have to compete with the high intracellular levels of ATP, thus 
allowing the identification of weak binders. Additionally, as allosteric binders do not need to 
interfere with interactions to native ligands, the effect of their binding is not limited to inhibi-
tion but can also amplify kinase activity. Understanding the structural details of kinase con-
formational changes eventually allows for the rational design of innovative type II, type III 
and type IV inhibitors and next generation activators, to circumvent the current limitations. As 
regulation of activity can vary greatly among the different kinases, strategies to interfere with 
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such mechanisms are equally diverse. Some general approaches for activation and inhibition 
have been employed such as regulating the cellular translocation of kinases, imitating native 
activators or preventing the formation of active or activated complexes. These regulatory 
mechanisms and structural characteristics of certain kinases have been exploited by small 
molecules, which can allosterically modulate that kinase’s enzymatic activity. Such com-
pounds offer the possibility of achieving high selectivity as these structural features and the 
related regulatory mechanisms are often unique and characteristic to a single kinase or kinase 
family. There exists a great variety in the complex regulation of protein kinase activity due to 
distinct structural features as discussed in chapter 1.1.1, and individual characteristics can be 
exploited and addressed by small organic molecules e.g. to gain selectivity based on structural 
uniqueness (Figure 4).
46
 
 
Figure 4 Examples of allosteric type IV inhibitors: GNF-2: Abl inhibitor, myristoyl agonist, facilitates auto-
inhibition state of Abl by bending of αI-helix. BI-78D3: JNK1 inhibitor, JIP1 antagonist, stabilises 
the inactive JNK1 conformation. 20: PDK1 inhibitor, destabilises active conformation of PDK1. 
MSC1609119A-1: IGF-1R inhibitor, arrests DFG motif in an inactive conformation, disrupts αC-
helix of IGF-1R. Rapamycin: mTOR inhibitor, stabilises mTOR-FKBP12 association, prevents 
formation of the active complex mTORC1. 21: Chk1 inhibitor, interferes with the substrate recog-
nition. ANS: CDK2 inhibitor, displaces αC-helix necessary for cyclin A binding. 25: CDK2 inhi-
bitor, peptidomimetic cyclin antagonist derived from cyclisation of octapeptide HAKRKLFG. 
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As it was described earlier, the activity of protein kinase Abl is regulated by its SH2 and SH3 
domains. In 2006, Adrián et al. reported on a series of N-phenylpyrimidinamines that specifi-
cally inhibited proliferation of BCR-Abl-transformed cell lines.
47
 Biochemical experiments 
and X-ray co-crystal structures of Abl with the most potent inhibitor GNF-2 (18) revealed the 
myristate pocket as its binding site (PDB entry 3K5V).
48,49
 GNF-2 binding induced Abl auto-
inhibition by bending of the αI-helix and resultant conformational fixation of the kinase  
domain by the SH3 and SH2 domains. 
Various scaffolds are known that inhibit Chk1 in a non-ATP-competitive manner (e.g. 
quinazolinone 21).50,51 Follow-up compound development and co-crystal structure analysis 
with Chk1 (PDB entries 3F9N, 3JVR and 3JVS) confirmed the allosteric binding site of these 
inhibitors, forming hydrogen bonds and hydrophobic interactions to the protein surface  
adjacent to the αD-helix at the start of the C-lobe. This shallow binding pocket has been  
priorly described as a substrate recognition site, suggesting that these allosteric inhibitors 
might interfere with the substrate recognition of Chk1.
52
 
 
Figure 5 Archetypical kinase domain (green) with αC-helix (cyan), activation loop (magenta), glycin-rich 
loop (yellow) and ATP binding site (orange spheres) shown in three orientations (front refers to 
conventional display with N-lobe at the top, C-lobe on the bottom and hinge region left). The  
binding sites of a few known type IV inhibitors are highlighted: 20 in PDK1 (red), ANS in CDK2 
(purple), BI-78D3 in JNK1 (blue), 21 in Chk1 (grey) and GNF-2 in Abl (beige). 
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1.2 Akt 
Protein Kinase B (PKB), also known as v-akt murine thymoma viral oncogene homologue 
(Akt) or related to A and C kinase (RAC) is a member of the AGC kinase family. First  
described by Jones et al. in 1991, it was quickly identified as an oncogene, and current phar-
maceutical research dedicates much efforts to developing small molecule inhibitors for Akt.
53
 
Akt plays a pivotal role in signalling pathways responsible for cell survival, proliferation and 
apoptosis, regulating these processes via its downstream targets such as FoxO1, MDM2, p21, 
p27, CREB, GSK-3, Bad and procaspase-9.
54-56
 It is most prominently known as key player in 
the PI3K/Akt/mTOR pathway. The biological role of its three isoforms PKBα/Akt1, 
PKBβ/Akt2 and PKBγ/Akt3 has been examined in knockout mice studies: Knockout of Akt1 
resulted in size reduction of all organs and overall growth, heart defects and general decrease 
of cell proliferation.
57
 Additionally, Akt1
-/-
 mice exhibited a shortened overall lifespan and 
increased susceptivity towards both induced and spontaneous apoptosis.
58
 Akt2-deficient 
knockout mice displayed a diabetic phenotype, unable to regulate blood glucose levels.
59
 In 
the case of Akt3 knockout, attenuated mTOR signalling in the brain and a reduced brain size 
due to a decrease of white matter fibre could be observed.
60,61
 While Akt3 is primarily  
expressed in brain cells, Akt1 and Akt2 are ubiquitously found in all cell types.
62
 An overex-
pression of all isoforms of Akt has been detected in many cancers such as breast, gastric,  
pancreatic, thyroid, colorectal, ovarian, prostate and melanoma.
63-68
 In addition, it has been 
demonstrated that cells overexpressing Akt showed resistance against death signals such as 
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), whereas a knockdown of 
Akt restored their apoptotic capability.
69
 Since Akt activity suppresses proapoptotic signals by 
e.g. FoxO, Bad or caspases, it can cause resistances in cancer cells.
70
 Tumour cells with over-
active Akt showed resistance to treatment by radiotherapy as well as chemotherapy.
71,72
  
Furthermore, in cells exhibiting high levels of Akt in the G1 and G2 stages such as Cdk1AS, 
it has been found that inhibition of Akt led to a restoration of Chk1 activity and damage  
processing capacities by G2 cell arrest.
73
 This shows that hyperactive Akt signalling is  
capable of overriding damage regulation by apoptosis and supports increased proliferation of 
misregulated cells. 
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The molecular structure of the Akt kinase is complex (Figure 10A). In addition to the catalyti-
cally active kinase domain, a domain conserved in overall conformation shared among all 
protein kinases, Akt possesses an N-terminal pleckstrin homology (PH) domain, and a C-
terminal hydrophobic motif. The hydrophobic motif is located at the C-terminus of the protein 
and has a regulatory role for the phosphorylation activity of Akt. 
Named after pleckstrin, a protein found in platelets, Haslam et al. have identified a number of 
proteins that possess segments which exhibited a protein fold resembling pleckstrin.
74
 The 
thusly termed pleckstrin homology domain can be found in some other kinases as well,  
usually in proteins which interact with the cell membrane, namely the Protein Kinase C mu 
type (PKCμ), Bruton's tyrosine kinase (BTK), the IL2-inducible T-cell kinase (ITK), the  
β-adrenergic receptor kinase 1 (βARK/BARK/GRK2/ARBK1/ADRBK1), the tyrosine kinase 
expressed in hepatocellular carcinoma (TEC), the epithelial and endothelial tyrosine kinase 
(ETK/BMX), the resting lymphocyte kinase (RLK/TXK), the Rho-associated protein kinase 
(ROCK) and the phosphoinositide-dependent kinase-1 PDK1. Via its PH domain, Akt binds 
to phosphatidylinositol lipids and is thereby recruited to the membrane. Until recently, it was 
unclear how the domains interacted with each other due to the lack of a crystal structure of the 
full length Akt. Using molecular modelling techniques, surface properties of the two domains 
like electrostatic potential, hydrophobicity and acidity were calculated to predict how they 
might interact with each other.
75
 A few amino acids were thusly identified as crucial for the 
inter-domain interaction. By expressing Akt with an N-terminal EGFP as donor and a  
C-terminal mRFP as acceptor, they could carry out FRET experiments which afforded infor-
mation on the spatial proximity of the PH and kinase domain towards each other. In sub-
sequent mutagenesis studies, they could determine that the exchange of the amino acids iden-
tified in silico did indeed impede the association of the two domains. In 2010, Wu et al.  
published an X-ray crystal structure (PDB entry 3O96), allowing for great insight into the 
structural characteristics of Akt caused by the interplay of the different domains.
76
 
1.2.1 Activation mechanism 
This particular composition of subunits defines the complex regulation mechanism of Akt, 
which is characterised by a multi-step conformational change to gain its phosphorylation  
activity. In its inactive state, the so-called PH-in or closed conformation, the PH domain 
forms tight interactions with the kinase domain via a salt bridge between Glu17/Arg273 and 
hydrogen bonds between Asn53/Asn269, Asn54/Val271, Thr81/Asp292, Thr82/Lys179, 
Lys39/Asp325 and Arg25/Glu322/Asp323/Asn324. In this closed conformation, the PH  
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domain not only buries the access to the ATP binding pocket, but also displaces the αC-helix 
from the side of the allosteric pocket, and locks the activation loop in the inactive DFG-out 
conformation. The hydrophobic motif (and in particular the amino acids Phe469 and Phe472) 
rests in the so-called hydrophobic groove, formed by the residues Ile186, Val187, Val192, 
Leu196, Asn199, Phe217, Leu223 and Phe225 on the N-lobe. 
The signalling cascade is initiated by the activation of the phosphoinositide 3-kinase (PI3K), 
which can be stimulated by external growth factors such as EGF, VEGF, IGF-1 or PDGF 
(Figure 6).
77-80
 PI3K phosphorylates the second messenger phosphatidylinositol (4,5)-bisphos-
phate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which binds to the PH do-
main of Akt. The PIP3 binding pocket of Akt is a groove consisting of the positively charged 
residues Lys14, Arg23, Arg25, Asn53 and Arg86, which form electrostatic interactions with 
the negatively charged phosphate moieties of PIP3.
81
 Upon coordination to PIP3, the overall 
positive charge of the binding pocket is reversed, causing an electrostatic repulsion towards 
the negatively charged residues on the kinase domain, and, as a result, dissociates from it. The 
kinase changes into the PH-out or open conformation, in which the activation loop now lies 
exposed. Consecutively, Thr308 on the activation loop can be phosphorylated by PDK1, an 
upstream kinase of Akt.
16
 Upon phosphorylation, the activation loop moves from the inactive 
DFG-out to the active DFG-in conformation, opening up the ATP binding pocket and effec-
tively initiating the kinase activity of Akt. Further phosphorylation of Ser473 in the hydro-
phobic motif by PDK2 increases this activity by a factor of up to 1000. Yang et al. observed a 
20° rotation of the N-lobe and the C-lobe against each other upon Ser473 phosphorylation.
82
 
It was proposed that this alignment stabilises the protein and augments its phosphorylation 
activity. Ser473 by itself, however, is not sufficient to induce the kinase activity of Akt. This 
has been proven by Vincent et al. in cell studies, in which no downstream targets of Akt were 
found phosphorylated when only Ser473 was phosphorylated, but not Thr308.
83
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Figure 6 Simplified schematic representation of the PI3K/Akt/mTOR signalling pathway: Receptor tyrosine 
kinases (RTK) activate PI3K, which phosphorylates PIP2 (grey box) to PIP3 (yellow box). This 
messenger facilitates the dissociation of the two Akt domains, thereby revealing the activation 
loop (green bar), which can be phosphorylated (red sphere) by PDK1. This activation induces an 
opening of the ATP binding pocket and enables the access of ATP (purple hexagon), leading to 
subsequent phosphorylation of downstream kinases such as GSK-3, FoxO or mTOR. 
To date, the identity of PDK2 is still under debate. Various kinases are being discussed as 
candidates for PDK2, each with supporting evidence. In a screening initiative conducted by 
Chua et al. in 2009 employing RNA interference in breast cancer cell lines, over 90 kinases 
have been found to cause Ser473 phosphorylation.
84
 The rictor-mTOR complex (mTORC2),
85
 
the DNA-dependent protein kinase (DNA-PK),
86
 the integrin-linked kinase (ILK)
87
 and the 
mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2)
88
 are  
being considered the most likely candidates for PDK2, while the possibility of autophospho-
rylation has been abandoned.
89
 In recent publications, it has been suggested that that the 
TANK-binding kinase 1 (TBK1) is involved in Akt activation by phosphorylation of both 
Thr308 and Ser473.
90,91
 
Recent studies show that conformational changes associated with occupation of the ATP 
binding pocket, either by ATP itself of by ATP-competitive inhibitors, arrange Arg273 and 
Lys297 to protect Thr308 from access by the phosphatase PP2A, thereby stabilising its phos-
phorylation.
92
 On the other hand, once the phosphotransfer from ATP onto the substrate has 
occurred, Thr308 is rapidly dephosphorylated due to the low affinity of the resulting ADP for 
the binding pocket. This would suggest that Akt activity is tightly regulated, only allowing 
one catalytic cycle at a time for each activation event, once again demonstrating the physio-
logical importance of Akt activity.
93
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Both Akt and its upstream kinase PDK1 are usually located in the cytosol and the nucleus. 
Upon increase of the basal PIP3 concentration from 50 nM to 5-200 µM, both kinases are  
recruited to the membrane, where PDK1 activates Akt.
94
 With the aid of cellular fluorescence 
imaging, Yoshizaki et al. determined that Akt is already closely associated to PDK1 in the 
cytosol without being phosphorylated.
95
 This shows that PIP3 does not only serve as a second 
messenger to bring these two kinases together, as mere spatial proximity between PDK1 and 
Akt is not sufficient to cause Akt activation, but is vital to cause a structural change of Akt 
necessary for its activation.  This was confirmed separately by Calleja et al. via FRET  
experiments in cells.
96
 
In 2007, a somatic mutation of Akt was found in breast, colorectal and ovarian cancers, where 
the Glu17 residue on the PH domain of Akt was mutated to a lysine.
97
 Since this mutation is 
located near the PIP3 binding pocket, the binding affinity towards phosphatidylinositols 
should be affected. Indeed, in vitro experiments showed that the exchange of the negatively 
charged glutamate to a positively charged lysine increased the affinity of Akt towards PIP2 as 
well. Therefore, no prior activation by PI3K was required anymore for a conformational 
change from the inactive Akt PH-in to the active PH-out conformation. In fact, these E17K 
mutants were found concentrated at the plasma membrane, exhibited higher activity in cells 
and induced leukaemia in mouse models.
98
 
1.2.2 Akt inhibitors 
Over the years, a number of ATP-competitive Akt inhibitors have been developed.
99-101
 Due 
to the high sequence identity in the ATP binding pocket among the AGC kinases, many of 
these inhibitors are derived from previously known PKA and PKC inhibitors (Figure 7). For 
example, the nanomolar PKA inhibitor H-89 displayed low micromolar activity against Akt 
as well. Subsequent optimisation yielded a series of Akt-focussed inhibitors based on this 
quinoline scaffold (e.g. NL-71-101 with a 2.4-fold selectivity against PKA). Docking experi-
ments of PKA inhibitor derivatives afforded a few pyrimidine derivatives that were predicted 
to bind to the Akt ATP pocket.
102,103
 A selection were tested for their biological activity,  
either in LNCaP cells (derived from human prostate adenocarcinoma cells) or in prostate 
mouse tumour models. From a high-throughput screening campaign, a series of pyridinyl-
indazoles were discovered as Akt inhibitors and co-crystallised with a PKA-Akt hybrid.
104
 
Subsequent optimisation resulted in the inhibitor A-443654 that was shown to induce apop-
tosis in MiaPaCa-2 cells.
105
 However, all ATP-competitive Akt inhibitors so far suffer from 
poor selectivity, particularly against other kinases of the AGC family. GlaxoSmithKline were 
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able to bring such an inhibitor (GSK690693) through the preclinical development by optimi-
sing CCT128930, but failed to pass phase I clinical trials, presumably due to off-target  
activity and hence toxic side effects.
106,107
 By addressing issues like low bioavailability and 
oral exposure, Array BioPharma followed up in 2012 with GDC-0068, which is currently in 
phase I trials.
108
 
 
Figure 7 A selection of classical, ATP-competitive Akt inhibitors. 
Although much effort has been put into the development of ATP-competitive Akt inhibitors 
by pharmaceutical companies, their development has been discontinued due to toxicity  
issues.
109
 Owing to its unique activation mechanism, different methods for the inhibition of 
Akt were pursued. 
An alternative strategy to inhibit Akt activity is to prevent its activation by PIP3. Meuillet et 
al. showed that D-3-deoxy-phosphatidyl-myo-inositols such as DPIEL (36) bind specifically 
to the PH domain of Akt with a high affinity and prevent Akt activity in both biochemical and 
cell assays.
110
 They also showed that sulfonamides such as 37 were also able to compete with 
PIP3 and inhibit Akt activation in cells.
111
 There are a number of further allosteric inhibitors 
known such as API-1,
112
 PIA23,
113
 and perifosine,
114
 whose inhibition strategy is mimicking 
PIP3 without effecting an opening of the Akt conformation. All these inhibitors mainly suffer 
from low solubility, aggregation and adverse pharmacokinetic properties.
115
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Figure 8 Allosteric Akt inhibitors, either interacting with the PH domain or with the activation loop. 
Recently, Jo et al. have reported another allosteric Akt inhibitor with a new scaffold and an 
entirely different mode of action.
116
 SC66 (40) and a group of similar compounds were found 
to prevent activation of Akt by PIP3 and translocation to the cell membrane. Instead, SC66 
primed Akt for ubiquitination and thereby proteosomal degradation in the pericentrosomal 
region. This is in conflict with findings that ubiquitination of Akt via Lys63 was detected in 
cases of breast and colon cancer, where it facilitated its activation.
117
 Interestingly,  
co-treatment with another allosteric inhibitor reduced the degradation of Akt. The exact  
binding mode of SC66, however, is unknown so far. 
During a high-throughput screening, Toral-Barza et al. have discovered that pyranonaphtho-
quinones (PNQs) such as the antibiotic lactoquinomycin (42) are potent inhibitors of Akt with 
a high selectivity against the related PKA and PKC kinases.
118
 Based on a novel scaffold, it 
exhibited a non-ATP-competitive, time-dependent mode of inhibition. By employing C296A, 
C310A and C29A/C310A mutants of Akt, they determined a dependence on the presence of 
Cys296 and Cys310 in the activation loop, as the PNQs only showed weak inhibition on the 
single mutants and no inhibition on the double mutant. As the time dependency implied an 
irreversible alkylation of the thiol residues via lactone opening, they later verified the addition 
of the PNQ to Cys310 by UV/Vis spectroscopy and mass spectrometry after tryptic digest.
119
 
It was reasoned, that the inhibitory activity of the PNQs might stem from either interfering 
with the substrate binding or facilitating an inactive conformation. 
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1.2.3 Allosteric Inter-Domain Akt Inhibitors 
In 2005, Lindsley et al. reported on the discovery of an Akt inhibitor with a novel scaffold 
from a high throughput screen (compound 45, from now on referred to as inter-domain or ID 
inhibitors).
120
 Unlike previous, ATP-competitive Akt inhibitors, this quinoxaline exhibited 
high selectivity against other closely related kinases of the AGC family such as Protein  
Kinase A (PKA), Protein Kinase C (PKC), Protein Kinase G (PKG), the serum-and gluco-
corticoid-induced protein kinase (SGK), PDK1, 70 kDa ribosomal protein S6 kinase 1 (S6K) 
and the ribosomal s6 kinase (RSK). Furthermore, it is the first Akt inhibitor, that displayed 
selectivity against the three Akt isozymes (IC50 Akt1: 3.4 µM, Akt2: 23 µM, Akt3: >50 µM). 
Remarkably, 45 only showed inhibitory activity against the full length kinase and no activity 
on the Akt kinase domain alone. This led to the assumption that the inhibitor might interact 
with structural features only present when PH and kinase domain come together. However at 
that time, no crystal structure of the full length protein had been published, so the interactions 
of the domains with each other and of the inhibitor-complex remained unknown. 
 
Figure 9 A selection of previously developed ID inhibitors. The nomenclature of the substituents’ orienta-
tion is indicated on the left. 
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In the following years, a number of inhibitors based on the initial hit have been synthesised in 
an attempt to establish an SAR and increase their activity, isozyme selectivity, solubility and 
bioavailability, leading to a number of inhibitor patents (Figure 9).
121-125
 The northern ring 
nitrogen of the central scaffold was quickly determined to be crucial for the inhibitory  
activity, as well as a methylene-bridged amine at the northern phenyl ring. Furthermore,  
extensive central aromatic rings exhibited better activity than a single heterocycle. As a wide 
range of groups transpired to be tolerated at both the western and the eastern ends, it soon led 
to the theory that the allosteric binding pocket might be open to both sides. The PIF binding 
pocket of Akt was speculated as possible binding pocket, with the two phenyl groups imita-
ting Phe469 and Phe472 of the Akt C-terminus. In light of the tight patent space, efforts were 
made to find alternative solutions. ImClone Systems had some success in exchanging the  
crucial phenyl groups against bioisosteric thiophene and furane rings.
126
 Due to the high  
hydrophobicity of the inter-domain pocket, all inhibitors have suffered from severe solubility 
issues. With this particular goal in mind, alternative scaffolds were explored by Kettle et al. 
and specifically tested for their solubility in aqueous solutions.
127
 And indeed, some of these 
heterocycles showed improved solubility while retaining some affinity for the allosteric  
pocket. 
Based on these SAR data and mutagenesis studies, evidence for the possible binding mode of 
these ID inhibitors was mounting.
128,129
 In 2009, Calleja et al. used molecular dynamics  
experiments to calculate how the PH and kinase domain would interact with each other in the 
full length Akt.
130
 Their simulations predicted the induction of a 9 Å wide cavity in the kinase 
domain near the hydrophobic groove by Trp80 in the PH domain, which was previously  
already identified to be vital for the binding of ID inhibitors to Akt. Docking of Akti-1/2 (49), 
one of the most used ID inhibitors at that time, indeed placed the inhibitor firmly inside the 
predicted cavity. In 2010, however, the publication of an X-ray crystal structure of full length 
Akt in complex with Akti-1/2 showed that, in fact, when the two domains came together,  
major reorganisation of the PH domain not predicted by the MD simulations enabled the  
formation of a new binding pocket at the domain interface (Figure 10).
76
 The ID inhibitor was 
sandwiched in between, forming π-π-interactions with Trp80 and hydrogen bonds to both 
domains, thereby stabilising a closed conformation, in which the ATP binding pocket is both 
inaccessible and disordered. In the co-crystal structure of Akt with an inter-domain inhibitor 
based on another scaffold, this arrangement of the domains in the full-length Akt was  
confirmed by Ashwell et al.
131
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Figure 10 A) X-ray crystal structure of the full length Akt in its closed conformation, co-crystallised with 
Akti-1/2 (PH domain red, kinase domain green, Akti-1/2 orange, PDB entry 3O96). B) Magni-
fication of the domain interface. Important interactions are highlighted and marked in the respec-
tive darker colour. C) Allosteric inhibitor occupying unique binding pocket at the interface of the 
Akt PH and kinase domain, forming π-π-interactions with Trp80 and hydrogen bonds with Asn54, 
Ser205, Lys268, Val271 and Trp272. 
As these inhibitors were isoform-selective Akt inhibitors, they finally enabled assessment of 
the role of the three isozymes and the physiological effect when inhibited individually. It was 
found that inhibiting both Akt1 and Akt2 had a higher apoptotic effect than inhibiting either 
of these isozymes alone.
120
 The induced apoptosis by inhibiting Akt1 and Akt2 could not be 
compensated by an upregulation of Akt3.
132
  
 
Figure 11 Overview of different inhibition modes of Akt: A) Classical ATP-competitive inhibitors (orange 
hexagon) occupies ATP binding pocket. B) Allosteric ID inhibitors (blue circle) bind into a unique 
pocket at the domain interface, locking them in a closed conformation. C) PIP3 antagonists (brown 
box) bind into the phosphate pocket at the PH domain and prevent the activation by PIP3. 
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In 2009, one of these ID inhibitors, the orally available MK-2206 (50), entered clinical phase 
I trials.
133
 So far, this drug showed good efficacies in treating tumours.
134
 A combined treat-
ment of non-small cell lung cancer with MK-2206 and erlotinib even showed promising ef-
fects in patient populations with resistances.
135
 MK-2206 entered phase II in April 2011 for 
the treatment of various cancers. In comparison to preceding Akt inhibitors, which all failed 
in the clinic, it exhibits superior selectivity, good pharmacodynamic properties, and is well 
tolerated in clinical studies.
136
 These favourable characteristics are owed to its allosteric mode 
of action by occupying the unique pocket at the domain interface of PH and kinase domain. 
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1.3 Fluorescence 
Fluorescence describes the emission of electromagnetic particles at a longer wavelength than 
the excitation wavelength, traditionally in the human visible range of the electromagnetic 
spectrum. It occurs predominantly in more rigid compounds, as the energy cannot be easily 
dissipated via radiationless thermal relaxation. Upon excitation, electrons are promoted from 
the S0 to the S1 state, where vibrational relaxation leads to loss of energy (usually within pico-
seconds) before returning back to the S0 ground state. This energy difference between  
excitation and emission is called the Stokes shift. A special case of fluorescence is phospho-
rescence, in which the S1 and T1 states overlap to some degree, so that excited electrons  
undergo a inter-system crossing from the singlet to triplet state. Since the direct relaxation 
from T1→S0 is a spin-forbidden process, the lifetime of this T1 state can last up to seconds, 
whereas fluorescence typically occurs on a nanosecond time scale.
137
 
 
Figure 12 Jablonski scheme for explaining fluorescence: Absorption from S0 ground state followed by rapid 
radiationless vibrational relaxation (internal conversion) and subsequent relaxation accompanied 
by emission of photons. Inter-system crossing from singlet S1 to triplet T1 state leads to a spin-
forbidden T1-to-S0 and hence slow relaxation. 
Depending on the experimental setup, competition with background luminescence signals can 
be eliminated, enabling the detection of fluorescence with a very high sensitivity and at much 
lower intensities than mere absorption. Measuring fluorescent signals can be quick and easy, 
and does not require elaborate instruments or meticulous safety precautions. Therefore, it has 
become the favourite analytical tool in the biological sciences. 
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1.3.1 Solvatochromic Fluorophores 
Fluorescence is a highly dynamic phenomenon that can be sensitive to environmental  
influences. For example, some fluorophores are sensitive to the solvent pH, as protonation 
changes conformation and electronic distribution, and therefore the fluorescence properties of 
the molecule. Fluorescein, the best known pH-sensitive fluorophore, loses its fluorescent  
capability below pH 4.2 as its carboxylate group gets protonated, hence disrupting the conju-
gation of π-electrons.138 Other fluorophores can quantitatively detect the presence of inorganic 
salts such as Ca
2+
 and Cl
-
 by measuring the quenching kinetics.
139
 These probes often feature 
a recognition site for the respective analyte and can be specific to a particular binding partner. 
As a more general principle, the polarity of the solvent can be detected by fluorophores that 
exhibit a different dipole moment in the excited state than in the ground state. Following exci-
tation and vibrational relaxation, the surrounding solvent molecules have to adapt to the new 
electric energy field (usually in the range of around 40 ns). This reorientation requires 
an energy transfer from the fluorophore to the surrounding molecules, resulting in a change of 
the energy levels (termed S1
*
 and S0
*
). Usually, the energy gap between S1
*
 and S0
*
 states 
reduces with higher solvent polarity, leading to a bathochromic shift (red-shift), also called 
positive solvatochroism. However, the opposite, negative solvatochroism, i.e. a hypsochromic 
shift (blue-shift) upon polarity increase, has been observed as well. By accounting for mole-
cular volume, solvent polarity and refractivity, Lippert and Mataga have derived a formula to 
calculate the excited dipole moment (equation (1)).
140
 In the resultant Lippert plot, a linear 
dependence of the Stokes shift and the solvent polarity can be observed. 
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(1) 
Δν = difference in wavenumbers between excited and ground state 
μE = dipol moment of fluorophore excited state μG = dipol moment of fluorophore ground state 
c = light speed = 299792458 m/s   h = Planck constant = 6.626 ∙ 10-34 Js 
η = solvent refractive index D = solvent dielectric constant V = fluorophore volume 
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Figure 13 Effect of solvent reorientation on the fluorescence energy states, leading to the S1
* state, which 
relaxes to S0
* before returning to S0 after solvent reorientation. 
In addition to the general polarity, fluorophores can also form specific solvent interactions.
141
 
2-Anilinonaphthaline, for example, experiences a 30 nm shift of its emission spectrum upon 
addition of 3% EtOH into an aqueous solution. While this amount of ethanol is insufficient to 
change the bulk polarity of the solution, the EtOH molecules associate with the fluorophore, 
thereby stabilising either the ground or excited state. In these cases, the Lippert plot of these 
fluorophore-solvent pairs will give misleading results. 
1.3.2 Förster Resonance Energy Transfer 
Förster Resonance Energy Transfer (FRET), also known as Fluorescence Resonance Energy 
Transfer, can occur when the emission spectrum of one fluorophore (the donor) overlaps with 
the excitation of another (the acceptor) and are sufficiently close together.
142
 In consequence, 
excitation of the donor leads to an emission of the acceptor. The rate of transfer is propor-
tional to the spectral overlap of donor emission and acceptor excitation (also determined by 
the donor fluorescence quantum yield and acceptor extinction coefficient), and the orientation 
and distance between donor and acceptor. Hence, the Förster radius, which is the distance of 
half-maximal energy transfer, can be calculated with equation (2). The orientation factor κ can 
only be reliably determined via X-ray crystallography or NMR.
143
 In practice, κ2 is assumed 
2/3 as a temporal mean value due to random motion of the fluorophores, and η = 1.4 for 
aqueous solutions.  
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(2) 
R0 = Förster radius    κ = orientation factor 
N = Avogadro constant = 6.022 ∙ 1023 mol-1  η = solvent refractive index 
ΦD = donor fluorescence quantum yield  εA = acceptor extinction coefficient 
 
Figure 14 For the occurrence of Förster resonance energy transfer, the emission spectrum of the donor (solid 
blue line) has to overlap with the acceptor excitation spectrum (dotted red line). 
As it becomes apparent from the equation above, the FRET efficiency is strongly dependent 
on the distance between the fluorophore pair and decays quickly at a rate to the power of 6. 
When selecting the donor-acceptor pairs accordingly, this steep efficiency-distance corre-
lation can be utilised as a molecular ruler that is able to provide very precise readings. In the 
biological sciences, however, the FRET phenomenon is mostly employed to detect whether 
two fluorescently labelled partners are in proximity or not. For simplification, the Förster  
radius is usually considered as the cutoff distance for the occurrence of FRET. 
Radiationless FRET is one of the main causes of fluorescence quenching, as it does not  
require the direct contact between the fluorophore and quencher like in the case of collisional 
quenching. 
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1.4 Assay Technologies 
The effect of an analyte on a biological system is the fundamental question that guides  
research in chemical biology and drug discovery. Studies on the whole target organism are 
often low throughput and are plagued by considerable complexity and unpredictability. There-
fore, simplified models are required for the earlier stages of research (e.g. preclinical phases 
in the case of drug development). In order to reduce their complexity, biological systems need 
to be broken down into smaller increments to answer questions about specific interactions 
within the entire complex network. While these simplifications represent an abstraction of the 
actual biological problem, these minimal interactions can still viably offer answers about the 
whole system. As a result, biochemical in vitro assays can still provide meaningful results 
when designed correctly, and can be a powerful tool for obtaining biologically relevant data. 
In the context of molecular biology, protein-ligand interactions are one of the key aspects of 
interest. They are characterised by parameters such as the dissociation constant, which is  
defined in equation (3) and describes the strength of a particular receptor-ligand complex, i.e. 
the binding affinity of a ligand for its receptor. For inhibitors, the concentration of half-
maximal inhibition (IC50) denotes the inhibitory potency of a compound and is a phenotypical 
yet standard parameter. 
 
   
     
   
 (3) 
cP = concentration of free protein   cI = concentration of free inhibitor 
cPI = concentration of protein-inhibitor complex 
The reliability and reproducibility of assays are often described by the Z-factor, which is a 
parameter based on the variation and relative differences of the assay’s minimal and maximal 
responses. This is achieved by including appropriate positive and negative controls to induce 
each response. Thus, the Z-factor characterises the capacity of an assay to react to changes in 
the desired biological system of interest. Assuming a normal Gaussian distribution of results, 
values are considered significant when exceeding 3 times standard deviation of the same sam-
ple. Therefore, the Z-factor is described by equation (4). A Z’-factor between 0.5 and 1 is 
generally considered ideal for high-throughput screening.
144
 While the Z-factor is a feature 
size describing the absolute capacity of an assay, the deductive Z’-factor is calculated from 
the positive and negative controls in each round of a screening scenario. 
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(4) 
μp = mean positive controls   μn = mean negative controls 
ζp = standard deviation positive controls  ζn = standard deviation negative controls 
1.4.1 KinEASE 
There are a variety of methods to measure kinase activity, such as the radioactive EasyTides 
assay by PerkinElmer
145
 or the LanthaScreen,
146
 Adapta,
147
 Omnia
148
 and Z'-LYTE
149
 assays 
marketed by Life Technologies. One of the most commonly employed assays is the KinEASE 
assay by Cisbio based on the HTRF (homogeneous time-resolved fluorescence) 
technology.
150,151
 KinEASE is a universally applicable method that indirectly measures the 
phosphorylation of promiscuously binding, biotin-labelled substrate peptides, either carrying 
a tyrosine (TK) or serine and threonine (STK1, STK2 and STK3). After incubation with the 
protein, ATP and MgCl2, the reaction is quenched by complexation of Mg
2+
 with EDTA, and 
visualised by incubation with a solution of streptavidine conjugated to the fluorophore XL665 
and an anti-phospho-tyrosine or anti-phospho-serine/phospho-threonine antibody conjugated 
to a europium cryptate fluorophore (Figure 15). If the peptide is phosphorylated, the two 
fluorophores are in close proximity (in this case within 90 Å) to each other, so that excitation 
of the donor europium at 317 nm leads to an emission of the acceptor XL665 at 665 nm via 
FRET. The ratio of fluorescence intensities at 665 nm (XL665) and 620 nm (europium  
cryptate) is equivalent to the degree of substrate phosphorylation and therefore kinase activity. 
Due to shielding of the f-electrons from oxygen quenching by the cryptate ligand, low  
extinction coefficients and spin-forbidden f-f-transistions, lanthanide fluorescence has a  
remarkably long lifetime of about 150 µs.
152
 Measuring the fluorescence after a delay of at 
least 40 µs, therefore, is instrumental to avoid extrinsic fluorescence by the analyte or buffer 
ingredients, and hence minimises background fluorescence. 
 
Figure 15 Assay principle of KinEASE: Using ATP as co-factor, the respective kinase transfers a phosphate 
(red) onto an artificial substrate peptide (yellow) with an N-terminal biotin tag (grey). After the 
phosphorylation reaction, the donor fluorophore (blue) conjugated to a phospho-specific antibody 
transfers energy onto the acceptor fluorophore (red) attached to streptavidin. 
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1.4.2 Fluorescent Labels in Kinases (FLiK) 
Kinase regulation is inevitably linked to conformational changes of structural elements  
particularly in the ATP binding pocket. In the FLiK assay, developed by Jeffrey Simard in our 
group, the solvatochromic fluorophore Acrylodan is introduced via Michael addition onto a 
cysteine to detect changes in its environment.
153
 In order to attach Acrylodan to the desired 
position and to avoid multi-labelling, all surface-exposed cysteines were mutated to serine, 
while a cysteine mutation was introduced to the position of interest. FLiK reports on confor-
mational changes induced by the binding of specific types of ligands and does not require 
kinase activity.
154
 In using the inactive form of the kinase, weak binders are more sensitively 
identified than in activity-based assays. To date, FLiK has been used to successfully monitor 
conformational changes of the A-loop and the glycin-rich loop associated with the slow  
binding of DFG-out binders as well as a method for identifying more selective allosteric  
ligands (type IV), including assays for the MAP insert pocket of p38α as well as the myristate 
pocket of Abl kinase.
155,156
 Recently, we were able to show that the same principle are  
applicable to phosphatases as well by detecting the binding of inhibitors against the protein 
tyrosine phosphatase 1B (PTP1B) with the FLiP assay (Fluorescent Labels in 
Phosphatases).
157
 
 
Figure 16 Assay principle of the FLiK assay: Binding of ligands into the ATP binding pocket induce con-
formational changes, which can be picked up by attaching the environment-sensitive fluorophore 
Acrylodan to either the glycin-rich loop (yellow) or the activation loop (magenta). Both loops  
undergo major reorientations upon ligand binding, often accompanied by a transition from DFG-in 
to DFG-out. This causes a dose-dependent change in the Acrylodan emission spectrum. 
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1.4.3 NanoTemper 
In a temperature gradient, molecules migrate from the warm to the cold region due to an  
increased Brownian motion.
158
 This phenomenon is known as thermophoresis, and the diffu-
sion velocity is dependent on the molecules’ hydrodynamic properties, mainly determined by 
their charge, hydrodynamic radius, shape and hydrational state. As these properties generally 
change upon binding of a ligand, the different diffusion velocities can be utilised to determine 
the binding state of a protein-inhibitor complex. With a steepening of the temperature  
gradient, these differences in velocity become more distinct. However, to avoid damage to the 
sensitive proteins, the temperature must not be so high as to induce thermal degradation of the 
proteins of interest. Consequently, in the NanoTemper assay by NanoTemper Technologies, 
this temperature gradient is produced by an IR laser, which produces a temperature difference 
of about 8 K over a distance of 150 µm inside a capillary (Figure 17).
159
 This microscale 
thermophoresis (MST) allows for a steep gradient under mild conditions. In order to selec-
tively track its movement the protein of interest is previously labelled unspecifically with a 
fluorophore, and the depletion of protein from the heat source can be followed by a decrease 
in fluorescence intensity. 
 
Figure 17 Assay principle of the NanoTemper assay: A protein solution in a capillary is heated up with an IR 
laser, creating a steep temperature gradient. Due to increased Brownian motion, the protein diffuse 
from the warm to the cold region. Their depletion can be followed selectively by fluorescence. 
 
  
 Introduction 31 
 
1.4.4 Biacore 
Surface plasmon resonance (SPR) is able to detect changes on a surface (e.g. thickness, 
roughness or composition), as these modulate the propagation of plasmons across a metal 
surface layer and therefore the refractive properties of that particular surface to incoming elec-
tromagnetic waves.
160
 In the Biacore assay by GE Healthcare, this phenomenon is utilised to 
detect ligand binding to a receptor by immobilising the protein onto a gold chip and monitor 
the refraction intensity of a laser at a fixed angle. As the inhibitors bind to the protein, the 
increase in mass is detected in real time, providing kinetic information on the association and 
dissociation from the protein-inhibitor complex.
161
 One drawback of this method is the pro-
tein immobilisation, as this can potentially interfere with ligand binding and therefore lead to 
false results. 
 
Figure 18 Assay principle of the Biacore assay: Ligand molecules (blue) dissolved in a buffer are passed in a 
laminar flow over a gold-coated surface (orange), binding to proteins (green) immobilised on this 
surface. This binding event and resultant mass increase changes the resonance of surface  
plasmons, thereby altering the refraction properties of an incoming laser (red). This can be  
detected by a signal increase at a fixed detector angle. 
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2 Aims and Objectives 
As it was demonstrated in the introduction, protein kinases are an attractive target for drug 
development (chapter 1.1). Many kinases are regulated via complex interactions with other 
proteins or low-molecular-weight ligands. Such interactions are often unique for a particular 
kinase or kinase family, which offers a chance of selectively modulating these kinases by  
addressing these characteristics with small molecules (chapter 1.1.1). 
One such example is the kinase Akt, which represents an important target in oncology and is 
known to be addressable by allosteric inhibitors (chapter 1.2). The clinical success of the  
candidate compound MK-2206 suggests a high therapeutic window for the inhibition of Akt 
with allosteric ID inhibitors (chapter 1.2.3). All known allosteric Akt inhibitors to this day, 
however, are based on the hit compound 45, that was discovered by chance in a high-
throughput screening campaign, in which it only inhibited full length Akt. The parallel  
screening of compounds against both full length Akt and the Akt kinase domain in activity-
based assays has remained the only method so far to reliably identify ID inhibitors. Recent 
studies indicate that allosteric inhibitors have a lower affinity and slow binding kinetics  
towards the active Akt.
162
 Activity-based assays are therefore prone to missing weak binders. 
In summary, there is currently no assay system that allows the selective screening for  
allosteric Akt inhibitors. 
In order to identify even low-potency compounds in a facile way, a novel assay system is 
needed that can report on the binding of ligands directly and that does not require the  
activated Akt. The aim of this thesis is to develop such an assay, that can detect the conforma-
tional changes within Akt and interactions between its regulatory PH domain and its catalyti-
cally active kinase domain, which are associated with the binding of allosteric ID inhibitors. 
This rationally designed assay will enable the targeted search for inter-domain inhibitors with  
novel scaffolds in the high-throughput screen of large libraries. To this end, the following 
steps have to be taken in the process: 
  
 34 Aims and Objectives 
 
1. Structure-guided assay design: As the assay should exploit the conformational changes 
of Akt, the assay design will be based on structural information about Akt. 
2. Protein expression and purification: On the one hand, the assay will require proteins 
bespoke engineered for detecting the conformational changes of Akt. These proteins 
will be expressed in insect cells and purified. 
3. Synthesis of probe molecules: On the other hand, reference compounds will be needed 
in order to validate the assay. Therefore, a focussed library of small molecules based 
on scaffolds of known inhibitors will be synthesised to be used as tool compounds. 
4. Assay development and optimisation: With the necessary components in hand (pro-
teins and probe compounds), proof-of-concept experiments will show whether this  
assay principle is able to provide the desired readout on the biological phenomenon of 
interest, i.e. reporting on the binding of allosteric Akt inhibitors and the resulting  
conformational changes. Subsequently, the assay will be optimised for future use in 
high-throughput screens. 
5. Assay validation: In order to validate the results obtained from this novel assay,  
orthogonal test systems based on different physical principles will be established and 
employed to measure the probe compounds. 
6. High-throughput screening: Following this assay optimisation and validation, various 
libraries will be screened for novel inhibitors. The resultant hits will be validated for 
their biological effect in vitro. In subsequent follow-up studies, other derivatives based 
on this new scaffold will be investigated to gain insight on their SAR and binding 
mode with Akt. 
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3 Results and Discussion 
3.1 Assay Design 
As it was described in the introduction, the activation of Akt is regulated via multiple mecha-
nisms. In addition to the more common regulation by phosphorylation and associated confor-
mational changes of the activation loop, the PH domain plays a major regulatory role by  
covering the kinase domain and thereby obstructing access to the ATP binding pocket. This 
inactive conformation is stabilised by ID inhibitors which bind into an allosteric pocket at the 
interface between the two domains, forming a number of interactions to both domains. 
For our novel assay, we set out to use environmentally sensitive fluorophores to detect Akt 
changing from the active open to the inactive closed conformation (Figure 6). In order to 
achieve the highest possible sensitivity, the reporter fluorophore has to be introduced close to 
the domain interface without disrupting the inter-domain interactions. At that time, no crystal 
structure of the full-length Akt had been published. However, through mutagenesis studies 
and calculations of surface polarity, electrostatic charges and acid-base reactions, Calleja  
et al. have identified residues 17-19, 50-52, 54-56, 58-61, 76 and 85 on the PH domain, and 
residues 185, 187-190, 320-324, 353-356, 358-359 and 362-363 on the kinase domain to be 
part of the domain interface (Figure 19).
96
 
 
Figure 19 X-ray crystal structures of the PH (red) and kinase domain (green) alone (PDB entries 1UNP and 
3CQW, respectively). The αC-helix (cyan), a-loop (magenta) and PIP3 binding pocket (beige) are 
highlighted. Amino acid residues known to be involved in the inter-domain interaction are marked 
in the respective darker colour. The residue Glu49 (purple) close to the domain interface on the  
PH domain was chosen as labelling position. 
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Analysing their data on the interaction between PH and kinase domain, we determined Glu49 
as a suitable labelling position for the reporter fluorophore. In retrospect, the subsequently 
published X-ray crystal structures of the full-length Akt (PDB entries 3O96 and 4EJN)  
confirmed that Glu49 is indeed sufficiently close to the domain interface.
76,131
 
In proteins, cysteine residues are sufficiently reactive and relatively rare, making them the 
residue of choice to covalently attach the reporter fluorophore. The 480 aa Akt1 protein fea-
tures 7 native cysteines: Cys60 and Cys77 form a disulphide bridge in the interior of the  
PH domain, Cys224 is part of the N-lobe and buried as well, whereas Cys296, Cys310, 
Cys344 and Cys460 are surface exposed, as X-ray crystal structures of the individual domains 
reveal. For a selective labelling of the reporter fluorophore to the desired position, three  
kinase constructs were designed for the conformation assay (Figure 20): 
- de91 comprises amino acids 1-446 of Akt1. An E49C mutation was introduced into 
Akt1 and all surface-exposed cysteines were removed (C296S, C310S, C344S) to 
avoid undesired labelling. Serine was chosen as a replacement for the original cysteine 
as it resembles it the most in terms of electrostatic and steric properties. This truncated 
construct lacks the C-terminal hydrophobic motif, which is known to undergo addi-
tional conformational changes that might interfere with the reporter fluorophore.  
Furthermore, it was hypothesised that removing the flexible hydrophobic motif would 
facilitate crystallisation of the protein. 
- pHT1023 encompasses the complete Akt1, also with the artificial E49C mutation and 
all surface-exposed cysteines removed (C296S, C310S, C344S, C460S). 
- de92 also includes the full length sequence of Akt1, differing from pHT1023 by  
retaining Cys460 in the hydrophobic motif, which is known to have a regulatory  
function for Akt. Therefore, the strategy with this construct is to keep as close to the 
wild type sequence as possible. 
 
Figure 20 The three constructs designed for the novel conformational assay. 
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3.2 Protein Production 
3.2.1 Protein Expression in Insect Cells 
The three constructs described above were cloned into pREN4427-HIS-DEST vectors with an 
N-terminal His6-Tag and a recognition sequence for cleavage by the Tobacco Etch Virus 
(TEV) protease, which were provided by Dr. Mark Schütte from Merck KGaA. In the next 
step, a baculovirus was generated from this vector by assembling the virus in adherent Sf21 
cells. After harvesting the thusly generated virus from the supernatant after centrifugation, the 
virus was amplified in TriEx Sf9 cells to achieve a higher virus concentration. 
For determining the virus titer, the insect cells were grown onto a polymer surface and  
infected with the respective viruses. After 45 h, the cells were subsequently treated with an 
anti-gp64 mouse antibody, an anti-mouse antibody/HRP conjugate and finally a Blue  
Peroxidase substrate. The virus hull protein gp64 is detected in this assay, causing a blue 
staining of infected cells via substrate oxidation (Figure 21). From the proportion of stained to 
unstained cells, which can be counted under the microscope, the virus titer is calculated:  
de92 = 5 · 10
7
 IFU/mL; pHT1023 = 1 · 10
7
 IFU/mL; de91 = 6 · 10
7
 IFU/mL. 
    
Figure 21 Microscope picture of TriEx Sf9 cells after incubation with a 1/10,000 diluted baculovirus solution 
for 45 h and immunostained with an anti-gp64 antibody and a Blue Peroxidase substrate, taken at 
10x (left) and 40x (right) magnification. 
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For the virus amplification, a low MOI (multiplicity of infection) and long incubation times 
are usually preferred to generate the maximum amount of virus from a virus aliquot.  
However, virus particles in high passages are known to become defective, losing their ability 
to induce protein expression while still being infectious. Therefore, virus solutions should be 
amplified from low-passage viruses that were frozen and stored at -80 °C. On the other hand, 
for the expression of proteins, the optimal conditions to obtain the maximum protein yield 
have to be found for each virus and cell combination. While it is obvious that a low MOI and 
short incubation times will not generate much protein, proteins could be lost at a high MOI 
and long incubation times as the infected cells eventually burst and release the protein into the 
medium. 
In order to optimise expression conditions, test expressions on a 20 mL scale were prepared 
for each virus. Various permutations of incubation time and MOI were assessed by transfec-
ting TriEx Sf9 cells with different amounts of virus and taking samples at fixed intervals. 
MOIs were covered over the large range of about 2 orders of magnitude. The samples were 
analysed for their protein content via unspecific Coomassie Brilliant Blue staining and His5-
specific Western Blot, which is specific for the desired protein as no proteins with such a se-
quence have been detected in the native Spodoptera frugiperda proteome so far (Figure 22). 
From the various small-scale test expressions, the optimal expression conditions were deter-
mined to be: 
- de92: 48 h at MOI = 3 
- pHT1023: 72 h at MOI = 0.5 
- de91: 72 h at MOI = 0.3 
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Figure 22 CBB-stained gels (left) and Western Blots (right) with an His5-specific antibody and a chromogen-
ic substrate of test expressions with de92 (top), pHT1023 (middle) and de91 (bottom) viruses. 
Bands are separated according to respective MOI and incubation times. PageRuler Plus Prestained 
by Fermentas was used as marker. Molecular weight is displayed in kDa. The molecule masses of 
interest are 59 kDa for de92 and pHT1023, and 55 kDa for de91. The lysate from uninfected TriEx 
Sf9 cells was used as negative control in the CBB-stained gels. An N-terminal His6-tagged Abl 
construct was used as positive control for the Western Blot. M = marker; neg = uninfected TriEx 
Sf9 cells; AblK = His6-tagged Abl construct. 
In the end, all three constructs were expressed in TriEx Sf9 cells at the conditions described 
above in 2 L insect cell medium each. The cells were centrifuged, and the cell pellet collected 
and stored at -80 °C for purification. 
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3.2.2 Protein Purification via FPLC 
All three kinase constructs were purified in the same manner: After ultrasonic and pressure-
assisted cell lysis, the desired protein was concentrated via Ni
2+
 affinity chromatography from 
the lysate. Competitive elution with a step-wise concentration increase of imidazole provided 
the target protein in multiple fractions, which was further purified via size exclusion chroma-
tography. Using a mixture of reference proteins, the correlation between retention times and 
molecule size could be roughly estimated. The appropriate fractions for further work-up were 
identified through SDS-PAGE and CBB-staining after each step. 
 
Figure 23 Left: Chromatograms of Ni-NTA chromatography for de92 (blue = UV absorption A210, green = 
imidazole gradient). Right: Corresponding CBB-stained analytical gel images with PageRuler Plus 
Prestained by Fermentas used as marker. Molecular weight is displayed in kDa. The target protein 
has a molecular weight of 59 kDa. L = lysate; M = marker; FT = flowthrough; X1 = 10 mM imi-
dazole; X2 = 20 mM imidazole; X3 = 50 mM imidazole; A2-A11 = 50-500 mM imidazole gradi-
ent. Fractions X3-A11 were combined for subsequent SX chromatography. 
 
Figure 24 Left: Chromatograms of SX chromatography for de92 (blue = UV absorption A210). Right: Corres-
ponding CBB-stained analytical gel images with PageRuler Plus Prestained by Fermentas used as 
marker. Molecular weight is displayed in kDa. The target protein has a molecular weight of 59 
kDa. Fractions A15-B7 were combined. 
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For de92, the fractions at 50-200 mM imidazole in the Ni-NTA chromatography were  
combined. In gel filtration, early fractions containing the exclusion volume and oligomeric 
proteins were discarded, and only the fractions with protein at the correct mass range of 
around 59 kDa were collected, combined, concentrated to about 30 µM, and frozen in liquid 
nitrogen for storage at -80 °C. Protein aliquots after each purification step were taken and 
analysed in SDS-PAGE (Figure 25). The final protein was analysed with ESI-MS and the 
corresponding protein mass determined by deconvolution. In the end, a yield of 3.7 mg  
purified de92 for every litre of expression medium could be obtained. 
 
 
Figure 25 Top: Overview of protein purity after each purification step of de92 with PageRuler Plus  
Prestained by Fermentas used as marker. Molecular weight is displayed in kDa. M = marker; Ni = 
Ni-NTA chromatography; SX = SX chromatography. Numbers displayed denounce the amount of 
sample applied to the gel in µL. Mass determination (right) determined from the deconvolution of 
ESI-MS data (left).  
The CBB-stained SDS-PAGE gel image suggests a very pure protein. The protein mass  
determined by ESI-MS, however, shows a difference of +240 Da. As the signal intensity  
indicates a low ion count, the high noise levels might have led to an unusually high instru-
mental inaccuracy (mass fluctuations of about 0.01% are normally observed on this machine). 
For a deeper investigation, de92 was digested with trypsin, which proteolyses after lysines 
and arginines, and measured via HPLC with coupled ESI-MS/MS (Figure 26). Using the 
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BioWorks Browser by Thermo, most of the expected fragments were identified with very 
high fidelity (probability score P < 10
-4
). Analysis of the detected fragments show the triple 
phosphorylation at Ser124, Ser129 and Thr450, which would explain the mass difference. 
These phosphorylation sites are known in literature and are commonly observed in Akt ex-
pressed in insect cells.
172-175
 While their function is not yet elucidated, it is established that 
they do not determine the basal kinase activity of Akt. 
 
MGSTSHHHHH HDHITSLYKK AGFENLYFQG SDVAIVKEGW LHKRGEYIKT 
WRPRYFLLKN DGTFIGYKER PQDVDQRCAP LNNFSVAQCQ LMKTERPRPN 
TFIIRCLQWT TVIERTFHVE TPEEREEWTT AIQTVADGLK KQEEEEMDFR 
SGSPSDNSGA EEMEVSLAKP KHRVTMNEFE YLKLLGKGTF GKVILVKEKA 
TGRYYAMKIL KKEVIVAKDE VAHTLTENRV LQNSRHPFLT ALKYSFQTHD 
RLCFVMEYAN GGELFFHLSR ERVFSEDRAR FYGAEIVSAL DYLHSEKNVV 
YRDLKLENLM LDKDGHIKIT DFGLSKEGIK DGATMKTFSG TPEYLAPEVL 
EDNDYGRAVD WWGLGVVMYE MMSGRLPFYN QDHEKLFELI LMEEIRFPRT 
LGPEAKSLLS GLLKKDPKQR LGGGSEDAKE IMQHRFFAGI VWQHVYEKKL 
SPPFKPQVTS ETDTRYFDEE FTAQMITITP PDQDDSMECV DSERRPHFPQ 
FSYSASGTAX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX 
Figure 26 Chromatogram and mass spectrum of the trypsinised de92. The expected fragments that were 
found in ESI-MS/MS are marked in blue. 
In the purification of the pHT1023 construct, the 50-100 mM imidazole fractions from the 
Ni
2+
 affinity chromatography were collected for further SX purification. Again, the fractions 
with the 59 kDa target protein were concentrated to approximately 30 µM and frozen in liquid 
nitrogen. This construct, too, proved pure on the analytical SDS-PAGE gel and displayed a 
mass difference of around 240 Da, which was attributed to the same phosphorylations as in 
de92. For this construct with the additional C460S mutation when compared to de92, the yield 
was only 1.7 mg/L. 
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Figure 27 Left: Chromatograms of Ni-NTA chromatography for pHT1023 (blue = UV absorption A210, green 
= imidazole gradient). Right: Corresponding CBB-stained analytical gel images with PageRuler 
Plus Prestained by Fermentas used as marker. Molecular weight is displayed in kDa. The target 
protein has a molecular weight of 59 kDa. P = cell pellet after lysis; S = supernatant after lysis; FT 
= flowthrough; M = marker; X1 = 10 mM imidazole; X2-3 = 20 mM imidazole; X4 = 50 mM imi-
dazole; A2-A11 = 50-500 mM imidazole gradient. Fractions X2-X4 were combined for subse-
quent SX chromatography. 
 
Figure 28 Left: Chromatograms of SX chromatography for pHT1023 (blue = UV absorption A210). Right: 
Corresponding CBB-stained analytical gel images with PageRuler Plus Prestained by Fermentas 
used as marker. Molecular weight is displayed in kDa. The target protein has a molecular weight 
of 59 kDa. Fractions B2-B6 were combined..  
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Figure 29 Top: Overview of protein purity after each purification step of pHT1023 with PageRuler Plus 
Prestained by Fermentas used as marker. Molecular weight is displayed in kDa. Ni = Ni-NTA 
chromatography; M = marker; SX = SX chromatography. Numbers display denounce the amount 
of sample applied to the gel in µL. Mass determination (right) determined from the deconvolution 
of ESI-MS data (left). 
The same procedure was repeated for de91, and the 50-100 mM imidazole fractions from the 
Ni-NTA column were combined for SX chromatography. The 55 kDa protein was collected 
accordingly, concentrated to roughly 30 µM and frozen in liquid nitrogen. The SDS-PAGE 
gel confirmed its purity. Interestingly, this protein without the C-terminal hydrophobic motif 
showed no mass difference that would correspond to a triple phosphorylation. This could  
suggest that the HM might serve as the recognition site for the upstream kinases responsible 
for Ser124, Ser129 and Thr450 phosphorylation. This construct lacking the HM had even 
lower expression rates, accumulating to 0.8 mg/L. SDS-PAGE gels suggest that a large  
proportion might be misfolded and remains in the insoluble part of the cell pellet after  
membrane disruption. 
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Figure 30 Left: Chromatograms of Ni-NTA chromatography for de91 (blue = UV absorption A210, green = 
imidazole gradient). Right: Corresponding CBB-stained analytical gel images with PageRuler Plus 
Prestained by Fermentas used as marker. Molecular weight is displayed in kDa. The target protein 
has a molecular weight of 55 kDa. FT = flowthrough; X1 = 10 mM imidazole; X2-3 = 20 mM  
imidazole; X4 = 50 mM imidazole; M = marker; A2-A11 = 50-500 mM imidazole gradient.  
Fractions X2-X4 were combined for subsequent SX chromatography.  
 
Figure 31 Left: Chromatograms of SX chromatography for de91 (blue = UV absorption A210). Right: Corres-
ponding CBB-stained analytical gel images with PageRuler Plus Prestained by Fermentas used as 
marker. Molecular weight is displayed in kDa. The target protein has a molecular weight of 
55 kDa. Fractions B2-B6 were combined. 
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Figure 32 Top: Overview of protein purity after each purification step of de91 with PageRuler Plus Pres-
tained by Fermentas used as marker. Molecular weight is displayed in kDa. M = marker; SX = SX 
chromatography. Numbers display denounce the amount of sample applied to the gel in µL. Mass 
determination (right) determined from the deconvolution of ESI-MS data (left). 
In summary, 3 different Akt constructs were expressed in insect cells and purified with a yield 
of 3.7 mg/L, 1.7 mg/L and 0.8 mg/L for de92, pHT1023 and de91, respectively. The highest 
expression rates, therefore, could be obtained with the construct closest to the wild type. The 
identity of these three proteins were confirmed by mass spectrometry and tryptic digest, the 
purity by SDS-PAGE analysis. 
Table 3 Summary of the expressed and purified Akt constructs. 
Construct 
Yield 
/ mg/L 
Calculated mass Detected mass Comments 
de91 0.8 55098 Da 55098 Da low solubility 
pHT1023 1.7 58965 Da 59215 Da +240 Da mass difference  due to 
de92 3.7 58981 Da 59221 Da phosphorylation of Ser124, Ser129 and Thr450 
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3.3 Synthesis of Probe Compounds 
With the protein in hand, the next step was to obtain allosteric Akt inhibitors, that can be used 
as reference compounds to establish the assay. Although many allosteric Akt inhibitors have 
been published and tested (chapter 1.2.3), only Akti-1/2 and the clinical candidate MK-2206 
are commercially available. Limited by the number of commercially available allosteric  
inhibitors as probe molecules to assess the functionality of our future assay, we decided to 
synthesise a focussed library of ID inhibitors. 
Based on the known inhibitors and studying their SAR, the 1,6-naphthyridinone core as  
scaffold for the western part represented a compromise of high efficacy and reasonable syn-
thetic accessibility (as was seen for compound 48). As the eastern part has a significant  
impact on its efficacy as inhibitor, it was decided to introduce diversity at this position, while 
maintaining the tertiary amine in β-position to the bridging benzyl group. 
In order to obtain the desired compounds, a convergent synthesis for the generation of the 
naphthyridinone core was pursued (Scheme 1): In the final step, the eastern part will be intro-
duced via reductive amination with commercially available amines. The 1,6-naphthyridinone 
will be converted from the corresponding chloro-naphthyridine, which can be obtained easier 
than the more reactive naphthyridinone. The naphthyridine core in turn will be formed by a 
Friedländer cyclocondensation of an ortho-formylated aminopyridine with a ketone. These 
building blocks will be synthesised from the starting compounds 2-chloropyridin-4-amine and 
4-formylbenzonitrile, respectively. The benefit of this convergent approach is yield maximi-
sation by reducing linearly dependent synthetic steps, whereas the diversity generating last 
reaction will provide an easy access to a variety of structurally related compounds. 
 
Scheme 1 Retrosynthesis of the planned naphthyridinone-based inhibitors. 
Adapting a protocol by Casiraghi et al., who used a phenol hydroxyl group to direct the 
formylation by paraformaldehyde into the ortho position via complexation with transition 
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metals, a direct formylation of 2-chloropyridin-4-amine (54) with MgCl2 was attempted 
(Scheme 2).
163
 Analysis of the reaction mixture with LC-MS, however, did not show the for-
mation of the desired product 57, demonstrating the need to mask the reactive amine group. 
Since introduction of the formyl group in the next step required basic conditions, the acid-
labile tert-butyloxycarbonyl was chosen as protecting group. Optimising the reaction  
conditions with respect to solvent, temperature and equivalents of reagents, following  
observations were made: 
- DCM at RT proved to be the best performing solvent. 
- Increasing base strength Et3N < DIPEA < NaOtBu led to an increase of by-products 
but not conversion. 
- Excess of Boc2O increased the amount of a double Boc-protected species. 
- Adding DMAP increased conversion of 54. 
While an excess of Et3N and Boc2O gave a complete conversion of 54, the resulting di-Boc-
protected aminopyridine proved to be unreactive in the following ortho-formylation, probably 
due to its steric bulk. For this reason, the amount of DMAP was increased to 0.5 eq while  
using substoichiometric amounts of Boc2O. Although conversion was not complete, the  
proportion of desired product 55 was maximised. Unreacted starting material was recovered 
in the purification process to be reused for future batches. 
Using DMF as formylating agent, the reaction of the mono-Boc-protected reagent to yield 55 
was successful with tBuLi as co-reagent but not with POCl3. Subsequent deprotection of the 
Boc group with HCl in anhydrous dioxane gave the desired product 57 as one component of 
the Friedländer cyclocondensation. 
 
Scheme 2 Attempted and successful formylations of 54 to obtain 57. 
  
 Results and Discussion 49 
 
For the other component, the aldehyde 58 was acetal-protected with ethylene glycol under 
Dean-Stark conditions with near-quantitative yields. The protected nitrile 59 was further re-
acted with the Grignard reagent benzylmagnesium chloride and hydrolysed in situ to produce 
the desired ketone 60. All steps went smoothly without major complications (Scheme 3). 
 
Scheme 3 Synthesis of the ketone component 60 for the Friedländer cyclocondensation. 
In the literature, a variety of catalysts have been used for Friedländer cyclocondensations. 
Depending on the substrate, either acids or bases can be more suitable for a particular  
reaction.
164
 Two different mechanisms for acid- or base-catalysis have hence been postulated 
(Scheme 4): 
 
Scheme 4 Two possible mechanisms of the Friedländer cyclocondensation of 57 and 60 to the naphthyridine 
61. The acid-catalysed (upper) and base-catalysed (lower) routes are shown. 
Following a protocol by Bilodeau et al., who employed an AcOH-catalysed Friedländer cy-
clocondensation, only a deprotection of 60 to the corresponding aldehyde was observed, but 
no formation of the product 61.165 Increasing the acidic strength by using TsOH gave the 
same results.
166
 When switching to base catalysis, NaOMe was able to catalyse the cyclo-
condensation, but also substituted the chloro substituent at the 5-position to methoxy.
167
 
Therefore, various non-nucleophilic bases such as NaH, Et3N, DIPEA and NaOtBu were  
tested for this reaction. None of the nitrogen bases were able to catalyse the cyclisation, 
whereas NaH was capable of catalysis but also produced a number of by-products. Finally, 
NaOtBu merged as the most successful catalyst, successfully facilitating the cycloconden-
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sation with a moderate proportion of side products. Since Friedländer cyclocondensations 
have been reported using iodine or metals of the lanthanide series as catalysts, we have tested 
I2, SmCl3, Pr(NO3)3 and La2(CO3)3 for the cyclisation of 57 and 60.
168,169
 However, none of 
these reagents provoked a reaction of the starting reactants. In the end, it was decided to use 
NaOtBu as catalyst for the synthesis of 61. 
Deprotection of the acetal and hydrolysis of the chloro substituent to a hydroxy group were 
combined into one step by heating 61 in aqueous HCl. The resulting phenole moiety of 62 
could not be deprotonated at pH 14, but instead was enriched in the aqueous solution when 
under acidic conditions, which indicates a basic rather than acidic nature of 62. This reactivity 
suggests that the tautomerisation of the hydroxypyridine moiety to a lactam structure is 
indeed the more stable state. 
 
Scheme 5 Formation of the naphthyridine core via Friedländer cyclocondensation and subsequent hydrolysis 
and deprotection. 
For the final diversity-generating step, the deprotected aldehyde 62 was derivatised with  
various commercially available amines to obtain the final probe molecules 63a-g via reduc-
tive amination. Two approaches were investigated, with NaBH3CN or NaBHOAc3 as  
reducing agents. While the milder acetate reagent produced fewer side reactions, the conver-
sion of the aldehyde was only marginal. Therefore, using the stronger NaBH3CN provided 
complete conversion while maintaining a good selectivity towards the desired product. 
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Scheme 6 Reductive amination of 62 to give final compounds 63a-g. 
This compound class is known to suffer from low solubilities, possibly due to extensive π-π 
intermolecular interactions between their aromatic units.
127
 And indeed, from the formation of 
the naphthyridine core onwards, compound handling became a major issue as these molecules 
were highly insoluble in any solvent besides DMSO. Purification via column chromatography 
always led to a significant drop in yield, presumably due to the formation of precipitates on 
the solid phase which cannot be re-dissolved into solution. Purification by precipitation was 
not a viable alternative, as no solvent combination was able to provoke a precipitation of the 
compound in significant amounts. Extraction and enrichment in a Soxhlet extractor was not 
successful either, resulting in loss of the entire product in the Soxhlet capsule. Therefore, the 
low yields associated with column chromatography had to be accepted. Introduction of the 
amine for the final compound increased the polarity of the molecule, thus enabling the purifi-
cation via reversed-phase preparative HPLC with still low yields (2-26%). 
In summary, the synthesis of the intended probe molecules was successful, providing seven 
compounds 63a-g with a naphthyridinone scaffold and various substituents on the eastern 
part. The identity of all compounds was confirmed by HR-MS, 
1
H- and 
13
C-NMR, as well as 
2-dimensional COSY, 
13
C-HSQC and 
13
C-HMBC. In addition to their use as probe molecules 
for the development of the conformational assay, their biological activity in vitro and ex vivo 
had to be examined. This will be discussed in chapter 3.4. 
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3.4 Biological Activity of Probe Compounds 
3.4.1 in vitro Activity 
In order to assess the biological activity of the synthesised probe molecules, their activity 
against the intended target Akt had to be determined. Two isoforms Akt1 and Akt2, as well as 
the kinase domain only construct ΔPH-Akt1 were purchased to use them in the activity-based 
KinEASE assay by CisBio. The KinEASE assay measures the phosphorylation activity of a 
kinase by FRET between an anti-phospo antibody and an acceptor fluorophore on the  
substrate (see a more detailed description in chapter 1.4.1). The ratio of the acceptor fluores-
cence intensity at 665 nm to donor fluorescence at 620 nm (from now on referred to as 
fl665/fl620) serves as the assay readout, and correlates directly to the extent of substrate phos-
phorylation and hence kinase activity. To establish this assay, the optimal reaction parameters 
for the assay had to be determined experimentally for each kinase and batch, i.e. the kinase’s 
activity, ATP- and substrate-Km have to be investigated. The process of establishing the  
KinEASE assay for Akt1, Akt2 and ΔPH-Akt1 is discussed in chapter 5.1. 
After these establishing steps, the IC50 for a known inhibitor was determined as reference. 
Even though IC50 values are often comparable under controlled conditions, each assay setup 
still provides different results. Therefore, reference values of known inhibitors have to be  
established to better range in the results of each particular assay. The clinical candidate  
MK-2206 was chosen as representative for an allosteric ID inhibitor and H-89 for an ATP-
competitive inhibitor. Their IC50s were determined from three independent measurements 
(Table 4) using the sigmoidal 4-parameter Hill equation (5). The IC50s correlate well with the 
reported values for Akt1 and Akt2. As expected, the allosteric inhibitor shows no effect on the 
kinase domain alone, but only on the full-length kinases. In conclusion, the assay was suc-
cessfully validated with these two reference compounds. Subsequently, other allosteric  
(Akti-1/2) and ATP-competitive Akt inhibitors (staurosporine, GSK690693 and CCT128930) 
were evaluated for further reference. 
 
 (    )    
 
  (
    
    
)
  (5) 
cI,0 = total inhibitor concentration  T = top asymptote B = bottom asymptote 
H = Hill coefficient   IC50 = concentration of half-maximal inhibition 
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Figure 33 IC50 determination of MK-2206 (blue) and H-89 (red) as reference inhibitors for the validation of 
the KinEASE assay with Akt1, Akt2 and ΔPH-Akt1. 
Table 4 Summary of determined IC50s for various allosteric and ATP-competitive reference inhibitors, 
including MK-2206 and H-89 for the validation of the Akt1, Akt2 and ΔPH-Akt1 KinEASE assay. 
n.i. = not inhibiting up to 200 µM. 
IC50 / µM Akt1 Akt2 ΔPH-Akt1 
 measured literature measured literature measured literature 
MK-2206 0.006 ± 0.002 0.008 0.020 ± 0.009 0.002 n.i. n.i. 
Akti-1/2 <0.001 0.058 3 ± 1 0.21 n.i. n.i. 
H-89 2 ± 1 1.4 2.1 ± 0.8 1.4 0.14 ± 0.02 1.4 
GSK690693 <0.001 0.002 0.004 ± 0.001 0.013 <0.001 0.002 
CCT128930 0.029 ± 0.009 0.006 0.20 ± 0.07 0.02 0.030 ± 0.007 0.006 
Staurosporine 0.014 ± 0.005 0.011 0.004 ± 0.003 0.011 0.018 ± 0.009 0.011 
In summary, the optimal assay parameters were determined to 0.12 nM kinase, 45 min incu-
bation time, 50 µM ATP and 250 nM STK3 substrate for Akt1, 0.51 nM kinase, 17 min incu-
bation time, 65 µM ATP and 300 nM STK3 substrate for Akt2, and 0.06 nM kinase, 20 min 
incubation time, 65 µM ATP and 300 nM STK3 substrate for ΔPH-Akt1. All KinEASE 
measurements were conducted with these parameters. 
Finally, the synthesised probe molecules 63a-g as well as 64a-d, which are allosteric ID  
inhibitors synthesised by Dr. Abu Taher in the lab of Prof. Willem V. A. van Otterlo, were 
measured with KinEASE against all three kinase constructs (Table 5). As expected, none of 
them had an inhibitory effect on ΔPH-Akt1 up to 200 µM, as it lacks the necessary PH  
domain to form the binding pocket at the domain interface. On the full-length kinases, how-
ever, all inhibitors exhibited inhibitory effects with different efficacies. On average, 63a-g 
showed a lower potency against Akt2 than Akt1 of about one order of magnitude. This is in 
congruence with the isoform selectivity known for this class of inhibitors, as Akt2 lacks the 
Ser205 that is addressed by the carbonyl group of the naphthyridinone scaffold.
170
 Within a 
single isozyme, 63a-g exhibit the same SAR, with 63a and 63b being the most potent  
inhibitors, and 63e and 63g the least. 
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Figure 34 Dose-response curves from IC50 determination of 63a-g and 64a-d with KinEASE against Akt1. 
Table 5 IC50s of synthesised probe molecules. Compounds 64a-d were provided by the group of Willem 
V. A. van Otterlo. n.i. = not inhibiting up to 200 µM. 
 
IC50 / µM Akt1 Akt2 ΔPH-Akt1 
63a 0.033 ± 0.005 0.43 ± 0.02 n.i. 
63b 0.010 ± 0.004 0.21 ± 0.04 n.i. 
63c 0.8 ± 0.2 7 ± 5 n.i. 
63d 0.6 ± 0.1 6 ± 1 n.i. 
63e 1.4 ± 0.5 12 ± 1x n.i. 
63f 0.40 ± 0.05 8.5 ± 0.6 n.i. 
63g 2.1 ± 0.2 24 ± 12 n.i. 
64a 3 ± 2 14 ± 4x n.i. 
64b 24 ± 13 132 ± 81x n.i. 
64c 64 ± 36 681 ± 396 n.i. 
64d 144 ± 132 122 ± 28x n.i. 
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In order to explain the observed SAR, a co-crystal structure of Akt with one of these  
compounds would provide an unambiguous answer. However, in the absence of an estab-
lished and functional crystallisation procedure, docking experiments with Glide from the 
Schrödinger Suite were performed. The crystal structure of the full length Akt1 co-crystallised 
with Akti-1/2 (PDB code 3O96) was used as template for molecular docking. After pre-
processing by adding hydrogens, removing water molecules and correcting bond lengths and 
angles, a binding pocket of a volume of 5 Å around the original ligand was calculated for the 
receptor grid. Ligands were prepared by calculating conformers and tautomers at pH 5-9. The 
thusly prepared ligands and binding pocket were combined in one docking experiment. 
  
  
Figure 35 Prediction of the binding mode of synthesised probe molecules (cyan sticks) with Glide, superim-
posed with the original ligand (orange sticks) in the X-ray crystal structure (PDB code 3O96). 63a 
is shown as an example for a potent binder, that fills out the pocket well, 63c as an example for 
one that does not fill out the pocket, and 63e and 63g as examples for ill-fitting allosteric  
inhibitors. 
The predicted binding mode for 63a, which possesses the same substituent as Akti-1/2, over-
lays well with the originally crystallised ligand, giving credit to the validity of the binding 
poses for this family of inhibitors. The only differences arise from the removal of the water 
molecule W455 that forms hydrogen bonds between the protein and the piperidine nitrogen. 
The simulations reveal the reasons for the in vitro SAR observed in the KinEASE assay: The 
most potent 63a and 63b nicely fill out the eastern part of the allosteric pocket with their 
bulky substituents. In contrast, 63c, 63d and 63f are too small and do not fill the pocket 
completely. On the other hand, 63c is linear and too long, not fitting well into the pocket. 
Similarly, the 63c substituent expands three-dimensionally as compared to the flat  
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substituents on the other compounds, due to its additional sp
3
 carbon atoms, which cannot be 
accommodated into the pocket easily. This order of favourable and unfavourable interactions 
is in congruence with the KinEASE results and can explain the observed SAR. Therefore, the 
docking results are likely to represent the actual binding modes of the probe compounds. 
In summary, after establishing activity-based in vitro assays, the synthesised probe  
compounds exhibited inhibition of full-length Akt1 and Akt2, but not the kinase domain 
alone. Docking experiments provided explanations for the SAR. These results suggest that 
63a-g are indeed allosteric Akt inhibitors occupying the allosteric pocket at the interface of 
PH and kinase domain. 
3.4.2 Cellular Activity 
Allosteric ID inhibitors are known to exhibit superior selectivity and reduced off-target effects 
in cells. In collaboration with the group of Prof. Dr. Roman K. Thomas, we investigated the 
biological effect of 63a-g on a cellular level to confirm their allosteric mode of action. These 
experiments were conducted by Dennis Plenker. With the allosteric MK-2206 and the ATP-
competitive GSK690693 as reference inhibitors, the breast ductal carcinoma cell line BT474 
and the lung adenocarcinoma epithelial cell line H441 were employed as model systems. The 
effect of the compounds were assessed in dose dependence with the CellTiter-Glo assay, 
which measures the ATP content of a cell by luciferase luminescence, which gives a quanti-
tative feedback about the cell viability. 
When incubated with 63a-g, MK-2206 and GSK690693, a dose dependent decrease in 
BT474 cell viability was observed (Figure 36). Mirroring the in vitro data, the same order of 
potency was observable, with 63a and 63b exhibiting the strongest effect, and 63e and 63g 
the weakest (Table 6). In contrast, H441 cells showed no significant decrease in viability upon 
treatment with any of these compounds up to 30 µM. While BT474 is known to be sensitive 
to Akt inhibition, H441 is resistant to its inhibition, i.e. their survival is not Akt-dependent.
171
 
These results therefore support the hypothesis that Akt is indeed the cellular target which is 
inhibited by these compounds rather than via unspecific toxicity. Interestingly unlike the ID 
inhibitors, the ATP-competitive GSK690693 is unable to reduce the viability of BT474 cells 
to zero, indicating a secondary cellular rescue mechanism when inhibiting Akt with ATP-
competitive inhibitors. 
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Figure 36 Dose reponse curves of BT474 and H441 cells upon treatment with 63a-g, MK-2206, Akti-1/2 
and GSK690693. Cell viabilities are expressed relative to DMSO controls. 
Table 6 Overview of cellular GI50s of synthesised probe compounds and reference inhibitors against 
BT474 and H441 cell lines. n.e. = no effect at concentrations up to 30 µM. 
GI50 / µM BT474 H441 
63a 7 ± 2 n.e. 
63b 3.2 ± 0.6 n.e. 
63c 17 ± 2x n.e. 
63d 18 ± 4x n.e. 
63e 19 ± 4x n.e. 
63f 13 ± 1x n.e. 
63g 19 ± 3x n.e. 
MK-2206 0.3 ± 0.1 n.e. 
Akti-1/2 1.8 ± 0.9 n.e. 
GSK690693 0.7 ± 0.2 n.e. 
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For a more thorough investigation of their effect ex vivo, BT474 cells treated with increasing 
concentrations of MK-2206 and 63b were harvested and lysed. The lysate was examined by 
immunostaining via Western Blot, using actin-, Akt- and phospho-Akt-specific antibodies. 
The Western Blots show a dose-dependent decrease of Akt phosphorylation upon treatment 
with the two compounds, both at the activity-determining Thr308 on the activation loop and 
the C-terminal Ser473 (Figure 37). Unsurprisingly, the clinical candidate MK-2206 exhibited 
a higher potency than the synthesised probe molecule 63b. In comparison, ATP-competitive 
Akt inhibitors promote hyperphosphorylation of Thr308.
92
 These findings further corroborate 
63a-g as allosteric ID inhibitors. 
 
Figure 37 Western Blot of the BT474 cells treated with increasing concentrations of MK-2206 and 63b. tAkt 
refers to total Akt, actin serves as loading control. 
Interestingly, the sub-nanomolar ATP-competitive Akt inhibitor GSK690693 reduced BT474 
viability to about 50% around 0.7 µM, but did not drop further regardless of increasing  
inhibitor concentration. This upkeep of survival might be attributed to the low selectivity of 
ATP-competitive Akt inhibitors, leading to stimulation of negative feedback loops by the  
inhibition of other AGC family kinases, once more demonstrating the benefits of selective 
Akt inhibition. 
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3.5 iFLiK Assay Development 
3.5.1 Selecting Appropriate Reporter Fluorophore 
As described in chapter 1.3.1, fluorophores react differently to changes in their environment. 
When attached to a protein, their fluorescence properties can be used to report on changes of 
the microenvironment, i.e. in the direct vicinity of the fluorophore. By labelling residues that 
are part of the respective binding pocket, the FLiK assay developed in our group was able to 
detect compounds binding to the ATP-, lipid- or myristate pocket of the respective kinase (for 
more details see chapter 1.4.2). The current challenge is to investigate whether such environ-
mentally sensitive fluorophores can report on the overall conformational changes of entire 
proteins by individual domain movements. As these are a direct result of a ligand binding 
event in the case of ID inhibitors of Akt, this binding would be concluded from such a con-
formational change. Being a further development of the FLiK assay, the novel assay system 
will hence be termed iFLiK (interface-FLiK). 
  
Figure 38 Cysteine-reactive fluorophores tested for iFLiK. 
A collection of cysteine-reactive fluorophores were purchased for their use in the iFLiK  
assay, namely Acrylodan, PyMPO maleimide, DY-647 maleimide, IANBD, Texas Red  
maleimide, Atto 565 maleimide, Eosin maleimide, Atto 610 maleimide (Figure 38). In order 
to assess their suitability for the assay, a series of tests with the fluorophores without labelling 
the protein were conducted to avoid unnecessary protein consumption. To imitate the redox 
state at the labelled cysteine, each fluorophore was reduced by overnight incubation with 
10 eq β-mercaptoethanol for these tests. As the spectral changes of solvatochromic fluoro-
phores are governed by the solvent polarity (see detailed discussion in chapter 1.3.1), the 
emission spectra of all 8 fluorophores were measured in a variety of solvents with different 
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polarities (buffer, 20% glycerol in buffer, 20% PEG6000 in buffer, iPrOH, MeCN, DMSO, 
DMF, acetone and dioxane). 
 
Figure 39 Fluorescence spectra of Acrylodan, PyMPO, DY-647, IANBD, Texas Red, Atto565, Eosin and 
Atto610 in buffer (black), 20% glycerol in buffer (orange), 20% PEG6000 in buffer (cyan), iPrOH 
(green), MeCN (violet), DMSO (blue), DMF (yellow), acetone (red) and dioxane (brown). The 
grey dotted lines mark the excitation spectra. 
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In these preliminary tests, the fluorophores exhibited different sensitivities towards polarity 
changes (Figure 39). Acrylodan and PyMPO, which have a strong dipol moment, displayed a 
bathochromic spectrum shift of up to 88 nm and 56 nm, respectively, with increasing solvent 
polarity (dioxane to buffer). The highly symmetrical fluorophores Atto 565, Atto 610 and 
Eosin only showed minor spectrum changes (16 nm, 14 nm and 10 nm). Interestingly, 
DY-647 responded with a 20 nm hypsochromic spectrum shift towards increasing solvent 
polarity, leading to negative solvatochroism. 
To test how these fluorophores perform as biosensors on Akt, de92 was chosen for these  
experiments, since it was the best expressing construct. All fluorophores were each incubated 
individually with de92 over night at 4 °C. To increase the nucleophilicity of the cysteine thiol, 
the labelling was conducted in the labelling buffer adjusted to pH 7.2. Unreacted fluorophores 
were removed by size exclusion. Subsequently, these labelled proteins were incubated with 
various concentrations of the allosteric inhibitor MK-2206 in 384-well plates to observe 
whether these fluorophores were capable of reporting on the conformational changes  
associated with the binding of ID inhibitors. For comparison, whether or not the observed 
effects were selective for this domain movement, the same experiment was conducted in  
parallel with the ATP-competitive GSK690693, which should not induce these conforma-
tional changes (Figure 40). Depending on their structure, the various fluorophores displayed 
differential responses upon binding of MK-2206, which are summarised in Table 7. Some 
fluorophores like PyMPO or IANBD exhibited a shift in the emission spectrum and therefore 
in their fluorescence maximum, whereas an overall intensity increase could be observed with 
Atto 565 or Eosin. In comparison, no changes in the emission spectra could be observed for 
any of the labelled Akt when incubated with GSK690693 (apart from fluctuations in the  
fluorescence intensity of roughly ±10%). Furthermore, mixtures of inhibitors with PyMPO-
labelled glutathione or β-mercaptoethanol displayed no such effect, confirming that the  
observed responses are specific to the conformational change of Akt, and not due to inter-
action with the fluorophores alone. As the binding pocket and labelling site are more than 
20 Å apart, an interaction between the ligand and the fluorophore (e.g. via resonance energy 
transfer or direct contact) is highly unlikely. These findings suggest that the observed changes 
are indeed owed to the conformational changes caused by allosteric inhibitors. 
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Figure 40 Fluorescence emission spectrum of de92 labelled with Acrylodan, PyMPO, DY-647, IANBD, 
Texas Red, Atto565, Eosin and Atto610 after incubation with increasing concentrations up to 
5 µM of MK-2206 or 63b in the case of Acrylodan (red = apo; green = saturated). 
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Depending on the type of response observed, different assay readouts were used to determine 
ligand binding affinities. In the case of an intensity change, the fluorescence intensity at the 
emission maximum was used as the readout. For the quantification of spectrum shifting, the 
two wavelengths in the emission spectrum with half-maximal emission intensities were  
recorded, and the ratio of their emission intensities served as the assay readout. By comparing 
the fluorescence of the kinase incubated with 5 µM MK-2206 to the apo kinase (n = 6),  
signal-to-noise ratios and Z’-factors were calculated for each fluorophore-labelled kinase as 
descriptors for the assay quality and reproducibility. Additionally, dose-response experiments 
were performed by incubating the labelled kinases with a dilution series of either MK-2206 or 
GSK690693 with final concentrations ranging between 0.8 nM and 50 µM. By plotting the 
respective assay response against the logarithmic inhibitor concentration, the Kd was deter-
mined by fitting the data to an asymmetric sigmoidal curve (equation (7)), which was derived 
from the law of mass action (equation (6)). 
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In order to adapt this formula to the binding curves, values for the upper and lower asymptote 
based on the fractional occupancy were worked in equation (8), as well as the Hill coefficient 
to account for positive and negative cooperative binding. The resultant asymmetric 5-point 
Hill function (9) was used for fitting the data. 
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cI = inhibitor concentration cP = protein concentration cPI = protein-inhibitor-complex concentration 
cI,0 = total inhibitor concentration T = top value B = bottom value  θ = fractional occupancy 
cP,0 = total protein concentration H = hill coefficient   Kd = dissociation constant 
Except for Atto 610 and Acrylodan, all fluorophores were able to detect MK-2206 binding to 
Akt with comparable Kds but with varying degrees of reliability. The response appeared to be 
specific to allosteric inhibitors since the labelled kinase was unresponsive to the addition of 
the ATP-competitive inhibitor GSK690693. In the case of Atto 610, no changes in the  
fluorescence spectrum could be observed with either inhibitor. For Acrylodan, high levels of 
MK-2206 auto-fluorescence at the Acrylodan excitation wavelength rendered the  
measurement with this reference inhibitor impossible. Therefore, experiments were repeated 
for Acrylodan- and PyMPO-labelled Akt using the less fluorescent 63b, which evoked the 
same assay response with PyMPO as MK-2206 did. With Acrylodan, its emission spectrum 
decreased in intensity and displayed a considerable bathochromic shift by 53 nm, revealing 
that Acrylodan is also able to report on the conformational changes of Akt induced by  
allosteric inhibitors. 
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Figure 41 Dose-response curves of the fluorophores tested with MK-2206, 63b and GSK690693. 
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Table 7 Overview of fluorophore probes. Structures of reporter fluorophores tested for iFLiK, the observed 
effects when treated with MK-2206, the chosen assay readouts, Z’-factors, signal-to-noise ratios 
and determined Kds for reference inhibitor MK-2206 and 63b in brackets (n.m. = not measurable 
due to compound auto-fluorescence). 
Fluorophore Excitation Effect Readout Z‘ S/N 
Kd MK-2206 
(63b) 
Acrylodan 386 nm 
53 nm red-shift 
0.5x signal decrease 
535/456 nm 
456 nm 
0.95 
0.69 
2.13 
1.84 
n.m. (207 nM) 
n.m. (180 nM) 
PyMPO 419 nm 16 nm red-shift 638/508 nm 0.90 1.92 96 nM (146nM) 
DY-647 640 nm 
2 nm blue-shift 
2.2x signal increase 
697/660 nm 
672 nm 
0.72 
0.56 
1.16 
2.21 
75 nM 
63 nM 
IANBD 484 nm 5 nm red-shift 596/514 nm 0.38 1.11 85 nM 
Texas Red 586 nm 
4 nm red-shift 
1.3x signal increase 
641/606 nm 
616 nm 
0.42 
0.15 
1.06 
1.25 
22 nM 
70 nM 
Atto 565 559 nm 1.3x signal increase 695 nm 0.23 1.27 63 nM 
Eosin 519 nm 1.2x signal increase 551 nm 0.36 1.16 62 nM 
Atto 610 606 nm no changes - - - - 
As expected, fluorophores with high dipole moments were most sensitive towards inhibitor 
binding, since their Stokes shifts are more susceptible to polarity changes.
140
 Indeed, the shifts 
observed in the assay correlate nicely with the preliminary tests, in which the fluorophores 
exhibited a hypsochromic (DY-647) or bathochromic (Acrylodan, PyMPO, IANBD, Texas 
Red) shift in more polar solvents, indicating a transition from a relatively unpolar to a more 
polar environment upon inhibitor binding (Figure 42). This effect was observed for all fluoro-
phores, suggesting a mechanism in which the reporter fluorophore is localised to the protein 
surface after labelling, and is displaced by conformational reorganisation of residues around 
the labelling site upon ligand binding, leading to an increased solvent exposure. Similar  
observations have been reported by Moreno et al. when investigating the effects of labelling 
human serum albumin with Acrylodan.
176
 The observed signal decrease of Acrylodan corro-
borates this model mechanism, as the energy transfer from the excited fluorophore to the  
surrounding molecules equals a smaller energy gap between the S1
*
 and S0
*
 state, resulting in 
an increased rate of internal conversion and therefore greater degree of radiationless relaxa-
tion via vibrational modes.
137
 On the other hand, fluorophores with an internal rotor are 
known to exhibit increased fluorescence in environments of higher viscosity as the rate of 
rotational relaxation is reduced.
170
 Therefore, an increased solvent exposure should lead to a 
reduced fluorescence quantum yield. In fact with Atto 565, Texas Red, Eosin and DY-647, a 
fluorescence increase was observed upon inhibitor binding, suggesting a hindered rotation due 
to their proximity to the protein surface. In comparison to Atto 565, Atto 610 lacks the rotata-
ble para-substituted phenyl moiety and hence does not display this emission increase. These 
intensity changes were marginal and unreliable, however, and might be governed by factors 
other than rotational relaxation (e.g. rate of quenching, pipetting inaccuracies). This again 
 Results and Discussion 67 
 
demonstrates the limitations of using fluorescence intensity at a single wavelength as an assay 
readout. Expressing assay readouts as ratios of fluorescence intensities are therefore always 
preferable as they compensate for such variations in absolute intensities. 
 
Figure 42 Correlation between protein-free tests of fluorophores and their response in the iFLiK assay. Left: 
Waterfall plot of emission shifts in pre-tests, coloured according to whether they displayed a  
significant emission shift in the assay as well (green = observable shift; red = no shift observed). 
Right: Spectrum shifts observed in pre-test plotted against shifts observed in the iFLiK assay. 
In summary, these experiments provided a proof of concept that fluorophores attached to the 
correct position on Akt were able to selectively report on conformational changes induced by 
inter-domain binders, and that they can distinguish between such allosteric and classic ATP-
competitive inhibitors. This is a major breakthrough by itself, as previous works in the group 
have shown that the choice of labelling position can be crucial for the feasibility of the entire 
assay. A variety of fluorophores have been shown to work for iFLiK, but Acrylodan and 
PyMPO proved to be the best performing probes in terms of reliability. However, in order to 
avoid inhibitor auto-fluorescence (the difficulties were nicely demonstrated by the strong  
intrinsic fluorescence of MK-2206), PyMPO was ultimately chosen for future experiments 
due to its excitation at longer wavelengths. 
3.5.2 Determining the Optimal Enzyme Construct 
After deciding on PyMPO as the best performing reporter fluorophore, the question of the 
construct best suited for iFLiK had to be investigated. To this end, the three purified proteins 
de91, pHT1023 and de92 were labelled with PyMPO maleimide over night and isolated via 
size exclusion. The purified proteins were analysed via ESI-MS maleimide (Figure 47), and 
the protein masses calculated from deconvolution of the differently charged species all  
exhibited a mass increase of about 376 Da, which is indicative for an addition of a single 
PyMPO (Table 8).
177
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Figure 43 Mass spectrometry results of unlabelled (left) and labelled (right) Akt constructs: de91 (top), 
pHT1023 (middle) and de92 (bottom). 
Table 8 Analytics summary of the PyMPO-labelled Akt constructs. Expected mass difference for PyMPO 
labelling of cysteine is +376 Da. 
Construct Unlabelled mass Labelled mass Mass difference 
de91 55098 Da 55482 Da +384 Da 
pHT1023 59215 Da 59587 Da +372 Da 
de92 59221 Da 59604 Da +383 Da 
Each construct was incubated with a dilution series of 63b and GSK690693. Again, the 
measured emission spectra of all constructs showed no response to the ATP-competitive 
GSK690693, but a dose-dependent red-shift with the allosteric inhibitor (Figure 44), which 
was quantified by calculating the fluorescence ratio of the half-maximum intensities  
(Table 9). 
While the truncated de91 responded with a bathochromic maximum shift from 554 nm to 560 
nm, pHT1023 and de92 displayed a shift from 562 nm to 570 nm and 558 nm to 570 nm, re-
 Results and Discussion 69 
 
spectively. This position towards shorter wavelengths indicates a more hydrophobic  
(i.e. solvent-protected) environment around the PyMPO sensor in the truncated construct, 
which matches the susceptibility towards increased aggregation observed during protein  
purification. The instability of the protein had ultimately resulted in a lower yield, and is the 
likely reason for the blue-shifted PyMPO fluorescence here. While the determined Kds for 
63b were in the same range for all three Akt1 constructs (70-164 nM), de92 displayed the 
most pronounced red-shift and (with a Z’-factor of 0.86) was the most reliable protein in the 
iFLiK assay. As it was also the best expression, it presents itself as the obvious choice for the 
future experiments. 
 
Figure 44 Left: PyMPO fluorescence emission of de91 (top), pHT1023 (middle) and de92 (bottom) upon 
treatment with increasing concentrations of allosteric inhibitor MK-2206 (red = apo; green =  
saturated). Right: Dose-response curves of iFLiK constructs with allosteric and ATP-competitive 
inhibitor. 
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Table 9 Overview of the iFLiK response for the three Akt1 constructs de91, pHT1023 and de92. 
Construct Maximum shift Readout Z‘ S/N Kd 63b 
de91 554 nm → 560 nm fl624/fl493 0.53 1.26 70 nM 
pHT1023 562 nm → 570 nm fl638/fl508 0.68 1.19 164 nM 
de92 558 nm → 570 nm fl638/fl508 0.86 1.43 78 nM 
Due to its extra cysteine at the C-terminus, the labelling selectivity in the case of de92 (i.e. the 
actual labelling positions of PyMPO maleimide) had to be investigated. Despite the additional 
potential labelling site, the PyMPO fluorescence of de92 was virtually identical to pHT1023, 
both in shape, position and intensity. To further corroborate this, the labelled de92 was  
denatured at 90 °C with added DTT, capped with IAA and digested with trypsin. A subse-
quent analysis with HPLC and coupled ESI-MS/MS revealed that no cysteine in the protein 
had reacted with the reporter fluorophore other than the desired Cys49 (Figure 45). This is in 
congruence with the observed 376 Da mass increase of the labelled de92 protein, which also 
suggests a mono-alkylation with PyMPO. 
 
aa B ions Y ions 
C* 329.31  
A 400.34 1720.85 
P 497.40 1649.81 
L 610.48 1552.76 
N 724.52 1439.68 
N 838.57 1325.63 
F 985.63 1211.59 
S 1072.67 1064.52 
V 1171.74 977.49 
A 1242.77 878.42 
Q 1370.83 807.39 
C 1530.86 679.33 
Q 1658.92 519.30 
L 1772.00 391.24 
M 1903.04 278.15 
K  147.11 
 
Figure 45 ESI-MS/MS spectrum of the fluorophore-labelled peptide after tryptic digest and mass-to-charge 
ratios of its resultant fragment ions expressen in Thomson. Precursor ion: 1025.20 Th. Probability 
score = 6 ∙ 10-13. C* = labelled cysteine. C = capped cysteine.  
In conclusion, de92 was chosen as the optimal construct for the iFLiK assay as it displayed 
the strongest spectrum shift with the highest Z’-factor and signal-to-noise ratio upon  
conformational changes induced by allosteric inhibitors and was the best expressing protein 
from insect cells. 
  
 Results and Discussion 71 
 
3.5.3 Optimisation of Assay Conditions 
After these proof-of-principle experiments, the assay had to be optimised for its use in future 
high-throughput screens. In the first step, different labelling procedures were investigated by 
labelling the recombinantly expressed Akt with varying amounts of PyMPO maleimide 
(0.8 eq, 1.2 eq or 2 eq) and work-up procedure to remove excess fluorophore (quenching with 
DTT and removal by size exclusion). The experiments show that the addition of DTT had a 
neither positive nor negative influence on the assay performance. Using an excess of PyMPO 
maleimide resulted in a reduced assay window, which can be attributed to the unreacted 
fluorophore that is still present and responsible for a heightened background signal. This  
excess appears to be unremovable, as it remained with the protein after purification with  
either FPLC, centricons or dialysis, presumably by tight non-covalent association to the  
protein. Only in an SDS-PAGE, a separation of the small-sized fluorophore from the  
denatured protein could be achieved. Furthermore, the SX-subjected proteins showed less 
stable curves, probably due to the stress put on them in the purification process. Therefore, 
using substoichiometric amounts of labelling reagent was the procedure of choice, since 
0.8 eq of PyMPO provided the best assay window and eliminated the need for removing  
excess fluorophore as confirmed via SX FPLC. 
 
Labelling Z‘ S/N 
Kd 
MK-2206 
0.8 eq 0.87 1.51 126 nM 
1.2 eq 0.77 1.36 83 nM 
1.2 eq 
DTT 
0.83 1.39 104 nM 
1.2 eq 
DTT SX 
0.80 1.39 101 nM 
2.0 eq 
DTT SX 
0.70 1.27 68 nM 
 
Figure 46 Performance of differently labelled Akt in the iFLiK assay. DTT refers to quenching with 10 eq 
DTT; SX to purification via size exclusion. 
Next, the optimal enzyme concentration and reaction volume for the iFLiK assay was  
determined in order to minimise protein and compound consumption. However, reducing the 
amount of labelled Akt inevitably lowers signal intensities and hence increases inaccuracies in 
the measurement. Incubating MK-2206 with 200 nM, 100 nM and 50 nM of PyMPO-labelled 
de92 in 20 µL and 10 µL each confirmed this prognosis. Ultimately, 10 µL of 200 nM Akt 
was chosen for the future assay setup, as it provided the most reliable curves with the least 
waste of material. 
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.1 1 10 100 1000 10000
fl
6
3
8
/f
l 5
0
8
 
MK-2206 concentration / nM 
0.8eq
1.2eq
1.2eq DTT
1.2eq DTT SX
2eq DTT SX
 72 Results and Discussion 
 
  
 
Amount kinase Z‘ S/N 
Kd 
MK-2206 
200 nM 20 µL 0.87 1.77 227 nM 
100 nM 20 µL 0.78 1.78 99 nM 
50 nM 20 µL 0.66 1.78 130 nM 
200 nM 10 µL 0.91 1.75 57 nM 
100 nM 10 µL 0.61 1.74 89 nM 
50 nM 10 µL 0.53 1.76 25 nM 
 
Figure 47 Comparison of different enzyme concentrations and reaction volumes. 
Each protein has its own optimal pH range, in which it is most stable. In the context of a  
conformational assay, protonation states of different residues can alter the minimum-energy 
protein conformation. Therefore, the pH might influence the assay readout as different protein 
conformations could be detected, both in the apo and the bound form. In addition, electronic 
charges around solvatochromic fluorophores influence their fluorescence characteristics, so 
changing these could lead to a varied assay response. In order to find the optimal pH for  
iFLiK, Z’ and S/N were determined for the pH range 7-8 (experience from prior handling 
with the protein showed that it is unstable at high pHs, whereas a calculated pI of 6.09 depicts 
the lower pH limit). Interestingly, all buffers were equally suited for our recombinantly  
expressed Akt construct across the whole range, although pH 7.4-7.6 provided the best long-
term stability of the protein. 
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Figure 48 Summary of iFLiK performance at different pHs. 
Proteins are known to be sensitive to DMSO, which is usually employed as solvent for stock 
solutions of small molecules in molecular biology. To investigate this effect on our recom-
binant Akt construct, the Z’-factor and signal-to-noise ratios were determined by incubating 
the labelled protein with MK-2206 at different DMSO concentrations. While concentrations 
between 1-5% did not significantly reduce either Z’ or S/N, the values at 0.5% DMSO  
exhibited high fluctuations in the bound state, presumably owed to bad solubility of the  
inhibitor. Since the protein was stable even in solutions up to 5% DMSO for longer incu-
bation times, this concentration was chosen for future experiments. 
 
Figure 49 Z’-factor and signal-to-noise ratios of iFLiK in dependence of DMSO present. 
In 384-well plates, the shape of the solution in the well is strongly affected by interactions 
with the polystyrene surface and overlying air due to high surface-to-volume ratios. General 
experience in high-throughput screening has shown that they tend to adopt irregular shapes, 
leading to big errors in the fluorescence intensity readouts. This can be ameliorated by the 
addition of detergents, which mediate interactions at the phase boundaries (both liquid-solid 
and liquid-air). However, they also have the tendency to destabilise the protein, so minimising 
the detergent concentration is desirable. Again, the assay was carried out with MK-2206 as 
positive control in 0.001%, 0.01% and 0.1% of Tween-20, Triton X-100, Brij-35, NP-40 and 
CHAPS each. As expected, the control wells without detergent exhibited very high  
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fluctuations resulting in a Z’ < 0, indicating an unacceptable reliability. In general, signal-to-
noise ratios were uniform across all detergents (except with very low concentrations of  
Triton X-100, Brij-35 and CHAPS). Apart from NP-40, higher detergent concentrations  
stabilised the assay readout, but also decreased protein stability (higher fluctuations with  
increasing incubation time). At the lowest concentrations with still good Z’-factor values (i.e. 
0.01%), Triton X-100 proved to give the most stable signals, even after 24 h incubation. 
Therefore, the optimal detergent concentration was appointed to 0.01% Triton X-100. In addi-
tion, this experiment (as well as previous ones) showed that the best results could be obtained 
after an incubation period of 2-3 h at RT. 
 
Figure 50 Overview of detergent effect on iFLiK results. 
A variety of inorganic salts are regularly used as buffer ingredients fulfilling different purpo-
ses. For kinases, magnesium and manganese salts in particular are often added to stabilise the 
enzyme, since Mg
2+
 is a native co-factor (and Mn
2+
 a magnesium mimic).
178
 To examine their 
effect in iFLiK, apo and MK-2206-incubated Akt was incubated with a combination of MgCl2 
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and MnCl2 concentrations between 0-50 mM. These experiments showed that signal-to-noise 
did not change significantly, regardless of the buffer composition. However, MgCl2 brought a 
40% decrease in fluorescence intensity of the PyMPO label in the apo Akt, but not in the  
ligand-bound state. In a control experiment with βME-labelled PyMPO in the same buffer, 
50 mM of either MgCl2 or MnCl2 did not have any effect on the fluorescence, thereby ruling 
out direct interactions between fluorophore and ions via changes in electrostatic charge, ionic 
strengths or collisional frequency (Figure 51). Instead, a specific interaction of Mg
2+
 with the 
apo protein has to be assumed. For this reason, the introduction of any unnecessary salts to the 
system was avoided to maintain the highest possible sensitivity. 
  
  
Figure 51 Influence of magnesium and manganese ions in iFLiK. A) PyMPO fluorescence of labelled protein 
in dependence of MgCl2 (left) and MnCl2 (right) concentration. B) Matrix of signal-to-noise ratios 
in buffers with different Mg2+ and Mn2+ concentrations. C) Comparison of free PyMPO fluores-
cence in standard iFLiK buffer, and with 50 mM MgCl2 and MnCl2.  
Recombinantly expressed Akt is known to be inactive, i.e. unphosphorylated at Thr308.
179
 
Therefore, a mixed population of different conformations can be assumed to exist in equili-
brium. As iFLiK detects the transition from the open to closed conformation, it was specu-
lated that shifting the equilibrium more to the open conformation prior to adding the ligand 
could provide an enhanced assay response. For that, PyMPO-labelled de92 was incubated 
with a concentration series of IP4 up to 10 µM. In a second experiment, the kinase was pre-
incubated with 10 µM IP4 before carrying out the assay as usual with MK-2206. The  
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phosphoinositol IP4 is commonly used as a PIP3 mimic as it is known to bind in the phosphate 
pocket of Akt, inducing an opening of the conformation. Therefore, any Akt in the closed 
conformation should open up, resulting in a blue-shifted emission spectrum of the apo kinase. 
Titration of the iFLiK construct with IP4, however, did not change the PyMPO fluorescence 
spectrum. Likewise, pre-incubation with the phosphoinositol did not have any effect on the 
assay curves with allosteric inhibitors. Taken together, these results suggest that the equi-
librium of the recombinantly expressed Akt essentially lies at the open state already. 
 
Figure 52 iFLiK response to the presence of the activator IP4. Left: titration series of PyMPO-labelled Akt 
with IP4. Right: MK-2206 dose-response curves with and without pre-incubation with 10 µM IP4. 
On the other hand, the PH and kinase domain can only be close towards each other in the 
DFG-out conformation. To investigate whether a prior occupation of the ATP binding pocket 
has any influence on the binding of allosteric inhibitors, Akt was pre-incubated with 10 mM 
ATP and 100 µM ATP-competitive inhibitors (GSK690693, CCT128930 and H-89) before 
adding MK-2206. Additionally, the apo protein was incubated in increasing concentrations of 
ATP up to 10 mM. Both experiments reveal that none of these ATP pocket binders have an 
effect on the assay readout or the binding of allosteric inhibitors, providing identical assay 
windows and Kds. The only differences were observed for GSK690693, which already caused 
a slight bathochromic shift at 100 µM (see Figure 44). The addition of MK-2206 produced the 
same end point, which was reached at slightly higher concentrations (Kd of GSK690693-
preincubated MK-2206 measurement about 2.5 times higher than the control measurements 
and preincubation with the other ATP pocket binders). This observation could suggest a  
partial occupation of the inter-domain binding pocket by GSK690693. Further implication of 
this will be discussed at the end of this chapter. 
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Figure 53 Response of PyMPO fluorescence in increasing ATP concentrations. Left: PyMPO emission  
spectra (red = apo; green = 10 mM ATP). Right: fl638/fl508 ratio plotted against ATP concentration. 
 
Figure 54 iFLiK assay response when pre-incubated with ATP or ATP-competitive inhibitors. Left: PyMPO 
emission spectra of pr-eincubated Akt before addition of MK-2206. Right: MK-2206 dose-
response curves after 1 h pre-incubated Akt. 
In their role as enzymes that have to dynamically catalyse phosphorylation reactions, kinases 
are rather unstable proteins. In fact, empirical data in our own group indicate that some  
kinases lose their activity after a few hours at RT, whereas others are stable for several days. 
In previous measurements, the recombinantly expressed Akt mutant displayed favourable 
stability, providing reliable iFLiK data even after 3 days at 4 °C. However, minute drifts in 
the PyMPO spectra causes slight decreases of the fl638/fl508 ratios over time, which increase 
more when left at RT for longer time periods (Figure 55A). After 8 days at RT, the maxima of 
all curves in a dilution series have reached the same shape with an emission maximum at 
543 nm, indicating that the protein is denatured and can no longer be distinguished between 
apo and bound form. To better understand the assay response towards the protein’s state, apo 
and MK-2206-bound de92 fluorescence was compared under different conditions: a) aggre-
gative denaturation by heating up hermetically to 50 °C for 5 h, b) dissociative denaturation 
by adding guanidinium chloride and c) standard treatment for comparison. While the standard 
measurement conformably provided different spectra for apo and bound protein (maximum at 
563 nm and 572 nm, respectively), the wells subjected to thermal denaturation did not, both 
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showing an emission maximum at 543 nm, indicating their inability to distinguish ligand 
binding. Consistent with the linearisation of proteins known to be caused by the denaturant, 
the GndCl-treated spectra were lower in intensity, red-shifted to 582 nm and did not distin-
guish between apo and MK-2206 measurements. All spectra correctly reflected the expected 
polarity changes upon denaturation and confirmed that the allosteric inhibitor MK-2206 was 
not able to bind to the denatured Akt anymore. In conclusion, as the protein in iFLiK  
experiments eventually also reached a fluorescence maximum at 543 nm, we can assume that 
the protein has denatured by aggregation after 8 days at RT. 
  
 
emission max apo saturated 
native 563 nm 572 nm 
aggregated 543 nm 543 nm 
linearised 582 nm 582 nm 
 
Figure 55 A) Hypsochromic emission shifts of PyMPO over long periods. B) Akti-1/2 dose-response curves 
over longer incubation periods at RT. fl508/fl638 ratios drop over time, describing the denaturing 
process of the protein. C) iFLiK response to denaturing conditions (apo = apo Akt, sat = saturated 
with MK-2206, nat = natively folded, agg = aggregated by thermal denaturing, lin = linearised 
with GndCl). 
After this extensive and careful assay optimisation, the iFLiK assay could now be used to 
determine binding affinities of all Akt inhibitors available in our lab. These include the allo-
steric commercially available MK-2206 and Akti-1/2, the synthesised 63a-g and 64a-d, as 
well as the ATP-competitive GSK690693, CCT128930 and H-89 (Figure 56). Intrinsic com-
pound auto-fluorescence was accounted for by subtracting fluorescence intensities of the re-
spective compound alone in buffer. All allosteric inhibitors provoked a bathochromic shift of 
the emission spectrum up to 16 nm, which allowed the determination of their Kds (Table 10). 
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Mixtures of inhibitors with PyMPO-labelled glutathione or β-mercaptoethanol displayed no 
change in their fluorescence spectrum, confirming that the observed responses are specific to 
the conformational changes of Akt, and not due to interaction with the fluorophores alone. 
The SAR gained from the Kds perfectly mirrors the IC50s determined in the activity-based 
KinEASE assay (Table 5). Interestingly, weak ID inhibitors seem to level out earlier and to 
not reach the same end point as the potent inhibitors, maybe due to solubility issues. Kd values 
were obtained using equation (9) with the MK-2206 end point as upper asymptote. In  
comparison, the classic ATP-competitive Akt inhibitors had no effect on PyMPO fluores-
cence. Only at very high concentrations (>100 µM), some very potent ATP-competitive  
inhibitors show an erratic behaviour. The subnanomolar inhibitor GSK690693 for example 
started to produce a bathochromic PyMPO shift that resembles the shift caused by ID inhi-
bitors. There are three explanations for this finding: 1) Occupation of the ATP binding site 
could be picked up by the PyMPO label. However, since the label is located at the  
PH domain, and this effect was not observed with other ATP-competitive Akt inhibitors, and 
only at high concentrations of GSK690693, this could not be substantiated by any rationale. 
2) Direct interaction of GSK690693 with the fluorophore could cause a spectrum change. 
However, control experiments with the free PyMPO and GSK690693 alone showed that the 
inhibitor did not have any influence on the emission spectrum, refuting this hypothesis. This 
leaves 3) a conformational change caused by unspecific binding of GSK690693 to another 
part of the kinase once the ATP binding pocket is saturated with the inhibitor, which could 
include the allosteric binding pocket. Earlier experiments, in which preincubation of Akt with 
100 µM GSK690693 decreased the binding affinity of MK-2206, might indicate in the same 
direction, further corroborating this hypothesis. To allow for an accurate interpretation of the 
data, this phenomenon will have to be investigated in more detail. In the status quo, however, 
this is pure speculation. 
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Figure 56 iFLiK assay response for allosteric and ATP-competitive Akt inhibitors. 
Table 10 Binding affinities for allosteric and ATP-competitive Akt inhibitors determined with iFLiK.  
n.r. = no response up to 500 µM. 
Ligand Kd / µM 
63a 0.41 ± 0.07 
63b 0.15 ± 0.04 
63c 6 ± 2 
63d 0.9 ± 0.3 
63e 7.2 ± 0.9 
63f 1.1 ± 0.2 
63g 8 ± 1 
64a 0.43 ± 0.01 
64b 1.2 ± 0.3 
64c 2.6 ± 0.9 
64d 18 ± 16 
MK-2206 0.09 ± 0.01 
Akti-1/2 0.08 ± 0.02 
GSK690693 n.r. 
CCT128930 n.r. 
H-89 n.r. 
In summary, the iFLiK assay has been successfully established. The optimal assay conditions 
were determined to be: incubation of inhibitors with 5% DMSO at RT for 2-3 h in 10 µL of a 
200 nM PyMPO-labelled Akt construct in a buffer of 50 mM HEPES, 200 mM NaCl, 0.01% 
Triton X-100, pH 7.4-7.6. iFLiK was proven to be very dependable, giving reproducible re-
sults even after a 3 day-incubation period at RT and with 2 year old proteins stored at -80 °C. 
Consistent and reproducible results could be repeatedly obtained with different batches of 
labellings and expressions. The ability of iFLiK to detect conformational changes of Akt  
induced by allosteric inhibitors was successfully demonstrated. ATP-competitive inhibitors do 
not facilitate the closed conformation and, therefore, were not detected by the iFLiK assay. 
0.4
0.45
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.1 1 10 100 1000 10000 100000
fl
6
3
8
/f
l 5
0
8
 
inhibitor concentration / nM 
MK-2206 Akti-12
63a 63b
63c 63d
63e 63f
63g 64a
64b 64c
64d GSK690693
CCT128930 H-89
 Results and Discussion 81 
 
3.5.4 Validation with NanoTemper Assay 
In order to validate the Kd values obtained with iFLiK, orthogonal assay systems were  
required. The NanoTemper assay was chosen, as it is based on an entirely different physical 
property: NanoTemper monitors the thermophoresis of proteins or ligands in a temperature 
gradient. This gradient of about 2-8 K is produced by an IR laser over a distance of 150 µm 
inside a capillary. Changes of their hydrodynamic properties such as hydration shells, charges, 
conformations or masses are reflected in an altered diffusion behaviour (see detailed descrip-
tion of the assay principle in chapter 0). To enable the selective tracking of the protein’s 
movements, it needed to be fluorescently labelled. Examining the available excitation and 
emission filters, Alexa Fluor 568 and Atto 550 were chosen as fluorophores (Figure 57). 
 
 
Figure 57 Structure and fluorescence spectra (solid lines = emission, dotted lines = excitation) of NHS ester 
conjugates of Alexa Fluor 568 (blue) and Atto 550 (green). The structure of Atto 550 is not public-
ly disclosed. 
For an orthogonal labelling, the NanoTemper labels were attached to amino substituents via 
NHS ester conjugates. To this end, de92 was incubated with 5 eq Alexa Fluor 568 at pH 8.3 
for 1 h at 4 °C. The AF568-labelled protein was purified over a size exclusion column. To 
calculate the ratio of fluorophore:protein, the concentrations of fluorophore and protein were 
determined by photometric measurements at 595 nm (where only the fluorophore absorbs) 
and 280 nm (where both fluorophore and protein absorb) with equation (10). After deter-
mining the molar extinction coefficient for both species at 280 nm and 595 nm, the labelling 
ratio was determined to 3.7:1 (Figure 58).  
    
    
       
    
                
      
 (10) 
cfl = fluorophore concentration     cp = protein concentration   
εfl,595 = molar extinction coefficient of fluorophore at 595 nm  A595 = absorption at 595 nm   
εfl,280 = molar extinction coefficient of fluorophore at 280 nm  A280 = absorption at 280 nm 
εp,280 = molar extinction coefficient of protein at 280 nm 
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εfl,280 = 41297 cm
-1 M-1    εfl,595 = 48606 cm
-1 M-1 
Figure 58 Left: Purification of AF568-labelled de92. Right: photometric calibration curves for determination 
of extinction coefficients and concentrations. 
Due to extreme surface-to-volume ratios inside the capillaries used for NanoTemper, many 
proteins tend to aggregate on the inner tube surface. To investigate the stability of the protein 
solution in the capillaries, a 100 nM Akt solution was transferred into standard treated glass 
capillaries. A cross-section spatial scan across the capillary diameter revealed a bifurcated 
fluorescence spectrum, indicative for protein aggregation on the surface. Several alternatives 
were explored: 1) Change capillaries to glycosyl-coated hydrophilic capillaries or PEG-coated 
hydrophobic capillaries to modulate phase boundary-effects, 2) change detergent from 0.01% 
Triton X-100 from the iFLiK buffer to 0.05% of the stronger Tween-20 and 3) sharply  
centrifuge protein solution prior to capillary transfer to separate aggregated proteins by  
pelleting. However, neither of these measures nor any of these combinations improved protein 
stability (Figure 59).  
 
Figure 59 Capillary scans of AF568-labelled de92 in A-C) standard treated, D) hydrophilically coated and E) 
hydrophilically coated capillaries. A, B, D and E are in a buffer consisting of 50 mM HEPES, 200 
mM NaCl, 0.01% Triton X-100, pH 7.4, whereas 0.05% Tween-20 was used as detergent in C. B 
represents the supernatant after centrifuging at 20,000 g  for 10 min. 
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Interestingly, when incubating Akt with increasing concentrations of MK-2206, a stabilisation 
of the protein was observed (Figure 60). Since stabilisation of proteins by complexation with 
ligands is a well-known phenomenon, it supports the assumption that the bifurcated spectrum 
in the apo form is indeed owed to protein instability. Eventually, stable fluorescence signals 
could be obtained using enhanced gradient capillaries that have a smaller diameter and  
therefore reduce aggregations. 
 
Figure 60 Capillary scan of AF568-labelled de92 incubated with dilution series of MK-2206 in standard 
treated (upper) and enhanced gradient (lower) capillaries. 
As a proof of concept, labelled de92 was incubated with a dilution series of 63b in both 
standard treated and enhanced gradient capillaries, and their thermophoresis upon temperature 
jump was monitored over time. In standard treated capillaries, the measurements were  
hampered by random (in some cases very substantial) fluctuations caused by protein aggre-
gates. These problems did not occur in enhanced gradient capillaries, where a nice dose  
dependence could be ascertained. 
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Figure 61 Thermophoretic curves for Akt-MK-2206 complexes in standard treated (left) and enhanced gradi-
ent capillaries (right). The red curves correspond to apo Akt, the green curves to saturated Akt. 
Having established that a change in thermophoretic behaviour could indeed be observed for 
different concentrations of ligands, we set out to optimise the assay conditions. First, the  
effect of laser and LED intensity were examined. While increasing the LED brightness  
produced a stronger fluorescence, bleaching of the fluorophore was also accelerated. 90% 
LED power was determined as a good compromise for the relatively photon-stable Alexa  
Fluor 568, which still gave good signal intensities. On the other hand, increasing the IR laser 
power creates a steeper temperature gradient inside the capillary, but also promotes thermal 
degradation of the protein. However, no adverse effects could be observed for our kinase  
under even strong irradiation, so laser intensities were set to 100%. To determine the optimal 
assay conditions and readout, the assay was carried out for different thermophoresis durations, 
and the ratio of fluorescence intensities was calculated for different combinations of the  
respective end points to intensities at various time intervals (just before temperature jump, 
immediately after temperature jump, and about 3 seconds later when the system has adjusted 
to equilibrium at the new temperature). With these values, the Z’-factor and signal-to-noise 
ratios for the different permutations were inspected using 6 measurements each of apo and 
MK-2206-bound Akt. These experiments revealed that a longer thermophoresis time  
uniformly provided higher S/N ratios. While calculating fluorescence ratios immediately after 
the T-jump gives a higher S/N, the data is less reliable than when thermal equilibrium has 
ensued. In consequence, a sequence of 5 s equilibration, 45 s thermophoresis and 5 s back 
diffusion was programmed, and the ratio of fluorescence intensities at 45 s to 9 s was chosen 
as assay readout. 
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Figure 62 Determining optimal assay readout for NanoTemper assay. Calculated Z’-factors and signal-to-
noise ratios for the various combinations depicted in the thermophoresis plot. Before refers to the 
time just before the temperature jump, after to the time immediate after the temperature jump, and 
delay to the time at which the system has adjusted to equilibrium at the new temperature. 
In these configurations, the synthesised probes 63a-g, and the references MK-2206 and 
GSK690693 were measured with NanoTemper, and the Kd values were calculated using the 
internal evaluation software with a 4-point Hill equation (11). Attempts to use the alternative 
Kd-driven equation (12) produced inapt fitting curves. Interestingly, re-measuring the inhi-
bitors after 6 h still inside the capillaries at RT produced the same results, suggesting that the 
protein solution was now stable in the enhanced gradient capillaries. After obtaining Kds with 
equation (11), mixtures of the same compounds incubated with Alexa  
Fluor 568 alone were recorded as a negative control. In accordance to expectations, no  
thermophoretic responses were observed, thereby ruling out those arise from direct inter-
actions of the compounds with the fluorophore. 
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  ( )  
  
     
 (11) 
c = ligand concentration  H = Hill coefficient  Kd = dissociation constant   
 
  ( )    
 (       √(      )      )
  
 (12) 
c = ligand concentration L = lower asymptote A = binding amplitutde T = protein concentration 
 
 
Figure 63 Upper: Exemplary thermophoretic plots of Akt with allosteric (MK-2206) and ATP-competitive 
inhibitors (GSK690693). Lower: Dose-response curves of allosteric and ATP-competitive Akt  
inhibitors measured with NanoTemper. 
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Figure 64 No thermophoretic response when Akt inhibitors were incubated with Alexa Fluor 568 alone. 
To investigate the effect of the PyMPO labelling on the binding affinity of the inhibitors to 
Akt, all previously described NanoTemper experiments were repeated for de92 that is labelled 
with both Alexa Fluor 568 via amine groups and PyMPO via the Cys49 thiol group. For this, 
the previously AF568-labelled de92 was further incubated with PyMPO following the same 
protocol as for iFLiK experiments. As the results in Table 11 show, the dually labelled Akt 
exhibits near-identical binding affinities to allosteric as well as ATP-competitive inhibitors as 
the single-labelled Akt did. This indicates that PyMPO labelling of Akt via Cys49 does not 
significantly change affinity towards its inhibitors. 
Table 11 Overview of Kds for the single AF568-labelled and the dually AF568/PyMPO-labelled de92 
measured with NanoTemper. 
Kd / µM AF568 AF568/PyMPO 
63a 0.33 ± 0.09 0.41 ± 0.03 
63b 0.18 ± 0.05 0.18 ± 0.05 
63c 3.9 ± 0.8 3.6 ± 1.5 
63d 1.3 ± 0.6 1.5 ± 1.0 
63e 27 ± 10 31 ± 9x 
63f 2.1 ± 0.1 2.5 ± 0.9 
63g 16 ± 8x 13 ± 8x 
MK-2206 0.06 ± 0.01 0.06 ± 0.02 
GSK690693 7.0 ± 2.1 5.9 ± 0.8 
Since this dually labelled Akt also carried the PyMPO label at Cys49, it was reasonable to 
assume that conducting iFLiK experiments would still be possible by exciting PyMPO.  
A comparative excitation scan of the single- and dual-labelled protein shows a near-zero  
absorption of the AF568-labelled kinase at 440 nm, whereas the AF568/PyMPO-labelled  
kinase exhibited sufficiently high absorptions at this wavelength. Therefore, dilution series of 
allosteric and ATP-competitive Akt inhibitors were incubated with both constructs and their 
emission spectra recorded upon excitation at 440 nm. As anticipated, the single-labelled  
protein showed negligible fluorescence, confirming that Alexa Fluor 568 was not excited  
under these conditions. Remarkably, in the AF568/PyMPO labelled protein, instead of a 
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broad emission spectrum with a maximum around 560 nm that would be expected for  
PyMPO, a narrow emission around 606 nm characteristic for Alexa Fluor 568 was observed. 
With increasing inhibitor concentration, this spectrum was not red-shifted, but exhibited an 
increase in intensity by up to about 2 times (Figure 65). No increase occurred for the ATP-
competitive GSK690693, suggesting that this effect is still iFLiK-specific. 
 
 
 
Figure 65 Left: Excitation spectra of AF568-labelled and AF568/PyMPO-labelled Akt. Right: Spectrum 
changes of these two differently labelled proteins (upper: Alexa Fluor 568; lower: Alexa Fluor 568 
+ PyMPO) when incubated with dilution series of the allosteric inhibitor 63b upon excitation at 
440 nm (red = apo; green = saturated). 
The only species in this system absorbing at 440 nm is PyMPO, so the most plausible  
explanations were an extreme bathochromic shift of PyMPO or an energy transfer from  
PyMPO to Alexa Fluor 568. PyMPO emission is much broader in general and unable to reach 
these long wavelengths (even in the most polar solvent H2O, the emission maximum is at 
586 nm), rendering the first explanation highly unlikely. Considering the excitation spectrum 
of Alexa Fluor 568, however, a great spectral overlap with the PyMPO emission can be  
discerned. As the PyMPO spectrum is bathochromically shifted upon incubation with  
allosteric inhibitors in the iFLiK setup, this overlap is increased even more, which explains 
the signal increase observed in the dually labelled kinase (and the lack thereof upon incu-
bation with ATP-competitive inhibitors). 
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Figure 66 PyMPO emission (solid lines) and Alexa Fluor 568 excitation (dotted line) exhibit a high spectral 
overlap, which is even increased further upon bathochromic shift of the PyMPO spectrum when 
incubated with allosteric inhibitors (red = apo; green = saturated). 
Using this signal increase for dose-response curves, sigmoidal curves were obtained for  
allosteric inhibitors, which were used to calculate the binding affinity analogous to the iFLiK 
experiments. Although very crude and subject to high fluctuations, a rough estimate for the Kd 
could be obtained, which seem to be higher by a factor of about 2-3. This might indicate that 
labelling with Alexa Fluor 568 slightly decreases the binding affinity of Akt to allosteric  
inhibitors. 
 
Inhibitor Kd / µM 
63a ~ 0.7 
63b ~ 0.3 
63c ~ 52 
63d ~ 7 
63e ~ 83 
63f ~ 8 
63g ~ 92 
MK-2206 ~ 0.1 
GSK690693 n.r. 
H-89 n.r. 
 
Figure 67 Dose-response curves of AF568/PyMPO-labelled de92 when incubated with allosteric and ATP-
competitive Akt inhibitors, using 440 nm as excitation wavelength and fl638/fl508 as assay readout, 
and their respective calculated Kds. n.r. = no response up to 500 µM. 
Interestingly, irradiating the dual-labelled Akt at 570 nm also produced a dose-dependent  
fluorescence increase of Alexa Fluor 568 specific to allosteric inhibitors, which cannot be 
observed in the single-labelled Akt (Figure 68). Although PyMPO does not absorb at this 
wavelength, this finding suggests that PyMPO has a role of some kind in this phenomenon.  
A more detailed investigation will be left for future work as this additional information did 
not impede the main purpose of NanoTemper to provide an orthogonal method to measure 
binding affinities of Akt. 
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Figure 68 Top: Excitation spectra of PyMPO and Alexa Fluor 568. At an excitation at λ = 550 nm, PyMPO 
does not absorb. Middle & bottom: Fluorescence emission spectra of AF568-labelled (left) and 
AF568/PyMPO-labelled Akt (right) when incubated with of the allosteric 63b (middle) and the 
ATP-competitive GSK690693 (bottom) at increasing concentrations (red = apo; green =  
saturated). 
Comparing the binding affinities obtained with NanoTemper to the iFLiK results, both assays 
produce very similar results. Figure 69 nicely shows that the Kd values are almost identical for 
all allosteric inhibitors, except for low affinity ligands such as 63e and 63g, which seem to 
be evaluated differently by the two assay systems and deviate from each other. The higher Kd 
determined with NanoTemper is probably owed to the unspecific labelling with Alexa Fluor 
568, which was shown to decrease the binding affinity of Akt to its inhibitors. Most  
importantly, while iFLiK distinguishes between allosteric and ATP-competitive, the Nano-
Temper assay does not. 
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Figure 69 Comparison of Kds obtained with NanoTemper for both proteins and with iFLiK for comparison. 
Finally for the sake of completeness, the binding of the inhibitors to Akt1 wt was investigated 
by labelling commercially available Akt1 wt (purchased from Millipore) with Alexa Fluor 
568. Since the commercial kinase has been activated by PDK1, its catalytic activity could be 
measured with the KinEASE assay before and after labelling with the fluorophore. The  
parallel experiments with different concentrations of the kinase show that Akt retained its 
catalytic activity after Alexa Fluor 568 labelling, but with a slightly lower activity  
(Figure 70): The concentration of half-maximal activity AC50 was reached at 55 pM for the 
unlabelled and 158 pM for the labelled enzyme. Like the binding affinity determined earlier, 
the potency of the AF568-labelled kinase was reduced by about 3-fold by the unspecific  
alkylation of amine residues. 
 
 
AC50 
/ pM 
unlabelled 55 ± 4 
labelled 158 ± 10 
 
Figure 70 Akt1 wt still shows activity after labelling with Alexa Fluor 568 with a slightly increased AC50. 
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Due to its high protein consumption, only a few experiments were possible with the  
commercially purchased kinase. These experiments, however, indicated that the activated 
kinase exhibited a higher affinity for ATP-competitive inhibitors than the inactive (Kd of 
GSK690693 was determined to 0.2 µM for the active and 5.9 µM for the inactive Akt), and 
show no response to allosteric inhibitors up to 500 µM. Preliminary, unpublished findings by 
the Zimmermann group obtained with Biacore reflect this phenomenon.
180
 It is also well 
known that ATP-competitive inhibitors bind preferably into active conformations of kinases, 
whereas allosteric inhibitors have a stronger affinity towards the inactive form. For this  
reason, to enable a direct comparison between wt and the iFLiK mutant, the Akt1 wild type 
would have to be expressed under the same conditions as de92. This could be subjected in 
future works. Previous studies in our own group with other kinase, however, have shown that 
most Cys-to-Ser mutations of surface-exposed cysteines had little impact on the kinase  
activity or binding affinity compared to the wild type.
153,181
 
As an alternative fluorophore, Atto 550 was explored for its use with the NanoTemper assay. 
In analogy to the previous experiments with Alexa Fluor 568, de92 was incubated with 5 eq 
of the Atto 550 NHS ester at pH 8.3 for 1 h at 4 °C and purified over a size exclusion column. 
After calculating its molar extinction coefficients with equation (10) shown below to  
εfl,280 = 13534 cm
-1
 M
-1
 and ε fl,595 = 4409 cm
-1
 M
-1
, the labelling ratio was determined to be 
1.5:1. The Atto 550-labelled protein, too, did not aggregate in the enhanced gradient  
capillaries. However, when performing thermophoresis measurements with dilution series of 
the various Akt inhibitors, the assay exhibited a highly erratic behaviour (Figure 71): With 
increasing residence time in the capillary, the thermophoretic diffusion increased as well (i.e. 
the fluorescence intensity ratio hot/cold dropped), as it was discovered by measuring the same 
concentrations at different times. This effect was observed for all measured Akt inhibitors and 
was independent of the inhibitor’s nature, mode of action or concentration. Like many  
Atto-Tec products, Atto 550 was now identified as a fluorophore unsuitable for NanoTemper. 
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Figure 71 Thermophoresis curves and NanoTemper response of Atto 550-labelled de92 incubated with  
increasing concentrations of MK-2206. Upper: Capillaries with the same concentrations measured 
at different capillary residence times (darker blue = 1-12 min; lighter blue = 13-24 min) exhibit  
increased thermophoresis. Lower: Independent measurements after a capillary residence time of 
30 min, no dose-dependent differences in thermophoresis were detectable. 
In summary, the NanoTemper assay has been established for the Akt constructs used in this 
thesis. Except for low affinity ligands, Kds obtained with iFLiK and NanoTemper exhibited a 
very good match, thereby validating the iFLiK assay as an eligible tool for determining  
binding affinities of Akt inhibitors. In contrast to iFLiK, however, NanoTemper cannot  
distinguish between allosteric and ATP-competitive inhibitors as it detects any binding event. 
By comparing two differently labelled constructs, it was shown that PyMPO labelling does 
not significantly alter binding affinity towards Akt inhibitors. On the other hand, AF568  
labelling does slightly reduce activity and binding affinity. Data also indicated that allosteric 
inhibitors preferred the inactive, whereas ATP-competitive inhibitors favoured the active Akt 
enzyme. 
3.5.5 Validation with Biacore Assay 
As an additional orthogonal assay to validate the iFLiK results, the Biacore assay by GE 
Healthcare was explored for this purpose, which is based on the detection of changes on  
surfaces via laser-stimulated surface plasmon resonance. In the present case, the protein is 
immobilised on a gold-coated chip, and the mass increase upon binding of a ligand is  
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measured in real time by a change in the refractive index (for a detailed description of the 
assay, see chapter 1.4.3). A variety of methods for protein immobilisation and protocols for 
the detection of ligand binding to Akt have been tested, which are described in more detail in 
the appendix, chapter 0. 
Even though the resultant protocol gave highly unreliable results, the synthesised probe com-
pounds 63a-g, MK-2206 and GSK690693 were measured nonetheless with this suboptimal 
protocol as a first proof of principle. Despite high fluctuations in the signal intensity, a dose-
dependent change of the gold surface refraction could be detected upon inhibitor binding. 
Using the internal steady state thermodynamics model, the dissociation constants were  
calculated for all inhibitors with limited success. These rough preliminary results indicate that 
the Kds determined with iFLiK and NanoTemper can be reproduced with Biacore, as the 
values are in a comparable range (Figure 72) and mirror the trends observed in the activity-
based KinEASE assay (Table 5). However, while these were single results based on low  
quality data, the inhibitors do exhibit different binding affinities, so they can only be treated 
as a rough guide. 
 
Figure 72 Comparison of dissociation constants determined with the different assay technologies. 
Since experiments with the NanoTemper assay have already provided the required infor-
mation, establishing the Biacore assay for Akt as an additional analytical method was  
eventually abandoned due to problems with the protein immobilisation, which is the most 
common bottleneck for establishing Biacore assays.  
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3.6 High-Throughput Screening 
After establishing a proof of concept, optimising the protocol and validating the results with 
orthogonal assay systems, the iFLiK assay can now be used in the high-throughput screening 
of compound libraries to identify novel allosteric inhibitors of Akt. 
3.6.1 Primary Screen of RL Library 
The RL library is an in-house collection of compounds that were synthesised in the Rauh 
group over time for various projects or bought from commercial sources. Therefore, it is  
highly enriched in ATP-competitive kinase inhibitors specifically developed for various  
kinase families. As a preparation for larger libraries, this RL library was screened first to 
gather experience in setting up primary screens and interpreting the resulting data. This pilot 
screen will help in further optimising the protocols for using iFLiK in HTS campaigns. At an 
compound concentration of 10 µM, all 1099 inhibitors were incubated for 2 h each with 
200 nM of PyMPO-labelled de92 and buffer in 384-well plates using several DMSO wells as 
negative and MK-2206 as positive controls. Fluorescence intensities at 508 nm and 638 nm 
when excited at 419 nm were recorded, the inhibitor-in-buffer signals subtracted as back-
ground correction, and the remaining fl638/fl508 ratio calculated. Compounds that produced at 
least 25% of the positive control signal response in either direction were considered as hits. 
In this 1-point primary screen, 25 compounds appeared as hits using this 25% cutoff (apart 
from the known allosteric Akt inhibitors), representing an initial hit rate of 2.27%. However, 
12 of these compounds exhibited an intrinsic fluorescence of more than 50% of the PyMPO 
signal. It was therefore very likely that the detected changes in the fl638/fl508 ratio purely arose 
from fluctuations in the compounds fluorescence. And indeed, when following up on these 
hits in dilution series iFLiK experiments, none of these strongly fluorescent molecules were 
able to provoke the expected dose-dependent bathochromic shift of PyMPO emission up to 
500 µM. 7 of the other non-fluorescent hits in the primary screen at 10 µM exhibited a highly 
erratic behaviour in the follow-up and displayed no clear dose dependency. A closer look  
revealed that although their auto-fluorescence only became significant at higher  
concentrations, a low fluorescence at 10 µM had been the cause for the false hit. In addition,  
4 compounds that gave a >25% response in the single 1-point measurement did not produce 
any response in the triplicate dilution series experiment, which is owed to random outliers  
unavoidable in single point measurements and can only be detected by repetition or multi-
plicate measurements.
182
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Ultimately, 2 compounds evoked the expected dose-dependent bathochromic PyMPO 
 emission shift. However, these compounds are K252a, a known broadband kinase inhibitor 
derived from staurosporine, and GSK690693, a known commercially available Akt inhibitor. 
Although both being not allosteric, this is consistent with the finding that only very potent 
ATP-competitive inhibitors seem to produce a slight PyMPO red-shift at high concentrations, 
as it was discussed in chapter 0. This still shows that ATP-competitive Akt inhibitors are not 
detected by iFLiK in general as they do not facilitate inter-domain interactions between the 
PH and kinase domain, which is corroborated by the fact that the less potent CCT128930 and 
H-89 (IC50s of 29 nM and 2 µM, respectively) were not picked up in the primary screen. As a 
result, the actual validated hit rate in this screen is 0.18%. This is a pleasantly low value, as it 
indicates that iFLiK does not produce many random false positives. 
 
Figure 73 Validated hits found in the screen of the RL library with iFLiK. 
For validation purposes, all 25 hits were tested for their inhibitory activity on Akt1 with the 
KinEASE assay. As expected, none of the fluorescent compounds were confirmed as actual 
Akt inhibitors, whereas the inhibition by K252a and GSK690693 could be shown. This means 
that the screen of the RL library with iFLiK produced a 0.18% validated hit rate with no false 
positives. However, intrinsic compound fluorescence presented the main limitation in identi-
fying inhibitors with iFLiK. This screen has shown that compounds with an auto-fluorescence 
of 50% of the PyMPO signal can not be investigated with iFLiK. Furthermore, singlicate 
measurements were prone to give false positives, which however can be easily alleviated in 
subsequent dose depency tests. The knowledge from this pilot screen can now be used to  
improve the future screen of larger libraries. 
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3.6.2 Primary Screen of Waldmann Library 
Similar to the RL library, the Waldmann library is an in-house collection consisting both of 
compounds from commercial screening libraries and products and intermediates from past 
synthesis projects in the Waldmann group. It contains about 40,000 compounds and covers a 
greater chemical space than the RL library, including many natural products and their  
derivatives. Following the pilot screen of the Rauh group library, 10,680 compounds from this 
library were screened at 10 µM in 384-well plates, again using MK-2206 as positive and 
DMSO as negative controls. 
As a lesson from the pilot screen, the emission intensities at 508 nm and 638 nm were  
maintained, but an additional excitation wavelength at 440 nm was added (Figure 74): In  
order to avoid intrinsic compound fluorescence, which is more likely at shorter wavelengths, 
irradiation at 75% of the excitation maximum (440 nm in the case of PyMPO) was considered 
a good compromise of signal intensity and interference by auto-fluorescence. However,  
compounds that do still fluoresce at 440 nm are more likely to emit at 508 nm due to their 
smaller Stokes shift than PyMPO. In this case, excitation at 419 nm will provide the signal 
with less background fluorescence. This and the greater signal intensity are the reasons for 
retaining 419 nm as excitation wavelength. Furthermore, comparing the results of the two 
wavelength channels, outliers from random systematic errors can be identified and excluded 
from the final hit list. 
 
Figure 74 Schematic representation of assay strategy employed in the Waldmann library screen to handle 
compound fluorescence and to identify outliers. Excitation (dotted lines) at two different  
wavelengths (419 nm and 440 nm), record emission intensity (solid lines) at 508 nm (red = apo) 
and 638 nm (green = saturated). 
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With 10 µM of each compound in buffer alone as background correction, the fl638/fl508 ratio at 
each excitation wavelength was determined for every compound. A cutoff of more than 25% 
signal change of the MK-2206 control was employed, and the hits were categorised according 
to the following criteria: 
- Promising: Hits that exhibited >25% binding on both channels. 
- Interesting: Hits that exhibited >25% binding on either the 419 nm or 440 nm channel 
or <-25% binding on both channels. 
- Questionable: Hits with borderline affinities on one channel only or an auto-
fluorescence of 0-50% of the PyMPO signal. 
- Artefact: Hits with an auto-fluorescence of more than 50% of the PyMPO signal. 
Applying these selection filters, 215 compounds met these criteria, categorised into 13 promi-
sing, 11 interesting, 35 questionable and 156 artefacts. From experience gained in the pilot 
screen, the results categorised as questionable or artefacts should not be considered as hits and 
were therefore not further investigated. The remaining 24 compounds were picked for follow-
up, representing a 0.22% hit rate for a 1-point screen. In triplicate dose-response  
measurements with iFLiK up to 50 µM, 13 out of these 24 hits from the primary screen were 
validated to produce a dose-dependent change in the fl508/fl638 ratio (Figure 75), which 
amounts to an actual hit rate of 0.12% and a false hit rate of 0.10% for the singlicate screen of 
the Waldmann library. This low value again demonstrates the selectivity of the iFLiK assay, 
as it did not pick up any random compounds. Also, the false hit rate was exquisitely low  
despite being a 1-point measurement. 
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Figure 75 Validated hits from the primary screen of the Waldmann library with iFLiK. 
While all these 13 compounds gave an increase in the fl508/fl638 ratio, a differential response 
can be discerned at a closer look. While 75a-c evoked a bathochromic shift of the PyMPO 
fluorescence spectrum and 77 a hypsochromic shift, the other compounds 67-74 and 76  
primarily caused a reduction of the fluorescence intensity. 
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Figure 76 Different effects of hit compounds in dose dependency studies. While all hits produced an increase 
in the fl508/fl638 ratio, 75a-c effects a bathochromic shift of the PyMPO fluorescence, compounds 
like 67-74 mainly reduced the overall fluorescence intensity. The peptide derivative 77 induced a 
hypsochromic shift and hence a decrease in the fl508/fl638 ratio. 
In order to investigate their inhibitory activity, all 24 hits of the primary screen were  
measured against Akt1 and ΔPH-Akt1 with the KinEASE assay (Table 12). As expected, 
none of the false hits inhibited Akt, whereas 12 of the 13 validated hits from the screen indeed 
were active against the full length Akt1, demonstrating the high selectivity and reliability of 
the iFLiK assay. However, the compounds that quenched the PyMPO fluorescence in the  
iFLiK experiments (except 76, which was inactive overall), as well as 77, which produced a 
hypsochromic PyMPO spectrum shift, showed inhibition of ΔPH-Akt1 as well. Only the  
3 compounds that solely provoked a bathochromic emission spectrum shift were selective for 
the full-length kinase, as would be expected for allosteric inhibitors. 
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Table 12 Biological activity of hits from the primary screen of the Waldmann library. Binding affinities 
were determined with iFLiK, inhibitory activity with KinEASE. Compounds in red cells were 
negative in the iFLiK follow-up (structures not shown), yellow had quenched PyMPO fluores-
cence, green provoked a hypsochromic shift of PyMPO emission, blue a bathochromic shift. n.r. = 
no response up to 500 µM. n.i. = not inhibiting up to 200 µM. 
Compound 
Kd 
/ µM 
IC50 (Akt1) 
/ µM 
IC50 (ΔPH-Akt1) 
/ µM 
67 >500 9 ± 1 3.3 ± 0.1 
68 >500 26 ± 17 10 ± 4x 
69 432 ± 303 56 ± 79 5 ± 2 
70 >500 4.9 ± 0.9 3.4 ± 0.6 
71 >500 11 ± 6x 5 ± 3 
72 >500 7 ± 6 5 ± 3 
73 >500 1.5 ± 0.9 1.1 ± 0.3 
74 >500 11 ± 4x 5 ± 3 
75a 8 ± 4 35 ± 17 n.i. 
75b 22 ± 5x 97 ± 42 n.i. 
75c 194 ± 93x >200 n.i. 
76 >500 - - 
77 9 ± 1 37 ± 22 9 ± 7 
hit 1 n.r. n.i. n.i. 
hit 2 n.r. n.i. n.i. 
hit 3 n.r. n.i. n.i. 
hit 4 n.r. n.i. n.i. 
hit 5 n.r. n.i. n.i. 
hit 6 n.r. n.i. n.i. 
hit 7 n.r. n.i. n.i. 
hit 8 n.r. n.i. n.i. 
hit 9 n.r. n.i. n.i. 
hit 10 n.r. n.i. n.i. 
hit 11 n.r. n.i. n.i. 
The peptide derivative 77 produced a 5 nm blue-shift, which indicates a decrease in the  
polarity surrounding the PyMPO sensor (Figure 76). In our working model for the assay, such 
a decrease can be interpreted as an equilibrium shift of the kinase towards the open confor-
mation. Since this peptide shows Akt inhibition regardless of the PH domain presence, it  
suggests an inhibition by occupying the substrate pocket, which is only accessible in the open 
conformation. Interestingly, the sequence of 77 (CKKRRLKC) does not resemble any of the 
known peptide inhibitors of Akt so far.
56,183,184
 However, this peptide will have to be further 
investigated in more detail for a more accurate statement about its mode of action. 
Compounds 67-74 also showed inhibition of both Akt1 and ΔPH-Akt1 and a slight redshift of 
2 nm, but most prominently reduced the intensity of PyMPO fluorescence by up to 75% (Fig-
ure 76). Such hydrophobic, aromatic, poly-hydroxylic compounds are known to facilitate pro-
tein aggregation and unfolding, and regularly appear in screening campaigns.
185-187
  
Therefore, the fluorescence decrease could be attributed to contact quenching by inter-
molecular collisions with the protein molecules, due to a high local concentration in the  
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aggregates. Usually, such compounds are not followed up on, as their mode of action is very 
unspecific and they do not provide a clear SAR. 
 
Figure 77 Nomenclature of the pyrrolo[2,3-d]pyrimidines found in this screen. 
Only 75a-c provoked a red-shift of the PyMPO emission spectrum by up to 8 nm and inhi-
bited the full-length Akt but not the truncated kinase, suggesting an allosteric mode of action. 
3.6.3 Secondary Screen 
To further explore the binding of 75a-c, another 88 commercially available compounds based 
on this pyrrolopyrimidine scaffold were ordered and tested with iFLiK and KinEASE  
(Table 13). Some of these compounds also showed an effect in the iFLiK assay and exhibited 
selective inhibitory activity on the full-length Akt1, displaying a wide range of Kds deter-
mined with iFLiK and IC50s determined with KinEASE, providing a distinct SAR. 
Table 13 Structures and results of pyrrolopyrimidine inhibitors in binding (iFLiK) and activity (KinEASE) 
assays. n.r. = no response up to 500 µM. n.i. = no inhibition up to 200 µM. 
 
Name R1 R2 
Kd 
/ µM 
IC50 Akt1 
/ µM 
IC50 ΔPH-Akt1 
/ µM 
75d 
75e 
75h 
75a 
75g 
 
H 
3’-Me 
3’-CF3 
4’-Me 
3’-Cl, 4’-Me 
2.2 ± 0.7 
99 ± 61 
n.r. 
2.2 ± 0.5 
264 ± 284 
71 ± 30 
n.i. 
n.i. 
196 ± 102 
1435 ± 132x 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
75i 
 
H n.r. n.i. n.i. 
75j 
 
4’-Cl n.r. n.i. n.i. 
75f 
 
4’-Me 6 ± 4 2760 ± 4431 n.i. 
75b 
75k 
75l  
H 
3’-Cl 
4’-OMe 
7.8 ± 0.7 
n.r. 
n.r. 
160 ± 44x 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
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Name R1 R2 
Kd 
/ µM 
IC50 Akt1 
/ µM 
IC50 ΔPH-Akt1 
/ µM 
75m 
75c  
H 
4’-F 
n.r. 
20 ± 7x 
n.i. 
n.i. 
n.i. 
n.i. 
78a 
78b 
78c 
78d 
78e 
OH 
3’-Me 
4’-Me 
4’-OMe 
4’-OEt 
4’-F 
n.r. 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
79a SMe 4’-F n.r. n.i. n.i. 
79b 
79c 
SEt 
4’-OMe 
4’-OEt 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
80a NHPr 4’-OEt n.r. n.i. n.i. 
80b 
80c 
80d 
80e 
NHiPr 
H 
3’-CF3 
4’-F 
4’-Br 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
80f 
80g 
NEt2 
H 
4’-OMe 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
81a 
81b 
81c 
81d 
 
4’-OMe 
4’-OEt 
4’-F 
4’-Cl 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
81e 
81f  
4’-OMe 
4’-Br 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
81g 
 
H n.r. n.i. n.i. 
81h 
81i  
H 
4’-Br 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
81j 
 
4’-Me n.r. n.i. n.i. 
81k 
 
4’-OEt n.r. n.i. n.i. 
81l 
81m 
81n  
H 
4’-OEt 
4’-Cl 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
81o 
81p 
81q 
81r 
 
H 
3’-Me 
3’-CF3 
4’-F 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
81s 
81t 
81u 
81v 
 
H 
3’-CF3 
3’-Cl, 4’-Me 
4’-F 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
81w 
 
3’-CF3 n.r. n.i. n.i. 
82a 
 
4’-OEt n.r. n.i. n.i. 
82b 
 
3’-F n.r. n.i. n.i. 
83a 
83b 
83c 
83d 
83e 
 
H 
3’-CF3 
4’-Me 
4’-OMe 
4’-Cl 
n.r. 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
83f 
 
4’-OMe n.r. n.i. n.i. 
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Name R1 R2 
Kd 
/ µM 
IC50 Akt1 
/ µM 
IC50 ΔPH-Akt1 
/ µM 
83g 
83h 
83i 
83j 
83k 
 
H 
3’-Me 
3’-Cl, 4’-Me 
4’-OMe 
4’-OEt 
n.r. 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
83l 
 
4’-OMe n.r. n.i. n.i. 
83m 
 
4’-Br n.r. n.i. n.i. 
83n 
 
3’-Cl n.r. n.i. n.i. 
84a 
84b  
3’-Me 
4’-OEt 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
84c 
84d  
4’-F 
4’-Br 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
84e 
 
3’-Me n.r. n.i. n.i. 
84f 
84g  
4’-OEt 
4’-Br 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
84h 
 
4’-OEt n.r. n.i. n.i. 
84i 
84j 
84k  
H 
3’-CF3 
4’-OEt 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
84l 
 
4’-OEt n.r. n.i. n.i. 
84m 
84n 
 
4’-OMe 
4’-Br 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
84o 
84p 
84q  
H 
3’-CF3 
4’-Br 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
85a 
 
4’-OEt n.r. n.i. n.i. 
85b 
85c 
 
H 
4’-OMe 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
85d 
 
4’-OMe n.r. n.i. n.i. 
85e 
85f 
85g 
85h 
85i 
 
H 
3’-Me 
3’-CF3 
4’-OMe 
4’-Br 
n.r. 
n.r. 
n.r. 
n.r. 
n.r. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
n.i. 
86a Cl 4’-OH 14 ± 3x 336 ± 111 n.i. 
86b 
 
3’-OH, 4’-OH n.r. n.i. n.i. 
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Despite this amount of data, a few key facts can be established for the SAR. Most obviously, 
the substituent on the 4-position played a decisive role. It appears that an aromatic system is 
required at the 4-position, as no compound showed any affinity that featured simple small 
groups (like the 78, 79 and 80 family), purely aliphatic chains (like the 81 and 82 family) or 
saturated carbo and heterocycles (like the 83 family) as R1. Even very bulky, hydrophobic 
substituents of the 84 family do not seem to produce the desired activity. Not every aromatic 
group, however, seems to be eligible, as the missing efficacy of the 85 family testify.  
Apparantly, while heterocycles are tolerated (thiophenes and pyridines were active), the  
aromatic ring must not be substituted (like in 85a-i). Positioning of the heteroatom affects the 
efficacy (meta substitution of 75b binds more strongly than ortho-substituted 75c). Further-
more, both the free NH (the N-methylated 75i completely lost activity compared to the fairly 
active 75d) as well as the distance to the core scaffold (longer linker of 75j abolishes activity) 
were identified as crucial parameters. Substitution in the meta position of ring 7 negatively 
affects their affinity (complete loss of activity in 75h and 75k, strong reduction in 75e and 
75g). While a relatively small methyl group in ring 7 para position is well tolerated (affinities 
of 75d and 75a about equal), the methoxy substituent caused a loss of activity, perhaps due 
to its electron-donating nature (75b compared to 75l), whereas the electron-withdrawing 
fluoro substituent restored an otherwise low affinity (75c compared to 75m). Interestingly, 
the 86 family with a cropped down imidazole core instead of pyrrolopyrimidine also  
displayed an allosteric mode of action. Here, too, the meta substitution of the R2 phenyl ring 
reduced their activity (86b compared to 86a). 
In order to understand this SAR, a knowledge of these pyrrolopyrimidines’ binding mode is 
necessary. In the literature, some ATP-competitive Akt inhibitors with a pyrrolo[2,3-d]-
pyrimidine scaffold and their binding mode are known, such as the commercially available 
CCT128930. However, X-ray crystal structures show that these inhibitors form hinge contacts 
to Glu228 and Ala230 via nitrogen atoms at the 1- and 7- position (PDB code 2V06).
188
 An 
analogous binding mode is not possible for the 75 family due to their phenyl substituents at 
the 7- and 5-position. The preferred solution for elucidating their actual binding mode is  
co-crystallisation with Akt for an X-ray structural investigation. However, since the crystal-
lisation has been unsuccessful so far (for a detailed description of the crystallisation experi-
ments see chapter 3.7), a computational approach to calculate their binding modes was chosen 
by docking these structures into published full-length crystal structures of Akt (PDB codes 
3O96 and 4EJN).
76,131
 Without imposing constraints for the modelling, which could bias the 
results computed by Glide, both crystal structures yielded the same two main binding modes  
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(Figure 78): Binding mode A resembles the conformation of Akti-1/2 in 3O96, with the  
phenyl group at the 7-position exerting π-π-interactions with Trp80, and the phenyl group at 
the 5-position occupying the binding pocket of Akti-1/2’s phenyl groups. In this position, the 
N1 atom of the pyrrolopyrimidine might replace the N5 atom of Akti-1/2, which is known to 
be crucial for inhibitory activity for these allosteric inhibitors.
176
 Presumably, this nitrogen 
atom forms hydrogen bonds to Gln79, Thr81, Thr82, Asp292 and Gly294, mediated by a 
complex network of water molecules, that can be seen in the co-crystal structure of Akt1 with 
53.131 In addition, the thiophene group of 75a, 75d, 75e and 75g, as well as the pyridine 
group of 75b and 75c could take the place of the Akti-1/2’s piperidine group. In fact, this 
might explain the low efficacy of 75c compared to 75b, as the nitrogens in the meta-
substituted pyridine overlap better than the ortho-substituted. In binding mode B, the  
pyrrolopyrimidines are oriented like the original ligand 53 in the crystal structure 4EJN. Their 
N7 phenyl substituents expel the water molecules close to the protein surface, leading to a 
favourable entropic contribution to the Gibbs free energy of binding. In this conformation, the 
thiophene/pyridine/phenyl substituents at the 4-position and the phenyl group at the 5-position 
occupy the original ligand’s pyridine and phenyl position, respectively. Additionally, the  
exocyclic nitrogen atom at the 4-position might establish the aforementioned water network to 
the protein. Furthermore, the substituents of ring 4 in the 85 family would not fit into the  
inter-domain binding pocket in this orientation. 
 
Figure 78 The two main binding modes for the pyrrolopyrimidines found in the screen (75a shown as an 
example in cyan sticks) as calculated by Glide. For reference in binding mode A (left) and B 
(right), the co-crystallised inhibitors Akti-1/2 from PDB entry 3O96 and 53 from PDB entry 4EJN 
are displayed as orange sticks, respectively. 
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In both binding modes, the lack of aromatic groups at the 4-position (like in the 78-84  
family) would lead to a loss of affinity, as either one of the phenyl group pockets would not 
be occupied any more. Also, both are sensitive towards the nitrogen position of the ring 4 
pyridine, as the meta nitrogen coincides well with the piperidine nitrogen of Akti-1/2 in mode 
A, and the SAR of 53 also showed a stronger activity of the pyridine moiety with a meta  
nitrogen in mode B. However, binding mode A cannot describe the retained affinity of 75f, as 
its phenyl group is unable to form the water-mediated hydrogen bond to Gln79. Binding mode 
B can explain, why the 75i shows no effect on Akt, since its additional methylene unit causes 
a misalignment of the thiophene group with the pyridine group of 53. Furthermore, the loss of 
activity upon substitution of ring 4 is illustrated in mode B, whereas mode A can easily  
tolerate these substituents. On the other hand, only binding mode A can plausibly describe the 
binding affinity of the truncated imidazole derivative 86a. However, neither of these binding 
modes can explain the dramatic decrease in affinity upon N-methylation (as in 75i) or intro-
duction of a meta substituent at ring 7 (as in 75e, 75g, 75h and 75k). Also, neither binding 
mode provides a rational explanation for the activity loss with the electron-donating methoxy 
group of 75l or activity gain with the electron-withdrawing fluoro group of 75c. 
In summary, the 91 compounds in the secondary screen displayed a wide range of potency, in 
which the trends in the binding affinities (determined with iFLiK) mirrored the inhibitory  
activities (determined with KinEASE). A few key observations could be derived to formulate 
a preliminary SAR, but they were insufficient to provide conclusive evidence for one of the 
binding modes predicted by molecular modelling. A more focussed library of pyrrolo[2,3-d]-
pyrimidines is hence required to further explore their SAR, develop a pharmacophore model 
and clarify their binding mode. As such specialised compounds are not commercially  
available, further work should revolve around synthesising more potent inhibitors based on 
the insights gained from the previously discussed SAR. 
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3.7 Crystallisation 
A co-crystal structure of Akt with the newly discovered pyrrolopyrimidines would greatly 
improve our understanding of their binding mode. As the crystallisation of Akt has not been 
established in our lab, the protocol of the first published X-ray crystal structure of full length 
Akt with an ID inhibitor was adapted first with the Akt strong binders MK-2206 and 63b. A 
small crystallisation screen was carried out on a 24-well plate, using the two constructs de91 
and de92 incubated with 250 µM of each inhibitor in the hanging drop method. The general 
reservoir buffer conditions (12.5 mM NaOAc, 25 mM sodium citrate) were varied from  
19-24% PEG 2000 in a pH range from 5.0-5.6 and incubated at 20 °C. The crystal growth was 
checked regularly. However, even after 7 months, no crystals have grown for either inhibitor 
in either protein construct. 
  
  
Figure 79 Representative pictures of hanging drops in the crystallisation screen with de91 (left) and de92 
(right) co-crystallised with MK-2206 (upper) and 63b (lower). Pictures were taken at a magni-
fication of 4x after incubating for 7 months. 
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Wu et al. have reported that they were not able to obtain crystals of Akt with the full length 
protein, but only after cutting off all amino acids after Met446, which seemed to reduce  
flexibility.
76
 In fact, the only two crystal structures published in the PDB so far both  
employed a construct consisting of the residues 1-446 of Akt1.
131
 Therefore, it was not  
surprising that the full-length de92 did not yield protein crystals. However, even the truncated 
construct de91, which comprises the residues 1-445, did not crystallise in the reported  
conditions. Apparently, the mutations introduced into de91 (E49C,C296S,C310S,C344S) 
have changed its crystallisation behaviour. Therefore, in order to obtain X-ray crystal  
structures with the expressed iFLiK constructs of Akt, a larger screen covering a wider range 
of buffer systems and conditions has to be implemented in future works. 
Due to the unsuccessful crystallisation experiments, in silico molecular modelling has been 
chosen to elucidate the binding mode for the pyrrolopyrimidine hit compounds (discussed in 
chapter 3.6.3).   
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3.8 Summary and Conclusion 
In summary, the iFLiK assay was successfully developed as a biochemical assay that can  
selectively detect the binding of allosteric Akt inhibitors and the resulting conformational 
changes by employing environmentally sensitive fluorophores (Figure 80). 
Having studied the cellular, mutagenesis and X-ray data in the literature, it was decided to 
introduce the conformation sensor via an artificial cysteine at position Glu49, which is at the 
PH domain close to the domain interface, where conformational changes induced by allosteric 
inhibitors should be most perceptible. Three Akt constructs were created according to this 
structure-guided assay design, which were merged into a baculovirus in order to obtain the 
required proteins by insect cell expression and protein purification via FPLC. A series of 
fluorophores have been systematically tested for their applicability as biosensors. Nearly all of 
the selected fluorophores were able to report on the conformational changes of Akt when 
choosing the appropriate readouts, providing a proof of concept for the iFLiK assay. Using 
the solvatochromic PyMPO as fluorophore label, which reacts to the binding of ID inhibitors 
by a bathochromic shift of the emission spectrum, the assay has been optimised with respect 
to construct design, buffers, additives and reaction conditions. This extensive optimisation has 
resulted in an assay with excellent reproducibility and reliability, which was able to selec-
tively detect allosteric Akt inhibitors and measure their binding affinities. 
 
  
Figure 80 iFLiK assay principle: Top) Conformational changes induced by inter-domain inhibitors (blue 
circle) affect the environment around the PyMPO sensor (blue and orange star), leading to a  
bathochromic shift of the fluorescence emission (left). This can be quantified by calculating the  
intensity ratios at two different wavelengths left and right of the emission maximum and plotting a 
dose-response (right). 
In the wake of developing the assay, a focussed library of naphthyridines based on known 
inter-domain inhibitors have been synthesised as probe compounds in the assay following 
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Scheme 7. After establishing the respective activity-based assays, these probes displayed  
nanomolar to low-micromolar activities in vitro as well as micromolar activities in human 
Akt-sensitive cell lines. 
 
Scheme 7 Synthesis route for the preparation of 63a-g. 
The dissociation constants produced by iFLiK could be verified with orthogonal assay  
systems based on completely different biophysical principles. The NanoTemper assay, which 
measures the thermophoretic behaviour of protein solutions, was successfully established and 
yielded comparable Kds for both reference and synthesised Akt inhibitors. It also indicated 
that PyMPO labelling of the kinase does not significantly influence the binding of inhibitors. 
Although the Biacore assay, which detects ligand binding-correlated mass increases by  
surface plasmon resonance, could not be robustly established as an additional orthogonal as-
say, preliminary results seemed to give similar results to iFLiK and NanoTemper. In contrast 
to iFLiK, however, these commercial assays were not able to distinguish between allosteric 
and ATP-competitive inhibitors. 
Following optimisation and validation of the iFLiK assay, it was employed in the screening of 
the RL and the Waldmann library. The primary screens displayed a hit rate of 0.12%, which is 
evidence for the high selectivity of iFLiK. A few compounds belonging to the family of  
pyrrolo[2,3-d]pyrimidines have been identified as hits from these screens, as they produced a 
dose-dependent bathochromic shift of the PyMPO emission spectrum. Their selective  
inhibitory effect on the full-length kinase over the kinase domain alone has been validated in 
activity-based assays, signifying the discovery of a novel class of allosteric Akt inhibitors 
which have not been described in the literature so far. 
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Figure 81 Compound class of pyrrolo[2,3-d]pyrimidines identified as novel allosteric Akt inhibitors in 
screening campaigns with the iFLiK assay. 
In order to determine their binding mode, a structural examination by X-ray crystallography 
was attempted, but the crystallisation of Akt was unsuccessful. As an alternative, these  
pyrrolopyrimidines were docked into known crystal structures of Akt, yielding two plausible 
binding modes. To substantiate the actual binding orientation, their SAR was further explored 
by testing 91 of such derivatives in a secondary screen for their binding affinity with iFLiK 
and inhibitory activity with KinEASE. The following conclusions for the SAR could be 
drawn by studying the results of this follow-up study, supporting either of these two binding 
modes (for nomenclature of pyrrolopyrimidine substitution see Figure 77 on page 102, for 
their structures see Table 13 on page 102, for their binding mode see Figure 78 on page 106): 
- Heterocycles are tolerated: thiophenes 75d, 75e, 75a and 75g, and pyridines 75b 
and 75c are active (binding mode B). 
- Positioning of heteroatom important: meta substitution of 75b binds more strongly 
than ortho-substituted 75c (binding mode A & B). 
- Aromatic group must not be substituted: 85a-i are not active (binding mode B). 
- Free NH at 4-position is crucial: methylated 75i is not active (neither binding mode). 
- Correct distance to the core scaffold: longer linker of 75j abolishes activity (binding 
mode B). 
- Substitution in the meta position of ring 7 negatively affects affinity: complete loss of 
activity in 75h and 75k, strong reduction in 75e and 75g (neither binding mode). 
- Substitution in the para position of ring 7 is tolerated well in general: methylated 75a 
is just as active as unsubstituted 75d (binding mode A & B). 
- Substitution in the para position of ring 7 with electron-donating or sterically more 
demanding groups causes a loss of activity: methoxy group in 75l is not active in  
constrast to the unsubstituted 75b, while the small electron-withdrawing fluoro group 
of 75c restored affinity compared to 75m (neither binding mode). 
Although many findings seem to point towards binding mode B, the activity of 86a can 
only be explained by binding mode A, so the actual binding mode still remains uncertain.  
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3.9 Future Work 
In order to identify the actual binding mode of the pyrrolo[2,3-d]pyrimidines, additional  
experiments are necessary. By employing saturation transfer difference (STD) NMR  
spectroscopy, protein-bound ligands are measured with off-resonance irradiation. Ligand  
protons that are in contact with the protein receive a stronger enhancement than those exposed 
to the solvent. Therefore, STD NMR experiments can be used to determine which parts are 
interacting with the protein.
189,190
 Ultimately, crystallisation of the novel scaffolds would  
provide the best structural information on the binding mode. As a consequence, a screen  
covering a wide range of buffer systems and conditions should be carried out to establish a 
working crystallisation protocol for full-length Akt. 
Due to the limited commercial availability of suitable pyrrolo[2,3-d]pyrimidines that fit well 
into the Akt inter-domain pocket, more sophisticated compounds based on the SAR  
determined in this thesis should be synthesised. 
 
Figure 82 A few exemplary structures proposed for future pyrrolopyrimidine- and imidazole-based  
inhibitors. 
Although the iFLiK assay was able to reliably identify novel Akt inhibitors from the  
Waldmann library screen, these hits are far from potent with their micromolar affinities. The 
main limitation to finding novel scaffolds is the chemical space covered in a compound  
library. With the encouraging results from screening the RL and Waldmann libraries, the HTS 
of much larger libraries can be approached, which should hopefully provide a more diverse 
set of hit structures. 
For a more pronounced sensitivity of conformational changes, other labelling positions on 
both the PH and the kinase domain can be tested. Furthermore, previous work in the group 
has shown that the labelling position can decisively determine whether conformational  
changes can be detected by fluorophore sensors. The difference might be as much as one  
amino acid as have been demonstrated before.
191
 Even today, after analysing the successful 
and unsuccessful labelling positions in FLiK, FLiP and iFLiK experiments, there is no  
rationale that can guide the search for the optimal labelling position. Further mutagenesis 
studies with the FLiK, FLiP and iFLiK technology can help in understanding the factors that 
determine the conformational sensitivity.  
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Various publications and the screens in this thesis have demonstrated that the choice of  
compounds that can be investigated can be strongly limited by intrinsic compound  
fluorescence.
182
 However, fluorophores with long-wavelength excitations are nearly  
inevitably associated with low solvatochroism, attributable to their structure which predicates 
on an extensively conjugated π-electron system. In order to increase their sensitivity towards 
changes in their environment, their excitation dipol moment has to be increased. Therefore, 
more sensitive fluorophores have to be developed that can be used as cysteine-reactive  
sensors. A reactive variant of the solvatochromic anthradan could be such a solution, as it 
shows high sensitivity to polarity (emission maxima ranging from 490 nm to 610 nm in  
various solvents) and an excitation maximum of around 470 nm.
192
 
 
Figure 83 Proposed structure of an anthradan-derived solvatochromic fluorophore 
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4 Experimental 
4.1 General Experimental 
If not noted otherwise, all buffers were formulated with Milli-Q grade purified water. 
For visualisation of protein structures, PyMol version 1.5.0.4 by Schrödinger was used. Data 
management was handled with Pipeline Pilot version 6.1 by Accelrys. 
4.1.1 Instruments 
Microtiter plate reader Tecan Infinite M1000 
NanoTemper   NanoTemper Monolith NT.115 G008 
Biacore   Biacore T100 
Centrifuges   Beckman Coulter Avanti J-25 
    Beckman Coulter Avanti J-26 
    Beckman Coulter JA-10 
    Beckman Coulter JLA 8.1 
    Eppendorf Centrifuge 5415 D 
    Heraeus Multifuge 3 S-R 
Gel electrophoresis  Bio-Rad Mini-PROTEAN 3 Cell 
Incubator shaker  New Brunswick Scientific Innova 4430 
Photometer   Eppendorf Biophotometer 
FPLC    ÄKTA Purifier 
Preparative HPLC  Agilent 1200 series 
4.1.2 Materials and Consumables 
Crystallisation plates  Qiagen EasyXtal 24-well 
384-well plate   Greiner Bio One 384 Well Small Volume HiBase Polystyrene 
Greiner Bio One 384 Well Polystyrene Microplates solid bot-
tom 
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Pipette tips   Starlab TipOne system 
Desalting Columns  Thermo Scientific Protein Desalting Spin Columns 7 kDa 
Insect cell medium  Invitrogen Gibco Sf-900 III SFM 
Biacore chips   Biacore CM5 
    Biacore NTA 
HPLC columns  Macherey-Nagel Nucleodur C18 Gravity 5 µm 21/125 
    Macherey-Nagel VP50/21 
FPLC columns  GE Healthcare Superdex HiLoad 200 16/600 pg 
    GE Healthcare Superdex 75 10/300 GL 
4.2 Protein Production 
4.2.1 Expression 
construct de92: 
Human Akt1 (residues 1-480) containing the mutations E49C, C296S, C310S and C344S was 
codon-usage optimised for insect cell expression and synthesised synthetically (Geneart AG). 
The amino acid and nucleotide sequence are shown below with artificial mutation sites under-
lined and coloured blue. 
Mutated amino acid sequence (artificial mutations are marked blue and underlined): 
MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQRCA 
PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT 
TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF 
EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR 
VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA 
RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLSKEGI 
KDGATMKTFS GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMSGRLPFY 
NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK 
EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT 
PPDQDDSMEC VDSERRPHFP QFSYSASGTA 
Mutated nucleotide sequence: 
   1 atgagcgacg tggctattgt gaaggagggt tggctgcaca aacgagggga gtacatcaag 
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  61 acctggcggc cacgctactt cctcctcaag aatgatggca ccttcattgg ctacaaggag 
 121 cggccgcagg atgtggacca acgttgcgct cccctcaaca acttctctgt ggcgcagtgc 
 181 cagctgatga agacggagcg gccccggccc aacaccttca tcatccgctg cctgcagtgg 
 241 accactgtca tcgaacgcac cttccatgtg gagactcctg aggagcggga ggagtggaca 
 301 accgccatcc agactgtggc tgacggcctc aagaagcagg aggaggagga gatggacttc 
 361 cggtcgggct cacccagtga caactcaggg gctgaagaga tggaggtgtc cctggccaag 
 421 cccaagcacc gcgtgaccat gaacgagttt gagtacctga agctgctggg caagggcact 
 481 ttcggcaagg tgatcctggt gaaggagaag gccacaggcc gctactacgc catgaagatc 
 541 ctcaagaagg aagtcatcgt ggccaaggac gaggtggccc acacactcac cgagaaccgc 
 601 gtcctgcaga actccaggca ccccttcctc acagccctga agtactcttt ccagacccac 
 661 gaccgcctct gctttgtcat ggagtacgcc aacgggggcg agctgttctt ccacctgtcc 
 721 cgggagcgtg tgttctccga ggaccgggcc cgcttctatg gcgctgagat tgtgtcagcc 
 781 ctggactacc tgcactcgga gaagaacgtg gtgtaccggg acctcaagct ggagaacctc 
 841 atgctggaca aggacgggca cattaagatc acagacttcg ggctgagcaa ggaggggatc 
 901 aaggacggtg ccaccatgaa gacctttagc ggcacacctg agtacctggc ccccgaggtg 
 961 ctggaggaca atgactacgg ccgtgcagtg gactggtggg ggctgggcgt ggtcatgtac 
1021 gagatgatga gcggtcgcct gcccttctac aaccaggacc atgagaagct ttttgagctc 
1081 atcctcatgg aggagatccg cttcccgcgc acgcttggtc ccgaggccaa gtccttgctt 
1141 tcagggctgc tcaagaagga ccccaagcag aggcttggcg ggggctccga ggacgccaag 
1201 gagatcatgc agcatcgctt ctttgccggt atcgtgtggc agcacgtgta cgagaagaag 
1261 ctcagcccac ccttcaagcc ccaggtcacg tcggagactg acaccaggta ttttgatgag 
1321 gagttcacgg cccagatgat caccatcaca ccacctgacc aagatgacag catggagtgc 
1381 gtggacagcg agcgcaggcc ccacttcccc cagttctcct actcggccag cggcacggcc 
1441 tga  
construct pHT1023: 
Human Akt1 (residues 1-480) containing the mutations E49C, C296S, C310S, C344S and 
C460S was codon-usage optimised for insect cell expression and synthesised synthetically 
(Geneart AG). The amino acid and nucleotide sequence are shown below with artificial  
mutation sites underlined. 
Mutated amino acid sequence (artificial mutations are marked blue and underlined): 
MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQRCA 
PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT 
TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF 
EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR 
VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA 
RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLSKEGI 
KDGATMKTFS GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMSGRLPFY 
NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK 
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EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT 
PPDQDDSMES VDSERRPHFP QFSYSASGTA 
Mutated nucleotide sequence: 
   1 atgagcgacg tggctattgt gaaggagggt tggctgcaca aacgagggga gtacatcaag 
  61 acctggcggc cacgctactt cctcctcaag aatgatggca ccttcattgg ctacaaggag 
 121 cggccgcagg atgtggacca acgttgcgct cccctcaaca acttctctgt ggcgcagtgc 
 181 cagctgatga agacggagcg gccccggccc aacaccttca tcatccgctg cctgcagtgg 
 241 accactgtca tcgaacgcac cttccatgtg gagactcctg aggagcggga ggagtggaca 
 301 accgccatcc agactgtggc tgacggcctc aagaagcagg aggaggagga gatggacttc 
 361 cggtcgggct cacccagtga caactcaggg gctgaagaga tggaggtgtc cctggccaag 
 421 cccaagcacc gcgtgaccat gaacgagttt gagtacctga agctgctggg caagggcact 
 481 ttcggcaagg tgatcctggt gaaggagaag gccacaggcc gctactacgc catgaagatc 
 541 ctcaagaagg aagtcatcgt ggccaaggac gaggtggccc acacactcac cgagaaccgc 
 601 gtcctgcaga actccaggca ccccttcctc acagccctga agtactcttt ccagacccac 
 661 gaccgcctct gctttgtcat ggagtacgcc aacgggggcg agctgttctt ccacctgtcc 
 721 cgggagcgtg tgttctccga ggaccgggcc cgcttctatg gcgctgagat tgtgtcagcc 
 781 ctggactacc tgcactcgga gaagaacgtg gtgtaccggg acctcaagct ggagaacctc 
 841 atgctggaca aggacgggca cattaagatc acagacttcg ggctgagcaa ggaggggatc 
 901 aaggacggtg ccaccatgaa gacctttagc ggcacacctg agtacctggc ccccgaggtg 
 961 ctggaggaca atgactacgg ccgtgcagtg gactggtggg ggctgggcgt ggtcatgtac 
1021 gagatgatga gcggtcgcct gcccttctac aaccaggacc atgagaagct ttttgagctc 
1081 atcctcatgg aggagatccg cttcccgcgc acgcttggtc ccgaggccaa gtccttgctt 
1141 tcagggctgc tcaagaagga ccccaagcag aggcttggcg ggggctccga ggacgccaag 
1201 gagatcatgc agcatcgctt ctttgccggt atcgtgtggc agcacgtgta cgagaagaag 
1261 ctcagcccac ccttcaagcc ccaggtcacg tcggagactg acaccaggta ttttgatgag 
1321 gagttcacgg cccagatgat caccatcaca ccacctgacc aagatgacag catggagagc 
1381 gtggacagcg agcgcaggcc ccacttcccc cagttctcct actcggccag cggcacggcc 
1441 tga  
construct de91: 
Human Akt1 (residues 1-446) containing the mutations E49C, C296S, C310S and C344S was 
codon-usage optimised for insect cell expression and synthesised synthetically (Geneart AG). 
The amino acid and nucleotide sequence are shown below with artificial mutation sites  
underlined. 
Mutated amino acid sequence (artificial mutations are marked blue and underlined): 
MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQRCA 
PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT 
TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF 
EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR 
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VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA 
RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLSKEGI 
KDGATMKTFS GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMSGRLPFY 
NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK 
EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQM 
Mutated nucleotide sequence: 
   1 atgagcgacg tggctattgt gaaggagggt tggctgcaca aacgagggga gtacatcaag 
  61 acctggcggc cacgctactt cctcctcaag aatgatggca ccttcattgg ctacaaggag 
 121 cggccgcagg atgtggacca acgttgcgct cccctcaaca acttctctgt ggcgcagtgc 
 181 cagctgatga agacggagcg gccccggccc aacaccttca tcatccgctg cctgcagtgg 
 241 accactgtca tcgaacgcac cttccatgtg gagactcctg aggagcggga ggagtggaca 
 301 accgccatcc agactgtggc tgacggcctc aagaagcagg aggaggagga gatggacttc 
 361 cggtcgggct cacccagtga caactcaggg gctgaagaga tggaggtgtc cctggccaag 
 421 cccaagcacc gcgtgaccat gaacgagttt gagtacctga agctgctggg caagggcact 
 481 ttcggcaagg tgatcctggt gaaggagaag gccacaggcc gctactacgc catgaagatc 
 541 ctcaagaagg aagtcatcgt ggccaaggac gaggtggccc acacactcac cgagaaccgc 
 601 gtcctgcaga actccaggca ccccttcctc acagccctga agtactcttt ccagacccac 
 661 gaccgcctct gctttgtcat ggagtacgcc aacgggggcg agctgttctt ccacctgtcc 
 721 cgggagcgtg tgttctccga ggaccgggcc cgcttctatg gcgctgagat tgtgtcagcc 
 781 ctggactacc tgcactcgga gaagaacgtg gtgtaccggg acctcaagct ggagaacctc 
 841 atgctggaca aggacgggca cattaagatc acagacttcg ggctgagcaa ggaggggatc 
 901 aaggacggtg ccaccatgaa gacctttagc ggcacacctg agtacctggc ccccgaggtg 
 961 ctggaggaca atgactacgg ccgtgcagtg gactggtggg ggctgggcgt ggtcatgtac 
1021 gagatgatga gcggtcgcct gcccttctac aaccaggacc atgagaagct ttttgagctc 
1081 atcctcatgg aggagatccg cttcccgcgc acgcttggtc ccgaggccaa gtccttgctt 
1141 tcagggctgc tcaagaagga ccccaagcag aggcttggcg ggggctccga ggacgccaag 
1201 gagatcatgc agcatcgctt ctttgccggt atcgtgtggc agcacgtgta cgagaagaag 
1261 ctcagcccac ccttcaagcc ccaggtcacg tcggagactg acaccaggta ttttgatgag 
1321 gagttcacgg cccagatg 
The gene retained a His6-tag at the N-terminus followed by a TEV protease cleavage site. The 
Akt1 constructs were cloned into a pREN4427-HIS-DEST vector and introduced into a  
baculovirus with the BacMagic Kit (Calbiochem) in Sf21 cells (Invitrogen). The virus was 
amplified by infecting TriEx Sf9 cells (Millipore) at an MOI = 0.01 and incubating for 5 d at 
28 °C in an incubator shaker.  
The virus titer was determined with the BacPAK Baculovirus Rapid Titer Kit (Clontech)  
according to protocols: TriEx Sf9 cells (Millipore) were seeded at 6.5 ∙ 104 cells/well into a 
sterile 96-well plate and incubated at 27 °C for 1 h. After aspirating the medium, 25 µL of 
virus dilution series of each virus were added at final dilutions of 10
-3
, 10
-4
 and 10
-5
 and  
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incubated for 1 h at RT. The inoculum was aspirated, and 50 µL of the provided methyl  
cellulose overlay was added and incubated at 27 °C for 46 h. Afterwards, the cells were  
fixated with a 4% paraformaldehyde solution for 10 min at RT. The solution was removed 
and the wells washed 3x 5 min with 200 µL PBS + 0.05% Tween-20. After pre-incubation 
with 50 µL normal goat serum, 25 µL diluted mouse anti-gp64 antibody was incubated at 
37 °C for 25 min, washed 2x 5 min with 200 µL PBS + 0.05% Tween-20. Subsequently, 
50 µL diluted goat anti-mouse/HRP conjugate were added, incubated at 37 °C for 25 min and 
washed 3x 5min with 200 µL PBS + 0.05% Tween-20. The infection was visualised by  
addition of 50 µL Blue Peroxidase substrate and developed for 10 min. Stained cells were 
counted to calculate the virus titer. 
All Akt1 constructs were expressed in stably transfected Spodoptera frugiperda TriEx Sf9 
cells (Millipore) at 28 °C. de92 (His6-TEV-(2-480) E49C,C296S,C310S,C344S): MOI = 3 
and incubation time = 48 h. pHT1023 (His6-TEV-(2-480) E49C,C296S,C310S,C344S, 
C460S): MOI = 0.5 and incubation time = 72 h. de91 (His6-TEV-(2-446) E49C,C296S, 
C310S,C344S): MOI = 0.3 and incubation time = 72 h. Cells were harvested by centrifugation 
with 2000 g at 4 °C for 10 min and removal of the medium. 
4.2.2 Purification 
Lysis buffer: 50 mM Tris, 500 mM NaCl, 10% v/v glycerol, 1 mM DTT, 5 mM MgCl2, 0.1% 
Triton X-100, cOmplete EDTA-free Protease inhibitor cocktail, 10 U/L Benzoase, pH 8.0 at 
4 °C. 
Ni
2+
 affinity chromatography buffer: 50 mM Tris, 500 mM NaCl, 0-500 mM imidazole, 
10% glycerol, 1 mM DTT, pH 8.0 at 4 °C. 
Size exclusion buffer: 50 mM HEPES, 200 mM NaCl, 10% glycerol, 6 ppm Triton X-100, 
pH 7.3 at 4 °C. 
Ni-NTA affinity chromatography 
The His-tagged protein was enriched from the TriEx Sf9 cell lysate in lysis buffer on a 3 mL 
nickel-affinity column (Qiagen) at 1 mL/min and washed with 0 mM imidazole Ni-NTA  
buffer. The protein was eluted stepwise with 20 mM, 50 mM and 100 mM imidazole, then in 
a buffer gradient up to 500 mM imidazole. 
Size exclusion chromatography 
The protein was further purified on a Superdex HiLoad 200 16/600 pg column (GE 
Healthcare) using the size exclusion buffer and concentrated to approximately 50 µM. All 
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purification steps were performed at 4 °C, and the final protein was flash frozen in liquid  
nitrogen and stored at -80 °C. 
4.3 Biochemical Assays 
4.3.1 KinEASE 
Akt1 wt 
Kinase buffer: 50 mM HEPES, 5 mM MgCl2, 0.1 mM Na3VO4, 0.02% (w/v) NaN3, 0.01% 
(w/v) BSA, 1 mM DTT, 0.01% Triton X-100, pH 7.0. 
Start solution: 1 µM STK substrate 3, 200 µM ATP, 50 mM HEPES, 5 mM MgCl2, 0.1 mM 
Na3VO4, 0.02% (w/v) NaN3, 0.01% (w/v) BSA, 1 mM DTT, 0.01% Triton X-100, pH 7.0. 
Stop solution: 50 mM HEPES, 0.1% (w/v) BSA, 800 mM KF, 20 mM EDTA, 31.25 nM 
XL665, diluted STK antibody, pH 7.0. 
An inhibitor dilution series was created by diluting an 8% DMSO inhibitor solution in kinase 
buffer into 8% DMSO in kinase buffer. 2.5 µL of each inhibitor dilution were added in dupli-
cates into 5 µL of a 240 pM kinase solution (Akt1 wt from Millipore, Lot # D8MN034U-L) in 
a 384-well plate and pre-incubated in a dark wet chamber for 1 h at RT. To start the reaction, 
2.5 µL of the start solution were added to each well and incubated in a dark wet chamber for 
45 min at RT. To stop the reaction, 10 µL of the stop solution were added to each well and 
incubated in a dark wet chamber for 1 h at RT. Each well was excited at 317 nm and emission 
was measured at 620 nm and 665 nm with a 60 µs delay. The fl665/fl620 ratio was used as assay 
readout. 
Akt2 wt 
Kinase buffer: 50 mM HEPES, 5 mM MgCl2, 0.1 mM Na3VO4, 0.02% (w/v) NaN3, 0.01% 
(w/v) BSA, 1 mM DTT, 0.01% Triton X-100, pH 7.0. 
Start solution: 1.2 µM STK substrate 3, 260 µM ATP, 50 mM HEPES, 5 mM MgCl2, 0.1 mM 
Na3VO4, 0.02% (w/v) NaN3, 0.01% (w/v) BSA, 1 mM DTT, 0.01% Triton X-100, pH 7.0. 
Stop solution: 50 mM HEPES, 0.1% (w/v) BSA, 800 mM KF, 20 mM EDTA, 37.5 nM 
XL665, diluted STK antibody, pH 7.0. 
An inhibitor dilution series was created by diluting an 8% DMSO inhibitor solution in kinase 
buffer into 8% DMSO in kinase buffer. 2.5 µL of each inhibitor dilution were added in  
duplicates into 5 µL of a 1.02 nM kinase solution (Akt2 wt from Invitrogen, Lot # 
PV3184_28770N) in a 384-well plate and pre-incubated in a dark wet chamber for 1 h at RT. 
To start the reaction, 2.5 µL of the start solution were added to each well and incubated in a 
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dark wet chamber for 17 min at RT. To stop the reaction, 10 µL of the stop solution were 
added to each well and incubated in a dark wet chamber for 1 h at RT. Each well was excited 
at 317 nm and emission was measured at 620 nm and 665 nm with a 60 µs delay. The 
fl665/fl620 ratio was used as assay readout. 
ΔPH-Akt1 
Kinase buffer: 50 mM HEPES, 5 mM MgCl2, 0.1 mM Na3VO4, 0.02% (w/v) NaN3, 0.01% 
(w/v) BSA, 1 mM DTT, 0.01% Triton X-100, pH 7.0. 
Start solution: 1.2 µM STK substrate 3, 260 µM ATP, 50 mM HEPES, 5 mM MgCl2, 0.1 mM 
Na3VO4, 0.02% (w/v) NaN3, 0.01% (w/v) BSA, 1 mM DTT, 0.01% Triton X-100, pH 7.0. 
Stop solution: 50 mM HEPES, 0.1% (w/v) BSA, 800 mM KF, 20 mM EDTA, 37.5 nM 
XL665, diluted STK antibody, pH 7.0. 
An inhibitor dilution series was created by diluting an 8% DMSO inhibitor solution in kinase 
buffer into 8% DMSO in kinase buffer. 2.5 µL of each inhibitor dilution were added in dupli-
cates into 5 µL of a 120 pM kinase solution (ΔPH-Akt1 wt from Millipore, Lot # 1600485-E) 
in a 384-well plate and pre-incubated in a dark wet chamber for 1 h at RT. To start the  
reaction, 2.5 µL of the start solution were added to each well and incubated in a dark wet 
chamber for 20 min at RT. To stop the reaction, 10 µL of the stop solution were added to each 
well and incubated in a dark wet chamber for 1 h at RT. Each well was excited at 317 nm and 
emission was measured at 620 nm and 665 nm with a 60 µs delay. The fl665/fl620 ratio was 
used as assay readout. 
4.3.2 iFLiK 
Labelling 
Labelling buffer: 50 mM HEPES, 200 mM NaCl, 10% glycerol, pH 7.3 @ 4 °C. 
The protein was dissolved in labelling buffer to a resulting concentration of 2 mg/mL. 
0.9 equivalents of 10 mM PyMPO in DMF were dissolved in an equal volume of labelling 
buffer. Both solutions were mixed and incubated in the dark at 4 °C over night. The labelled 
protein was purified by concentrating and passing over a gel filtration column  
(Superdex 75 10/300 GL by GE Healthcare). The purified protein was shock-frozen in liquid 
nitrogen and stored at -80 °C. 
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Optimisation 
All experiments for the assay optimisation were either determined with end-point  
measurements (according to ―Z’-factors and signal-to-noise ratios‖) or with dose-dependency 
(according to ―Measuring Kd‖) in variations of the parameter to be investigated. 
Z’-factors and signal-to-noise ratios 
iFLiK buffer: 50 mM HEPES, 200 mM NaCl, 0.01% Triton-X 100, pH 7.4. 
If not noted otherwise, 200 nM of the PyMPO labelled protein was incubated with 5 µM  
MK-2206 and DMSO, each in hexuplicates. After 2 h incubation, each well was excited at 
419 nm and 440 nm, and emission was measured at 638 nm and 508 nm. Background-
corrected intensity ratios fl638/fl508 nm was used as assay readout. 
Primary screen 
iFLiK buffer: 50 mM HEPES, 200 mM NaCl, 0.01% Triton-X 100, pH 7.4. 
0.5 µL of each inhibitor were added at 21x final concentration into 10 µL of a 200 nM  
labelled protein solution in a 384-well plate and into 10 µL of buffer as background  
correction. After shaking at 1500 rpm for 30 s, all solutions were incubated in a dark wet 
chamber for 2 h at RT. Each well was excited at 419 nm and 440 nm, and emission was 
measured at 638 nm and 508 nm. Background-corrected intensity ratio fl638/fl508 nm was used 
as assay readout, with a cutoff of 25% of maximum binding of MK-2206 as positive control. 
Measuring Kd 
iFLiK buffer: 50 mM HEPES, 200 mM NaCl, 0.01% Triton-X 100, pH 7.4. 
An inhibitor dilution series was created by diluting an DMSO inhibitor solution into wet 
DMSO. 0.5 µL of each inhibitor dilution was added in triplicates into 10 µL of a 200 nM  
labelled protein solution in a 384-well plate and into 10 µL of buffer in quadruplicates as 
background correction. After shaking at 1500 rpm for 30 s, all solutions were incubated in a 
dark wet chamber for 2 h at RT. Each well was excited at 419 nm and emission was measured 
at 638 nm and 508 nm. Each background data point was averaged for substraction, and  
background-corrected intensity ratios fl638/fl508 nm were used as assay readout.  
4.3.3 NanoTemper 
Labelling 
Labelling buffer: 50 mM HEPES, 200 mM NaCl, 10% glycerol, pH 8.3 @ 4 °C. 
Storage buffer: 50 mM HEPES, 200 mM NaCl, 10% glycerol, pH 7.3 @ 4 °C. 
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The protein was dissolved in labelling buffer to a resulting concentration of 40 µM.  
3 equivalents of 10 mM Alexa Fluor 568 maledimide in DMF were added, mixed and incu-
bated in the dark at 4 °C for 1 h. The labelled protein was purified over a gel filtration column  
(Superdex 75 10/300 GL by GE Healthcare) into the storage buffer, shock-frozen with liquid 
nitrogen and stored at -80 °C. 
Measuring Kd 
NanoTemper buffer: 50 mM HEPES, 200 mM NaCl, 0.05% Tween-20, pH 7.4. 
An inhibitor dilution series were created by diluting an DMSO inhibitor solution into wet 
DMSO. 0.5 µL of each inhibitor dilution was added into 10 µL of a 100 nM labelled protein 
solution in a 384-well plate. All solutions were incubated for 2 h at RT. The solutions were 
transferred into enhanced gradient standard treated NanoTemper capillaries and analysed  
using green excitation and emission filters. Excite capillaries at 25 °C with 90% LED power 
for 5 s, track thermophoresis for 45 s at 100% laser intensity, track back-diffusion for 5 s. 
Fluorescence intensities were measured at 8-9 s and 49-50 s, and intensity ratios of hot/cold 
were used as assay readout.  
4.3.4 Biacore 
Biacore buffer: 50 mM Tris, 200 mM NaCl, 5 mM MgCl2, 0.05% Tween-20, 2% DMSO, 
pH 7.5. 
Washing solution was passed at 10 µL/min. Solvent correction was calculated using 1.4%, 
1.6%, 1.8%, 2.0%, 2.2%, 2.4%, 2.6% and 2.8% DMSO in Biacore buffer and extrapolated 
with the evaluation software to 5000 RU. Each assay cycle consisted of the following steps: 
The NTA chip was conditioned with a 500 µM NiCl2 solution at 10 µL/min for 45 s and  
stabilised for 20 s. A 20 µg/mL protein solution in Biacore buffer was passed over the chip at 
10 µL/min for 2 min for immobilisation. After stabilising the signal for 1 min, the ligand solu-
tion was passed at 10 µL/min for a contact time of 2 min and dissociation time of 4 min with 
Biacore buffer, followed by 30 s stabilisation. The chip surface was regenerated with 350 mM 
EDTA for 45 s and a 3 min stabilisation period. All steps except the NiCl2 immobilisation 
were conducted in parallel and used as background substraction. Kinetic fits were conducted 
with the evaluation software and single site kinetics, or with a steady state affinity model. 
4.3.5 Tryptic Digest 
Dialysis buffer: 40 mM Tris, 200 mM NaCl, pH 8. 
Reaction buffer: 50 mM NH4HCO3, pH 8. 
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DTT stock: 200 mM DTT, 100 mM NH4HCO3, pH 8. 
IAA stock: 1 M iodoacetamide, 100 mM NH4HCO3, pH 8. 
Separately, unlabelled and labelled de92 (1.5 nmol) were dialysed in dialysis buffer, desalted 
with Pierce columns and lyophilised. After resuspension in 100 µL reaction buffer, the disul-
phide bridges were reduced by incubating with 5 µL of DTT stock for 10 min at 95 °C. Free 
thiol groups were capped with 4 µL of IAA stock at RT for 1 h in the dark and subsequently 
quenched with 20 µL DTT stock. Both samples were incubated with proteomics grade trypsin 
(60 pmol by Sigma) overnight at 37 °C, frozen in liquid nitrogen and lyophilised. The lyophi-
lised powder was then resuspended in 40 µL of a water:MeCN 1:1 + 0.2% formic acid  
solution for analysis via MS. 
4.3.6 Mass Spectrometry 
5 µL of the digested sample was injected onto an Atlantis dC 18 HPLC column (Waters,  
column dimensions: 2.1x150 mm, 3 µm particle size). The separations were carried out using 
a series 1100 HPLC-system (Agilent, system consisting of binary pump, thermostated  
autosampler, and diode array detector) coupled on-line to a LTQ XL linear ion trap (Thermo 
Electron Corporation) using the standard electrospray ionisation source. For the HPLC sepa-
ration a flow rate of 200 µL/min and a linear gradient starting with 100% solvent A / 0% sol-
vent B for 5 min and increasing to 40% solvent A / 60% solvent B in 55 min was used,  
followed by a linear gradient increasing to 20% Solvent A / 80% solvent B in 10 min. After 
that the column was washed with 20% solvent A / 80% solvent B for 5 min and re-
equilibrated to starting conditions for additional 10 min (solvent A: water containing 0.1% 
formic acid, solvent B: acetonitril containing 0.1% formic acid). For mass spectrometric  
detection the electrospray ionisation was carried out in positive ionisation mode using a 
source voltage of 4.5 kV. The capillary voltage was set to 46 V, the capillary temperature to 
275 °C, and the tube lens voltage to 160 V. Spectra were acquired in triple play mode. First a 
full mass spectrum with a mass-to-charge range from 200 to 2000 was acquired, followed by 
a zoom scan of the most intense ion with a minimum signal intensity of 10 000 and a MS/MS 
spectrum using collision induced fragmentation for all at least doubly charged ions. For CID 
fragmentation the isolation width was set to 2 and the normalised collision energy to 35%. 
The AGC target was set to 30000 for full scan spectra, to 1000 for zoom scans, and to 10000 
for MS/MS spectra. After performing one MS/MS spectrum the parent mass was set onto an 
exclusion list for 180 s.  
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4.4 Cellular Experiments 
NCI-H441 and BT-474 were provided from the American Type Culture Collection (ATCC). 
Both cell lines were maintained in RPMI-1640 Medium with L-Glutamine (PAA) supple-
mented with 10% fetal calf serum (PAA) and 1% penicillin-streptomycin (Gibco) in a humidi-
fied incubator with 5% CO2 at 37 °C. Inhibitors were dissolved in DMSO at a stock concen-
tration of 10 mM and stored at -20 °C. Compound treatment was carried out using serial  
dilutions 16 hours after plating. The viability was assessed in 96-well plates starting from 
3000 cells/well. 96 hours after compound treatment, the cellular ATP content was determined 
(CellTiter.Glo, Promega). Luminiscence was measured with an Infinite200 Pro microplate 
reader (Tecan). All experiments were performed in triplicates at 3 independent time points. 
4.5 Protein Crystallisation 
Constructs de91 and de92 were transferred into the storage buffer (25 mM Tris, 100 mM 
NaCl, 10% glycerol, 5 mM DTT, pH 7.5) via gel filtration chromatography and concentrated 
to approximately 10 mg/mL. Crystals were grown by the vapor diffusion method. Both  
constructs were adjusted to 4.7 mg/mL and incubated with both MK-2206 and ZF176 at 
250 µM. Hanging drops were set up in the presence of 50% precipitant, consisting of 
12.5 mM NaOAc, 37.5 mM sodium citrate, 21% PEG 2000, pH 5.2 at 20 °C. Pictures were 
taken on an Olympus DT21 with a Plan 4x/0.10 air lens. 
4.6 Molecular Docking 
Molecular docking experiments were conducted with the Maestro software version 9.1.207 
and Glide version 5.6 by Schrödinger. The crystal structure of the full length Akt1 co-
crystallised with Akti-1/2 (PDB code 3O96) was used as template for molecular docking.  
After pre-processing by adding hydrogens, correcting bond lengths and angles, severing 
bonds to metal atoms and removing water molecules with the protein preparation wizard, a 
binding pocket of a volume of 20 Å around the original ligand was calculated without any 
constraints for the receptor grid with Glide, allowing for full rotation of tyrosine, threonine 
and serine residues. Conformers of the ligands were generated with ConfGen Standard using 
the OPLS_2005 force field. Tautomers and protonation states at pH 5-9 were calculated with 
Epik. The thusly prepared ligands were docked flexibly with Glide at a van der Waals radius 
cutoff of 0.8 and partial charge cutoff 0.15 with standard precision. 50 poses per ligand were 
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calculated after post-docking minimisation and 10 poses retained for final results. Scoring was 
computed according to GlideScore, nonplanar conformations were penalised. 
4.7 Compound Synthesis 
Commercially available solvents and reagents were obtained from Sigma-Aldrich, Alfa Aesar, 
ABCR Chemicals, Acros Organics, Maxbridge, Fluka, Riedel-de Häen, Lancaster or Carl 
Roth and used without further purification unless noted otherwise. Brine refers to a saturated 
NaCl solution in water. For ultrasonic treatment of suspensions, a VWR Ultrasonic Cleaner 
was employed. 
1
H-NMR and 
13
C-NMR spectra were recorded at ambient temperature on a Bruker DRX-400 
operating at 400 MHz, Bruker DRX-500 operating at 500 MHz, Bruker DRX-600 operating 
at 600 MHz and Varian Mercury 400 operating at 400 MHz, with tetramethylsilane as an  
internal standard. Chemical shifts (δ) are expressed in ppm, referenced to an internal tetrame-
thyl silane standard for 
1
H-NMR and relative to solvent for 
13
C-NMR. Abbreviations for 
NMR data: s = singlet; d = doublet; t = triplet; q = quartet; sept = septet; m = multiplet; br s = 
broad signal. J values are given in Hz. NMR raw data were evaluated with MestreNova 
6.0.5604 by Mestrelab. 
ESI-MS spectra were recorded on a LTQ XL linear ion trap (Thermo Electron Corporation), 
high resolution ESI-MS spectra were recorded on a LTQ Orbitrap by Thermo Electron.  
Detected ion masses (m/z) are expressed in Th. 
Analytical thin layer chromatography (TLC) was performed using commercially available 
aluminium backed plates coated with Merck Kieselgel 60 F254 0.20 mm (ALUGRAM® sil 
G/UV254) and visualised under ultra-violet light at 254 nm, or by staining with iodine,  
potassium permanganate, vanillin, ninhydrin or cerium molybdate solution. If not noted  
otherwise, varying mixtures of ethyl acetate and PE or methanol and dichloromethane were 
used as eluents. Flash column chromatography was carried out using J. T. Baker silica gel 
(particle size: 0.040-0.060 mm). 
4.7.1 tert-Butyl 2-chloropyridin-4-ylcarbamate (55) 
2-Chloropyridin-4-amine (409.0 mg, 3.181 mmol), Et3N (884 µL, 6.362 mmol) and DMAP 
(116.6 mg, 0.9543 mmol) were dissolved in 25 mL DCM and degassed for 20 min with argon. 
Boc anhydride (416.6 mg, 1.909 mmol) were added to the reaction and stirred for 24 h at RT. 
The RM was quenched with 100 mL of a saturated aqueous NH4Cl solution and extracted 
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with 3x50 mL EtOAc. The combined organic phases were washed with 50 mL saturated  
NaHCO3 and brine, dried over MgSO4, and evaporated to yield orange crystals. The crude 
product was purified by flash column chromatography (PE:EtOAc = 3:1) to afford a white 
solid (241.7 mg, 0.946 mmol, 49.8%). 
LR-MS [M+H]
+
 = calculated 229.07, found 228.80 (-0.12%) 
1
H-NMR (500 MHz, CDCl3): δ = 8.21 (1H, d, J = 6, H-2), 7.52 (1H, s, 
H-5), 7.19 (1H, d, J = 6, H-3), 6.97 (1H, br s, H-6), 1.54 (9H, s, H-9) 
ppm.  
13
C-NMR (125 MHz, CDCl3): δ = 152.84 (C-4), 151.95 (C-7), 150.31 
(C-2), 148.18 (C-1), 112.48 (C-5), 111.71 (C-3), 82.62 (C-8), 28.55 (C-9) ppm. 
4.7.2 tert-Butyl 2-chloro-3-formylpyridin-4-ylcarbamate (56) 
The following steps were carried out in an argon atmosphere: A solution of tert-butyl  
2-chloropyridin-4-ylcarbamate (203.7 mg, 0.891 mmol) was dissolved in 10 mL of dry THF, 
cooled to -78 °C and degassed. A 1.7 M solution of tert-butyl lithium in pentane (1.5 mL, 
2.55 mmol) was added dropwise. The reaction was stirred for two hours before dry DMF 
(0.25 mL, 3.25 mmol) was added. The reaction was allowed to slowly warm to room tempera-
ture over a 12 h period. The reaction mixture was quenched with 6 mL of a 3 M HCl solution 
and extracted with 3x20 mL Et2O. The combined ether layers were washed with saturated 
NaHCO3 and brine, dried over MgSO4, filtered and evaporated under reduced pressure. The 
resulting orange solid was purified with flash column chromatography (PE:EtOAc = 5:1), 
affording a white solid (123.1 mg, 0.480 mmol, 53.8%). 
LR-MS [M+H]
+
 = calculated 256.06, found 256.72 (+0.26%) 
1
H-NMR (400 MHz, CDCl3): δ = 11.00 (1H, br s, H-7), 11.52 (1H, d, J 
= 1, H-6), 8.38 (1H, dd, J = 6 and 1, H-3), 8.31 (1H, dd, J = 6 and 1, 
H-2), 1.54 (9H, s, H-10) ppm. 
13
C-NMR (100 MHz, CDCl3): δ = 194.32 (C-6), 156.7 (C-1), 154.01 
(C-2), 151.92 (C-4), 151.03 (C-8), 113.24 (C-5), 112.43 (C-3), 82.94 (C-9), 28.30 (C-10) 
ppm. 
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4.7.3 2-Chloro-3-formylpyridin-4-amine (57) 
tert-Butyl 2-chloro-3-formylpyridin-4-ylcarbamate (51.0 mg, 0.199 mmol) was dissolved in 
5 mL of a dioxanic HCl solution and stirred for 4 h at RT. The RM was evaporated under  
reduced pressure and dried in vacuo, affording an offset white solid in quantitative yields. 
LR-MS [M+H]
+
 = calculated 157.02, found 157.02 (+0.00%) 
1
H-NMR (400 MHz, MeOD): δ = 10.39 (1H, d, J = 1, H-6), 7.82 (1H, d, J = 6, 
H-2), 6.68 (1H, dd, J = 6 and 1, H-3) ppm. 
4.7.4 4-(1,3-Dioxolan-2-yl)benzonitrile (59) 
4-Cyanobenzaldehyde (131.2 mg, 1 mmol), ethylene glycol (248.3 mg, 4 mmol) and catalytic 
amounts of tosylic acid were dissolved in toluene and refluxed for 8 h with a fitted Dean 
Stark. The RM was cooled to RT, washed with 2x20 mL saturated NaHCO3 solution and 
20 mL brine. The combined aqueous layers were extracted with 2x20 mL EtOAc. The  
combined organic layers were evaporated in vacuo. The solid residue was triturated in  
n-hexane, yielding 700 mg of a white solid. 
LR-MS [M+H]
+
 = calculated 176.07, not ionisable 
1
H-NMR (400 MHz, CDCl3): δ = 7.69 (2H, d, J = 8, H-3), 7.60 (2H, d, 
J = 8, H-4), 5.86 (1H, s, H-6), 4.14-4.05 (4H, m, H-7) ppm. 
13
C-NMR (100 MHz, CDCl3): δ = 143.48 (C-5), 132.62 (C-3), 127.58 
(C-4), 119.01 (C-1), 113.27 (C-2), 102.83 (C-6), 65.85 (C-7) ppm. 
4.7.5 1-(4-(1,3-Dioxolan-2-yl)phenyl)-2-phenylethanone (60) 
4-(1,3-Dioxolan-2-yl)benzonitrile (787.6 mg, 4.496 mmol) was dissolved in anhydrous THF 
(25 mL), cooled down to 0 °C and degassed with argon. A 2 M solution of benzyl magnesium 
chloride (8.0 mL, 16.0 mmol) was added slowly. After 1 h the mixture was warmed to room 
temperature and stirred for 4 h. The RM was quenched with saturated NH4Cl and extracted 
with 3x30 mL EtOAc. The combined organic layers were dried over MgSO4, filtered and 
concentrated. The resulting yellow oil was purified by flash column chromatography (5:1 
EtOAc:PE), affording a yellow solid (1.102 g, 4.107 mmol, 91.4%). 
LR-MS [M+H]
+
 = calculated 269.12, found 269.05 (-0.03%) 
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1
H-NMR (400 MHz, CDCl3): δ = 8.02 (2H, d, J = 8, H-9), 7.56 (2H, d, 
J = 9, H-3), 7.31 (2H, dd, J = 9 and 5, H-2), 7.28-7.22 (3H, m, H-1, H-8), 
5.84 (1H, s, H-11), 4.28 (2H, s, H-5), 4.16-3.98 (4H, m, H-12) ppm. 
13
C-NMR (100 MHz, CDCl3): δ = 197.69 (C-6), 143.35 (C-10), 137.50 
(C-4), 134.79 (C-7), 129.83 (C-3), 129.16 (C-2), 129.10 (C-8), 127.33 
(C-1), 127.12 (C-6), 103.31 (C-11), 65.81 (C-12), 46.06 (C-5) ppm. 
4.7.6 2-(4-(1,3-Dioxolan-2-yl)phenyl)-5-chloro-3-phenyl-1,6-naphthyridine (61) 
2-Chloro-3-formylpyridin-4-aminium chloride (93.5 mg, 0.484 mmol), 1-(4-(1,3-dioxolan- 
2-yl)phenyl)-2-phenylethanone (131.1 mg, 0.489 mmol), sodium tert-butoxide (117.3 mg, 
1.221 mmol) were dissolved in 20 mL dry dioxane. The reaction vessel was filled with an 
argon atmosphere and fitted with a drying tube, and the RM and stirred for 3 h at RT. The RM 
was evaporated under reduced pressure. The resulting yellow solid was washed with saturated 
NaHCO3 solution, water and Et2O, and dried azeotropically with toluene, affording a slightly 
yellow solid (29.4 mg, 0.076 mmol, 15.6%). 
LR-MS [M+H]
+
 = calculated 389.11, found 389.15 (+0.01%) 
1
H-NMR (400 MHz, CDCl3): δ = 8.58 (1H, s, H-6), 8.51 (1H, d, 
J = 6, H-2), 7.93 (1H, d, J = 6, H-3), 7.50 (2H, d, J = 8, H-15), 7.42 
(2H, d, J = 8, H-14), 7.38-7.31 (3H, m, H-4, H-12), 7.31-7.24 (2H, 
m, H-11), 5.82 (1H, s, H-17), 4.18-3.95 (4H, m, H-18) ppm.  
13
C-NMR (100 MHz, CDCl3): δ = 151.17 (C-8), 145.55 (C-2), 
140.11 (C-1), 139.04 (C-9), 138.91 (C-7), 137.47 (C-4), 136.29 (C-6), 135.44 (C-16), 135.34 
(C-13), 130.32 (C-15), 129.85 (C-11), 128.87 (C-10), 128.23 (C-12), 126.52 (C-14), 122.45 
(C-3), 122.06 (C-5), 103.52 (C-17), 65.48 (C-18) ppm. 
4.7.7 4-(5-Oxo-3-phenyl-5,6-dihydro-1,6-naphthyridin-2-yl)benzaldehyde (62) 
2-(4-(1,3-Dioxolan-2-yl)phenyl)-5-chloro-3-phenyl-1,6-naphthyridine (15.97 mg, 
0.041 mmol) and 3 mL conc. hydrochloric acid were mixed and stirred at 90 °C for 3 h. The 
RM was frozen in liquid nitrogen and lyophilised. 
LR-MS [M+H]
+
 = calculated 327.12, found 327.17 (+0.02%) 
HR-MS [M+H]
+
 = calculated 327.11280, found 327.11290 (+0.28940 ppm) 
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1
H-NMR (400 MHz, CDCl3): δ = 10.03 (1H, s, H-18), 9.10 (1H, s, 
H-7), 9.00 (1H, br s, H-2), 8.20 (1H, d, J = 5, H-3), 7.83 (2H, d, 
J = 8, H-15), 7.65 (2H, d, J = 8, H-16), 7.56 (1H, d, J = 5, H-4), 
7.40-7.31 (3H, m, H-11, H-13), 7.31-7.26 (2H, m, H-12) ppm. 
13
C-NMR (100 MHz, d6-DMSO): δ = 193.48 (C-18), 162.56 (C-1), 
160.72 (C-5), 153.57 (C-7), 145.83 (C-9), 139.07 (C-8), 137.75 (C-17), 136.27 (C-3), 134.60 
(C-10), 134.46 (C-14), 131.18 (C-16), 130.14 (C-12), 129.61 (C-15), 129.22 (C-11), 128.35 
(C-13), 121.40 (C-6), 106.43 (C-4) ppm. 
4.7.8 2-(4-((4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-
phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one (63a) 
4-(5-Hydroxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde (482 mg, 1.3 mmol) and 1-(pipe-
ridin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (201.2 mg, 0.926 mmol) were dissolved in 30 mL 
dry MeOH and stirred for 4 h at 75 °C. Then NaBH3CN (63.2 mg, 0.972 mmol) was added at 
RT and reacted over night. The reaction mixture was evaporated under reduced pressure. The 
residue was purified by preparative HPLC (H2O/MeCN + 5 mM NH4OAc), affording a  
yellow solid (14.5 mg, 0.028 mmol, 2.2%). 
LR-MS [M+H]
+
 = calculated 528.24, found 528.18 (-0.01%) 
HR-MS [M+H]
+
 = calculated 528.23940, found 528.23958 (+0.34695 ppm)  
1
H-NMR (400 MHz, CDCl3): δ = 8.40 (1H, s, H-2), 
7.51 (1H, d, J = 5, H-3), 7.46-7.40 (2H, m, H-7, 
H-28), 7.38-7.32 (5H, m, H-11, H-13, H-16), 7.29-
7.23 (5H, m, H-15, H-12, H-26), 7.00-6.96 (3H, m, 
H-23, H-24, H-25), 6.70 (1H, d, J = 5, H-4), 4.20-4.10 (1H, m, H-21), 3.53 (2H, s, H-18), 
2.93 (2H, d, J = 10, H-19), 2.42-2.31 (2H, m, H-20), 2.14-2.06 (2H, m, H-19), 1.64 (2H, d, 
J = 11, H-20) ppm. 
13
C-NMR (100 MHz, CDCl3): δ = 162.88 (C-1), 162.05 (C-5), 154.57 (C-29), 153.76 (C-9), 
139.87 (C-10), 139.77 (C-8), 138.97 (C-17), 137.64 (C-7), 134.56 (C-14), 134.40 (C-3), 
130.50 (C-16), 130.22 (C-12), 130.02 (C-22), 129.28 (C-11), 129.05 (C-15), 128.32 (C-13), 
129.16 (C-23), 127.40 (C-27), 121.23 (C-25), 121.06 (C-6), 109.67 (C-24), 109.56 (C-26), 
106.77 (C-4), 62.31 (C-18), 53.42 (C-19), 50.97 (C-21), 29.51 (C-20) ppm. 
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4.7.9 2-(4-((4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-
methyl)phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one (63b) 
4-(5-Hydroxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde hydrochloride (14.03 mg, 
0.039 mmol) and 4-chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (213.95 mg, 
0.850 mmol) were dissolved in 10 mL dry MeOH and stirred for 4 h at 75 °C. Then 
NaBH3CN (55 mg, 16.5 mg, 0.85 mmol) was added at RT and reacted over night. The  
reaction mixture was evaporated under reduced pressure. The residue was purified by prepara-
tive HPLC (H2O/MeCN + 5 mM NH4OAc), affording a yellow powder (5.5 mg, 0.010 mmol, 
26%). 
LR-MS [M+H]
+
 = calculated 562.20, found 562.14 (-0.01%) 
HR-MS [M+H]
+
 = calculated 562.20043, found 562.19992 (-0.90344 ppm), calculated 
564.19748, found 564.19707 (-0.72365 ppm)  
1
H-NMR (500 MHz, d6-DMSO): δ = 8.40 (1H, s, 
H-7), 7.51 (1H, d, J = 7 Hz, H-3), 7.36-7.31 (5H, m, 
H-11, H-13, H-16), 7.28-7.23 (5H, m, H-12, H-15, 
H-26), 7.03-7.01 (2H, m, H-23, H-24), 6.69 (1H, d, 
J = 7 Hz, H-4), 3.53 (2H, s, H-18), 2.92 (2H, d, 
J = 11 Hz, H-19), 2.38-2.27 (2H, m, H-20), 2.09 (2H, t, J = 11 Hz, H-19), 1.65 (2H, dd, 
J = 12 and 2 Hz, H-20) ppm. 
13
C-NMR (125 MHz, d6-DMSO): δ = 162.87 (C-1), 162.04 (C-5), 154.61 (C-29), 153.78 
(C-9), 139.89 (C-10), 139.78 (C-8), 138.99 (C-17), 137.66 (C-7), 134.55 (C-3), 134.44 
(C-14), 130.55 (C-22), 130.52 (C-16), 130.46 (C-27), 130.23 (C-12), 129.29 (C-11), 129.04 
(C-15), 128.32 (C-13), 125.55 (C-25), 121.08 (C-24), 120.83 (C-6), 110.67 (C-26), 109.55 
(C-23), 106.74 (C-4), 62.30 (C-18), 53.37 (C-19), 51.19 (C-21), 29.46 (C-20) ppm. 
4.7.10 2-(4-((3,4-Dihydroisoquinolin-2(1H)-yl)methyl)phenyl)-3-phenyl-1,6-
naphthyridin-5(6H)-one (63c) 
4-(5-Hydroxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde hydrochloride (14.03 mg, 
0.039 mmol) and 1,2,3,4-tetrahydroisoquinoline (88 µL, 0.7 mmol) were dissolved in 10 mL 
dry MeOH and stirred for 4 h at 75 °C. Then NaBH3CN (45.4 mg, 0.7 mmol) was added at 
RT and reacted over night. The reaction mixture was evaporated under reduced pressure. The 
residue was purified by preparative HPLC (H2O/MeCN + 5 mM NH4OAc), affording a  
yellow powder (0.9 mg, 0.002 mmol, 5%). 
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LR-MS [M+H]
+
 = calculated 444.20, found 444.02 (-0.04%) 
HR-MS [M+H]
+
 = calculated 444.20704, found 444.20647 (-1.28506 ppm) 
1
H-NMR (500 MHz, d6-DMSO): δ = 8.40 (1H, s, H-7), 
7.50 (1H, d, J = 7 Hz, H-3), 7.36-7.32 (5H, m, H-11, 
H-13, H-16), 7.30-7.24 (5H, m, H-12, H-15, H-21), 7.11-
7.08 (2H, m, H-24, H-23), 7.01-6.99 (1H, m, H-22), 6.70 
(1H, d, J = 6 Hz, H-4), 3.65 (2H, s, H-18), 3.52 (2H, s, H-19), 2.82 (2H, s, H-26), 2.67 (2H, s, 
H-27) ppm. 
13
C-NMR (125 MHz, d6-DMSO): δ = 162.42 (C-1), 161.60 (C-5), 153.33 (C-9), 139.22 
(C-10), 138.63 (C-8), 137.38 (C-7), 135.10 (C-17), 134.52 (C-25), 133.85 (C-20), 130.56 
(C-16), 130.24 (C-12), 129.31 (C-24), 129.26 (C-15), 129.04 (C-11), 128.57 (C-14), 128.30 
(C-13), 127.17 (C-21), 126.83 (C-23), 126.33 (C-22), 134.08 (C-3), 120.61 (C-6), 106.39 
(C-4), 61.97 (C-18), 55.94 (C-19), 50.72 (C-27), 29.13 (C-26) ppm. 
4.7.11 Methyl 1-(4-(5-oxo-3-phenyl-5,6-dihydro-1,6-naphthyridin-2-
yl)benzyl)piperidine-4-carboxylate (63d) 
4-(5-Hydroxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde hydrochloride (14.03 mg, 
0.039 mmol) and methyl piperidine-4-carboxylate (94.6 µL, 0.7 mmol) were dissolved in 
10 mL dry MeOH and stirred for 4 h at 75 °C. Then NaBH3CN (45.4 mg, 0.7 mmol) was  
added at RT and reacted over night. The reaction mixture was evaporated under reduced  
pressure. The residue was purified by preparative HPLC (H2O/MeCN + 5 mM NH4OAc), 
affording a yellow powder (4.1 mg, 0.009 mmol, 23%). 
LR-MS [M+H]
+
 = calculated 454.21, found 454.06 (-0.03%) 
HR-MS [M+H]
+
 = calculated 454.21252, found 454.21183 (-1.52357 ppm) 
1
H-NMR (600 MHz, d6-DMSO): δ = 8.38 (1H, d, J = 1, 
H-7), 7.50 (1H, d, J = 7, H-3), 7.34-7.29 (5H, m, H-11, 
H-13, H-16), 7.25-7.22 (2H, m, H-12), 7.20 (2H, d, 
J = 8, H-15), 6.68 (1H, dd, J = 7 and 1, H-4), 3.59 (2H, 
s, H-23), 3.43 (2H, s, H-18), 3.22 (1H, s, H-23), 2.71 (2H, dt, J = 11 and 4, H-19), 2.30 (1H, 
tt, J = 11 and 4, H-21), 1.97 (2H, dt, J = 11 and 2, H-19), 1.78 (2H, dd, J = 13 and 3, H-20), 
1.55 (2H, ddd, J = 15, 12 and 4, H-20) ppm. 
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13
C-NMR (150 MHz, d6-DMSO): δ = 175.50 (C-22), 162.67 (C-1), 161.84 (C-5), 153.59 
(C-9), 139.70 (C-10), 139.48 (C-8), 138.76 (C-17), 137.44 (C-7), 134.35 (C-3), 134.24 
(C-14), 130.28 (C-16), 130.03 (C-12), 129.07 (C-15), 128.85 (C-13), 128.11 (C-11), 120.90 
(C-6), 106.53 (C-4), 62.48 (C-18), 52.84 (C-19), 52.05 (C-23), 40.61 (C-21), 28.66 (C-20) 
ppm. 
4.7.12 2-(4-((4-(4-Methoxyphenyl)piperazin-1-yl)methyl)phenyl)-3-phenyl-1,6-naphthy-
ridin-5(6H)-one (63e) 
4-(5-Hydroxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde hydrochloride (14.03 mg, 
0.039 mmol) and 1-(4-methoxyphenyl)piperazine (139.62 mg, 0.726 mmol) were dissolved in 
10 mL dry MeOH and stirred for 4 h at 75 °C. Then NaBH3CN (45.4 mg, 0.7 mmol) was  
added at RT and reacted over night. The reaction mixture was evaporated under reduced  
pressure. The residue was purified by preparative HPLC (H2O/MeCN + 5 mM NH4OAc), 
affording a yellow powder (0.9 mg, 0.002 mmol, 5%). 
LR-MS [M+H]
+
 = calculated 503.24, found 503.09 (-0.03%) 
HR-MS [M+H]
+
 = calculated 503.24415, found 503.24320 (-1.88644 ppm) 
1
H-NMR (500 MHz, d6-DMSO): δ = 8.40 (1H, s, 
H-7), 7.51 (2H, d, J = 7 Hz, H-3), 7.38-7.31 (5H, m, 
H-11, H-13, H-16), 7.28-7.23 (4H, m, H-12, H-15), 
6.88 (2H, d, J = 9 Hz, H-22), 6.81 (2H, d, J = 9 Hz, 
H-23), 6.70 (2H, d, J = 7 Hz, H-4), 3.68 (3H, s, H-25), 3.52 (2H, s, H-18), 3.01 (4H, br s, 
H-20), 2.49 (4H, br s, H-19) ppm.  
13
C-NMR (125 MHz, d6-DMSO): δ = 162.86 (C-1), 153.74 (C-5), 153.60 (C-24), 146.31 
(C-21), 141.52 (C-9), 139.39 (C-10), 139.34 (C-8), 139.31 (C-17), 137.25 (C-7), 134.00 
(C-3), 130.16 (C-16), 129.93 (C-12), 129.27 (C-14), 129.18 (C-6), 128.94 (C-15), 128.90 
(C-11), 128.04 (C-13), 106.27 (C-4), 61.85 (C-18), 55.63 (C-25), 53.07 (C-19), 50.00 (C-20) 
ppm. 
4.7.13 3-Phenyl-2-(4-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)phenyl)-1,6-naphthyri-
din-5(6H)-one (63f) 
4-(5-Oxo-3-phenyl-5,6-dihydro-1,6-naphthyridin-2-yl)benzaldehyde hydrochloride 
(14.03 mg, 0.039 mmol) and 2-(piperazin-1-yl)pyrimidine (107.4 µL, 0.7 mmol) were  
dissolved in 5 mL dry MeOH and stirred for 4 h at 75 °C. Then NaBH3CN (45.4 mg, 
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0.7 mmol) was added at RT and reacted over night. The reaction mixture was evaporated  
under reduced pressure. The residue was purified by preparative HPLC (H2O/MeCN + 5 mM 
NH4OAc), affording a yellow powder (2 mg, 0.004 mmol, 10%). 
LR-MS [M+H]
+
 = calculated 475.22, found 475.09 (-0.03%) 
HR-MS [M+H]
+
 = calculated 475.22409, found 475.22335 (-1.55503 ppm)  
1
H-NMR (500 MHz, d6-DMSO): δ = 8.40 (1H, s, H-7), 
8.35 (2H, d, J = 5 Hz, H-22), 7.51 (1H, d, J = 7 Hz, 
H-3), 7.36-7.31 (5H, m, H-11, H-13, H-16), 7.28-7.24 
(4H, m, H-12, H-15), 6.70 (1H, d, J = 7 Hz, H-4), 6.62 
(1H, t, J = 5 Hz, H-23), 3.73 (4H, br s, H-20), 3.52 (2H, s, H-18), 2.41 (4H, br s, H-19) ppm. 
13
C-NMR (125 MHz, d6-DMSO): δ = 162.84 (C-1), 162.02 (C-21), 158.75 (C-22), 153.76 
(C-5), 151.09 (C-9), 139.84 (C-10), 139.24 (C-8), 139.07 (C-17), 137.63 (C-7), 134.56 
(C-14), 134.38 (C-3), 130.51 (C-16), 130.23 (C-12), 129.27 (C-11), 129.21 (C-15), 128.31 
(C-13), 121.09 (C-6), 110.93 (C-23), 106.75 (C-4), 62.47 (C-18), 53.20 (C-19), 44.13 (C-20) 
ppm. 
4.7.14 3-Phenyl-2-(4-((4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl)methyl)phenyl)-
1,6-naphthyridin-5(6H)-one (63g) 
4-(5-Hydroxy-3-phenyl-1,6-naphthyridin-2-yl)benzaldehyde hydrochloride (14.03 mg, 
0.039 mmol) and piperazin-1-yl(tetrahydrofuran-2-yl)methanone (131.69 mg, 0.719 mmol) 
were dissolved in 10 mL dry MeOH and stirred for 4 h at 75 °C. Then NaBH3CN (45.4 mg, 
0.7 mmol) was added at RT and reacted over night. The reaction mixture was evaporated  
under reduced pressure. The residue was purified by preparative HPLC (H2O/MeCN + 5 mM 
NH4OAc), affording a yellow powder (0.8 mg, 0.002 mmol, 5%). 
LR-MS [M+H]
+
 = calculated 495.24, found 495.09 (-0.03%) 
HR-MS [M+H]
+
 = calculated 495.23907, found 495.23827 (-1.60462 ppm) 
1
H-NMR (500 MHz, d6-DMSO): δ = 8.39 (1H, s, 
H-7), 7.50 (1H, d, J = 7 Hz, H-3), 7.34-7.31 (5H, m, 
H-11, H-13, H-16), 7.26-7.22 (4H, m, H-12, H-15), 
6.70 (1H, d, J = 7 Hz, H-4), 4.64 (1H, t, J = 6 Hz, 
H-22), 3.79-3.70 (2H, m, H-25), 3.50 (2H, s, H-18), 3.49-3.46 (4H, m, H-20), 2.38-2.28 (4H, 
m, H-19), 2.02-1.97 (2H, m, H-23), 1.84-1.79 (2H, m, H-24) ppm. 
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13
C-NMR (125 MHz, d6-DMSO): δ = 162.86 (C-1), 162.09 (C-21), 153.85 (C-5), 153.79 
(C-9), 139.85 (C-10), 139.11 (C-8), 139.07 (C-17), 137.18 (C-7), 134.01 (C-3), 130.43 
(C-14), 130.15 (C-16), 129.88 (C-12), 129.19 (C-6), 128.90 (C-13), 128.83 (C-11), 128.00 
(C-15), 106.38 (C-4), 75.29 (C-22), 68.60 (C-25), 61.85 (C-18), 52.77 (C-19), 45.17 (C-29), 
28.46 (C-23), 25.61 (C-24) ppm.  
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5 Appendix 
5.1 Establishing the KinEASE Assay 
The activity of a particular preparation batch determines the kinase concentration required for 
a stable and representative assay. To determine this value, the assay was performed at  
increasing kinase concentrations in duplicates and quenched after a incubation time of 30 min. 
The relative activity was determined from the fl665/fl620 ratio and then plotted logarithmically 
against the kinase concentration as shown in Figure 84. The optimal kinase concentration 
would be as high as possible but still in the linear range. This was found to be 0.12 nM for 
Akt1, 0.51 nM for Akt2, and 0.06 nM for ΔPH-Akt1. 
 
Figure 84 Determination of kinase activity for Akt1, Akt2 and ΔPH-Akt1. The relative activity is plotted 
logarithmically against the kinase concentration in the assay. 
In the next step, the optimal incubation time for the assay had to be determined by starting the 
phosphorylation reaction with the addition of ATP and substrate, and quenching the reaction 
with EDTA at different incubation times. Again, Figure 85 shows the relative activity plotted 
against the incubation time. The optimal incubation times were determined to be 45 min for 
Akt1, 17 min for Akt2, and 20 min for ΔPH-Akt1. 
 
Figure 85  Determination of kinase phosphorylation kinetics for Akt1, Akt2 and ΔPH-Akt1. The relative 
activity is plotted against incubation time. 
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According to the Michaelis-Menten kinetics, an assay running with a reactant concentration 
far below the enzyme’s Km (i.e. [R] << Km with [R] being the reactant concentration) is  
highly sensitive to fluctuations in its concentration.
193
 In the case of ATP, however, a high 
concentration would compete with the binding of ATP-competitive inhibitors, thereby  
unnecessarily increasing the observed IC50. In order to obtain comparable results across  
different assays, the convention for kinases is to operate at an ATP concentration of ATP-Km, 
which represents a good compromise of the above mentioned considerations. To this end, the 
assay was run with saturating amounts of substrate and a dilution series of ATP. All results 
were determined in duplicates and repeated in three independent experiments 
 
Figure 86 Michaelis-Menten curves of the phosphorylation reaction catalysed by Akt1, Akt2 and ΔPH-Akt1 
in dependence of ATP. The relative activity is plotted against the ATP concentration, a represen-
tative curve was selected out of 3 independent experiments. 
The same procedure was repeated for the artificial STK3 substrate peptide, which is able to be 
phosphorylated by all three kinases. In these experiments, saturating amounts of ATP were 
provided while measuring a dilution series of STK3 in duplicates. Since the substrate to 
fluorophore ratio needs to be kept at 8:1, the reactions were quenched with a dilution series of 
the stop solution as well. Here, too, three independent measurements were conducted for each 
kinase (Table 14). The experiments for ΔPH-Akt1 were executed by Patrik Wolle under my 
supervision. 
 
Figure 87  Michaelis-Menten curves of the phosphorylation reaction catalysed by Akt1, Akt2 and ΔPH-Akt1 
in dependence of the artificial substrate peptide. The relative activity is plotted against the ATP 
concentration, a representative curve was selected out of 3 independent experiments. 
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The kinetic parameters were calculated according to the Michaelis-Menten model by fitting 
the experimental data using equation (13). The thusly determined and derived parameters are 
summarised in Table 14. No significant differences between the three constructs were found 
for the apparent Km of ATP and STK3. There is no previously published data for the STK3-
Km, but the ATP-Km matched with the literature results.
194
 Unsurprisingly, the apparent turn-
over number kcat of ΔPH-Akt1 was much higher than Akt1 and Akt2, as this constructs har-
boured the activating mutation S473D. 
  ( )  
      
 
     
  (13) 
c = substrate concentration   Vmax = maximum reaction velocity 
Km = Michaelis constant    n = slope factor 
Table 14 Summary of the determined parameters in the Michaelis-Menten model. 
  Akt1 Akt2 ΔPH-Akt1 
A
T
P
 
vmax / nM s
-1
 0.57 ± 0.05 1.60 ± 0.05 1.16 ± 0.02 
Km / µM 43 ± 6x 64 ± 6x 28 ± 4x 
kcat / s
-1
 4.8 ± 0.4 3.2 ± 0.1 20.8 ± 0.4x 
kcat/Km = s
-1
 µM
-1
 0.113 ± 0.018 0.050 ± 0.005 0.752 ± 0.097 
S
T
K
3
 vmax / nM s
-1
 0.44 ± 0.02 1.16 ± 0.03 1.33 ± 0.08 
Km / µM 0.15 ± 0.03 0.26 ± 0.03 0.30 ± 0.02 
kcat / s
-1
 3.7 ± 0.2 2.3 ± 0.1 24.0 ± 1.4x 
kcat/Km = s
-1
 µM
-1
 25 ± 5x 11 ± 3x 81 ± 8x 
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5.2 Establishing the Biacore Assay 
In a first attempt, the CM5 chip was used, which possesses a carboxymethylated dextran  
matrix on the gold surface for an irreversible, undirected immobilisation of the protein via its 
NH2- and SH-groups. For optimal enrichment of the protein on the negatively charged  
surface, buffers at 3 different pHs below the pI of Akt were tested (3.5, 4.0 and 4.5). The  
refractogram in a pH scouting experiment (no addition of the coupling reagent EDC and 
hence no nucleophilic substitution on the carboxymethyl matrix) reports increasing levels of 
immobilisation with decreasing pH (Figure 88). However, the immobilised protein could not 
be removed by washing with a basic solution, indicating unspecific interactions with the  
surface due to aggregation. A test run was carried out by immobilising de92 at pH 4.5 onto 
the CM5 chip and passing increasing concentrations of MK-2206 over the thusly prepared 
chip produced highly irregular signals without dose dependency, confirming the denaturation 
of the kinase. 
 
Figure 88 Left: Refractogram of Akt immobilisation onto a CM5 chip via pH scouting. Right: Refractogram 
of de92-immobilised CM5 chip with increasing concentrations of MK-2206. 
To circumvent this problem, a reversible immobilisation on an NTA-modified carboxymethy-
lated dextran matrix via the protein’s His-Tag was chosen. After conditioning the NTA chip 
with NiCl2, Akt could be successfully immobilised on the gold surface in the standard iFLiK 
buffer, producing an intensity increase of 676 RU. This immobilisation level could not be 
improved by increasing the pH from 7.4 to 8.0 to deprotonate the His-Tag. After  
immobilisation, it became obvious that the protein was not stably immobilised by the Ni
2+
 
complexation, as the refraction signal continuously dropped within minutes. Attempts to 
measure MK-2206 by sequentially incubating with higher concentrations of the allosteric  
inhibitor failed, as protein levels continued to fall during each subsequent concentration step 
(Figure 89). 
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Figure 89 Refractogram of de92 protein immobilisation onto NTA chip via its His6-tag after conditioning 
with NiCl2 (left) and stability of immobilisation levels to repeated buffer injections (right). 
In order to compensate this bleeding of Akt, each inhibitor concentration as well as several 
DMSO blanks were measured with a freshly immobilised protein carpet. If the enzyme was 
washed away at the same rate in each measurement, a background subtraction of the DMSO 
blank should provide stable baselines. However, the protein dissociation was not uniform in 
every step, so refraction signals produced by the binding of inhibitors was very instable. As 
the signal did not drop to starting levels after decomplexation of the protein and Ni
2+
 with 
imidazole and EDTA, it was suspected that some protein still remained on the NTA surface, 
preventing fresh protein from binding in the next step. Therefore, additional washing steps 
with GndCl, SDS and DMSO were included in the method to remove protein residues from 
the surface under these harsh conditions. However, these reagents had an even worse  
influence on the signal stability. Especially the surfactant SDS exhibited a remarkable persis-
tency, corrupted the measurements and could only be removed from the system by washing 
for several hours. Studies by Nordin et al. have shown that Tris-based buffers produced more 
stable signals than HEPES, which was used in our experiments so far.
195
 Indeed, when  
replacing HEPES with Tris, the Biacore assay produced slightly more consistent signals. 
 
Figure 90 Left: Refractogram displaying the individual stages of each cycle with fresh immobilisation of 
de92 on NTA chips prior to applying the sample. Right: Dose-dependent increase of refraction 
changes upon treatment with Akt inhibitors. 
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5.3 NMR Spectra 
 
Figure 91 
1H- (left) and 13C-NMR spectra (right) of 55. 
 
Figure 92 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-NOESY-NMR spectra (lower 
right) of 56. 
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Figure 93 
1H-NMR spectrum of 57. 
 
Figure 94 
1H- (left) and 13C-NMR spectra (right) of 59. 
 
Figure 95 
1H- (left) and 13C-NMR spectra (right) of 60. 
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Figure 96 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 61. 
 
Figure 97 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 62. 
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Figure 98 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 63a. 
 
Figure 99 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 63b. 
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Figure 100 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 63c. 
 
Figure 101 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 63d. 
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Figure 102 
1H- (upper left), 1H-COSY- (upper right), 1H-13C-HSQC- (lower left) and 1H-13C-HMBC-NMR 
spectra (lower right) of 63e. 
 
Figure 103 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 63f. 
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Figure 104 
1H- (upper left), 13C- (upper right), 1H-COSY- (lower left) and 1H-13C-HSQC-NMR spectra (lower 
right) of 63g. 
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